var title_f24_40_25216="Germinal center";
var content_f24_40_25216=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=RHEUM%2F77980&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=RHEUM%2F77980&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Diagram of a germinal center",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 418px; height: 403px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Germinal centers are organized into several \"compartments,\" each devoted to particular processes in the generation of an antibody response. The dark zone contains many rapidly dividing B cells called centroblasts which do not express surface Ig. These cells continually give rise to centrocytes, non-dividing cells which have regained surface Ig which migrate into the basal light zone. If they contact their specific antigen, they enter the apical light zone, otherwise they die. The mechanisms determining whether cells will become memory cells or antibody-producing cells (plasma cells) may operate within the apical light zone.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from Bona, C, Bonilla, F. B Cells and Humoral Immunity. In: Textbook of Immunology, second edition, Harwood Academic Publishers 1996. Page 38, figure 2-20. Original source: Liu et al. Germinal centers in T-cell dependant antibody responses. Immunology Today 1992; 13:17- 21.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f24_40_25216=[""].join("\n");
var outline_f24_40_25216=null;
var title_f24_40_25217="Cystogram bladder rupture extraperitoneal";
var content_f24_40_25217=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=EM%2F57018&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=EM%2F57018&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Cystogram of extraperitoneal bladder rupture",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 382px; height: 382px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    This retrograde cystogram reveals an extraperitoneal bladder rupture. Extravasating contrast is seen adjacent to the bladder (arrow).",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Michael S Runyon, MD, FAAEM.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f24_40_25217=[""].join("\n");
var outline_f24_40_25217=null;
var title_f24_40_25218="Patient information: Anal fissure (The Basics)";
var content_f24_40_25218=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/wk_utd-rgb.myextg\" width=\"220px\">",
"   </img>",
"  </div>",
"  <div id=\"printHeaderText\">",
"   Official reprint from  UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"   <a href=\"file://www.uptodate.com\">",
"    www.uptodate.com",
"   </a>",
"   <br>",
"    &copy;2013 UpToDate",
"    <sup>",
"     &reg;",
"    </sup>",
"   </br>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div>",
"   &nbsp;",
"  </div>",
"  <div id=\"basicsTopicMinWidth\">",
"   <div id=\"basicsTopicRight\">",
"    <div id=\"placeholder\">",
"     <div id=\"basics-graphics\">",
"      <span class=\"basics-box-top\">",
"      </span>",
"      <h4>",
"       <img src=\"file://www.uptodate.com/images/basics-graphics-title.png\"/>",
"       <span class=\"openRelatedGraphics\" id=\"PI/82909\" rel=\"graphic_box\">",
"        <a href=\"#\" title=\"View All Related Graphics\">",
"         View All",
"        </a>",
"       </span>",
"      </h4>",
"      <ul>",
"       <li>",
"        <a class=\"graphic graphic_figure\" href=\"UTD.htm?14/56/15236\">",
"         Anal sphincter",
"        </a>",
"        <li>",
"         <a class=\"graphic graphic_figure\" href=\"UTD.htm?18/52/19265\">",
"          Colonoscopy versus sigmoidoscopy",
"         </a>",
"         <li>",
"          <a class=\"graphic graphic_figure\" href=\"UTD.htm?41/38/42598\">",
"           Foods with fiber",
"          </a>",
"          <li>",
"           <a class=\"graphic graphic_figure\" href=\"UTD.htm?38/31/39413\">",
"            Nutrition label",
"           </a>",
"          </li>",
"         </li>",
"        </li>",
"       </li>",
"      </ul>",
"      <a href=\"#\" id=\"basics-seeall\">",
"       See All Graphics",
"      </a>",
"     </div>",
"     <script type=\"text/javascript\">",
"      if ($(\"#basics-graphics li\").length &lt;= 4) {",
"				$(\"#basics-seeall\").remove();",
"			} else {",
"				$(\"#basics-graphics li:gt(3)\").addClass(\"hidden\");",
"				$(\"#basics-seeall\").click(function(){",
"					$(\"#basics-graphics li.hidden\").removeClass(\"hidden\");",
"					$(this).remove();",
"					return false;",
"				});",
"			}",
"     </script>",
"     <div class=\"ieSpacer\">",
"     </div>",
"     <div id=\"basics-more\">",
"      <h4>",
"       <img src=\"file://www.uptodate.com/images/basics-more-title.png\"/>",
"      </h4>",
"      <dl>",
"       <dt class=\"basics\">",
"        The Basics",
"       </dt>",
"       <dd>",
"        <a href=\"UTD.htm?18/11/18611\">",
"         Patient information: Colonoscopy (The Basics)",
"        </a>",
"       </dd>",
"       <dd>",
"        <a href=\"UTD.htm?20/59/21426\">",
"         Patient information: Constipation in adults (The Basics)",
"        </a>",
"       </dd>",
"       <dd>",
"        <a href=\"UTD.htm?34/51/35634\">",
"         Patient information: High-fiber diet (The Basics)",
"        </a>",
"       </dd>",
"       <dt class=\"beyondthebasics\">",
"        Beyond the Basics",
"       </dt>",
"       <dd>",
"        <a href=\"UTD.htm?43/31/44529\">",
"         Patient information: Anal fissure (Beyond the Basics)",
"        </a>",
"       </dd>",
"      </dl>",
"      <div id=\"tooltipper\">",
"      </div>",
"     </div>",
"    </div>",
"   </div>",
"   <div id=\"basicsTopicLeft\">",
"    <div id=\"topicTitle\">",
"     Patient information: Anal fissure (The Basics)",
"    </div>",
"    <span class=\"view\">",
"     View in",
"     <a class=\"lang\" href=\"./es-419/anal-fissure-the-basics?source=topic_page\">",
"      Spanish",
"     </a>",
"    </span>",
"    <a class=\"contributor contributor_credentials\" href=\"./authors-and-editors/patient-information\">",
"     Written by the doctors and editors at UpToDate",
"    </a>",
"    <div id=\"topicText\">",
"     <p class=\"headingAnchor\" id=\"H26738979\">",
"      <span class=\"h1\">",
"       What is an anal fissure?",
"      </span>",
"      &nbsp;&mdash;&nbsp;An anal fissure is a tear in the lining of the anus, the opening where your bowel movements come out (",
"      <a class=\"graphic graphic_figure graphicRef56581 \" href=\"UTD.htm?14/56/15236\">",
"       figure 1",
"      </a>",
"      ). Anal fissures cause pain, especially during a bowel movement.",
"     </p>",
"     <p>",
"      There is a muscle that wraps around the anus and holds it shut. It is called the &ldquo;anal sphincter.&rdquo; The sphincter gets tense when the anus is injured. In people with anal fissures, the sphincter goes into spasms, which can lead to further injury.",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H26738995\">",
"      <span class=\"h1\">",
"       What causes anal fissures?",
"      </span>",
"      &nbsp;&mdash;&nbsp;An anal fissure is most often caused by having a hard, dry bowel movement.",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H26739012\">",
"      <span class=\"h1\">",
"       What are the symptoms of an anal fissure?",
"      </span>",
"      &nbsp;&mdash;&nbsp;Most people who have an anal fissure feel a tearing, ripping, or burning pain when they have a bowel movement. This pain can last for hours. Some people also bleed slightly when they have a bowel movement. They might see bright red blood on the toilet paper or on the surface of the bowel movement. Some people with an anal fissure also have itching or irritation around the anus.",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H26739029\">",
"      <span class=\"h1\">",
"       Should I see my doctor or nurse?",
"      </span>",
"      &nbsp;&mdash;&nbsp;Yes. See your doctor or nurse if you bleed when you have a bowel movement.",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H26739046\">",
"      <span class=\"h1\">",
"       Are there tests I should have?",
"      </span>",
"      &nbsp;&mdash;&nbsp;Your doctor or nurse can check whether you have anal fissure by gently spreading your buttocks apart and looking at your anus.",
"     </p>",
"     <p>",
"      If you have had bleeding, your doctor or nurse might send you for a test called a &ldquo;sigmoidoscopy&rdquo; or a similar test called a &ldquo;colonoscopy&rdquo; (",
"      <a class=\"graphic graphic_figure graphicRef58734 \" href=\"UTD.htm?18/52/19265\">",
"       figure 2",
"      </a>",
"      ). For these tests, the doctor puts a thin tube into your anus and advances it into your colon. The tube has a camera attached to it, so the doctor can look inside your colon and check for causes of bleeding.",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H26739063\">",
"      <span class=\"h1\">",
"       What can I do on my own to help an anal fissure?",
"      </span>",
"      &nbsp;&mdash;&nbsp;You can:",
"     </p>",
"     <p>",
"      <ul class=\"bullet-block\">",
"       <li>",
"        Eat more fiber -- Eating more fiber can help keep your bowel movements soft. Fiber is found in most fruits, vegetables, and whole grains (",
"        <a class=\"graphic graphic_figure graphicRef79063 \" href=\"UTD.htm?41/38/42598\">",
"         figure 3",
"        </a>",
"        ). Doctors suggest eating 20 to 35 grams of fiber a day. The nutrition label on packaged foods can show you much fiber you are getting in each serving (",
"        <a class=\"graphic graphic_figure graphicRef51585 \" href=\"UTD.htm?38/31/39413\">",
"         figure 4",
"        </a>",
"        ).",
"       </li>",
"       <li>",
"        Take a stool softener &ndash; Stool softeners are medicines that help make your bowel movements easier to pass. You can buy them without a prescription. One stool softener that is often used is called",
"        <a class=\"drug drug_patient\" href=\"UTD.htm?8/14/8420?source=see_link\">",
"         docusate",
"        </a>",
"        (sample brand name: Colace&reg;).",
"       </li>",
"       <li>",
"        Soak your buttocks in a &ldquo;sitz bath&rdquo; &ndash; Soaking your buttocks in 2 or 3 inches of warm water is called taking a &ldquo;sitz bath.&rdquo; Do this 2 to 3 times a day for 10 to 15 minutes. Do not add soap, bubble bath, or anything else to the water. Sitz baths help relieve pain and relax the sphincter.",
"       </li>",
"      </ul>",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H26739080\">",
"      <span class=\"h1\">",
"       How are anal fissures treated?",
"      </span>",
"      &nbsp;&mdash;&nbsp;Treatment for anal fissures involves steps that are similar to the things you can do on your own.",
"     </p>",
"     <p>",
"      For the first month of treatment, doctors recommend that people:",
"     </p>",
"     <p>",
"      <ul class=\"bullet-block\">",
"       <li>",
"        Take fiber supplements, such as:",
"       </li>",
"      </ul>",
"     </p>",
"     <p>",
"      <ul class=\"hyphen-block\">",
"       <li>",
"        <a class=\"drug drug_patient\" href=\"UTD.htm?21/23/21876?source=see_link\">",
"         Psyllium",
"        </a>",
"        (sample brand name: &nbsp;Metamucil&reg;)",
"       </li>",
"       <li>",
"        <a class=\"drug drug_patient\" href=\"UTD.htm?14/14/14564?source=see_link\">",
"         Methylcellulose",
"        </a>",
"        (sample brand name: Citrucel&reg;)",
"       </li>",
"       <li>",
"        Calcium",
"        <a class=\"drug drug_patient\" href=\"UTD.htm?11/36/11844?source=see_link\">",
"         polycarbophil",
"        </a>",
"        (sample brand name: FiberCon&reg;)",
"       </li>",
"      </ul>",
"     </p>",
"     <p>",
"      <ul class=\"bullet-block\">",
"       <li>",
"        Wheat",
"        <a class=\"drug drug_general\" href=\"UTD.htm?21/5/21588?source=see_link\">",
"         dextran",
"        </a>",
"        (sample brand name: Benefiber&reg;)",
"       </li>",
"       <li>",
"        Take a stool softener, such as",
"        <a class=\"drug drug_patient\" href=\"UTD.htm?8/14/8420?source=see_link\">",
"         docusate",
"        </a>",
"        (sample brand name: Colace&reg;).",
"       </li>",
"       <li>",
"        Use",
"        <a class=\"drug drug_patient\" href=\"UTD.htm?9/10/9382?source=see_link\">",
"         nitroglycerin",
"        </a>",
"        cream, a prescription cream that relieves pain and helps the anus heal.",
"       </li>",
"       <li>",
"        Take sitz baths (see above).",
"       </li>",
"      </ul>",
"     </p>",
"     <p>",
"      If these steps to do not work, doctors can try other treatments, such as:",
"     </p>",
"     <p>",
"      <ul class=\"bullet-block\">",
"       <li>",
"        Botulinum toxin (&ldquo;BoTox&rdquo;) &ndash; This is a shot that can help the anal sphincter muscle relax and heal. It can help, but it can also cause short-term problems with leaking of gas or bowel movements. &nbsp;",
"       </li>",
"       <li>",
"        Surgery &ndash; During surgery, the doctor makes a small cut in the sphincter to help it relax. This surgery works in most patients, but doctors offer it only to people who do not get better with other treatments. Surgery can cause lasting problems with leaking of gas or bowel movements. &nbsp;",
"       </li>",
"      </ul>",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H26739163\">",
"      <span class=\"h1\">",
"       More on this topic",
"      </span>",
"     </p>",
"     <p>",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?34/51/35634?source=see_link\">",
"       Patient information: High-fiber diet (The Basics)",
"      </a>",
"      <br/>",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?20/59/21426?source=see_link\">",
"       Patient information: Constipation in adults (The Basics)",
"      </a>",
"      <br/>",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?18/11/18611?source=see_link\">",
"       Patient information: Colonoscopy (The Basics)",
"      </a>",
"     </p>",
"     <p>",
"      <a class=\"medical medical_patient\" href=\"UTD.htm?43/31/44529?source=see_link\">",
"       Patient information: Anal fissure (Beyond the Basics)",
"      </a>",
"     </p>",
"    </div>",
"    <div id=\"reviewProcess\">",
"     <span>",
"      All topics are updated as new evidence becomes available and our",
"      <a class=\"policy policy_editorialpolicy\" href=\"/home/editorial-policy\">",
"       peer review process",
"      </a>",
"      is complete.",
"     </span>",
"    </div>",
"    <div id=\"topicRetrievedDate\">",
"     <span class=\"emphasis\">",
"      This topic retrieved from UpToDate on:",
"     </span>",
"     Apr 14, 2013.",
"    </div>",
"    <div class=\"patTopicTool\" id=\"patTopicToolBottom\">",
"     <a class=\"toolbutton findicon findInPageLink\" href=\"#\" title=\"Find in Topic\">",
"      Find",
"     </a>",
"     <a class=\"toolbutton printicon\" href=\"UTD.htm?24/40/25218?view=print\" title=\"Print This Topic\">",
"      Print",
"     </a>",
"     <a class=\"toolbutton emailicon etacLink\" href=\"#\" title=\"Email This Topic\">",
"      Email",
"     </a>",
"    </div>",
"    <div id=\"disclaimer\">",
"     The content on the UpToDate website is not intended nor recommended as a substitute for medical advice, diagnosis, or treatment.  Always seek the advice of your own physician or other qualified health care professional regarding any medical questions or conditions.",
"The use of UpToDate content is governed by the",
"     <a class=\"legal legal_termsofuse\" href=\"/home/terms-use\" target=\"_blank\">",
"      UpToDate Terms of Use",
"     </a>",
"     . &copy;2013 UpToDate, Inc. All rights reserved.",
"    </div>",
"    <div id=\"topicVersionRevision\">",
"     Topic 82909 Version 1.0",
"    </div>",
"   </div>",
"   <!--  basicsTopicLeft -->",
"  </div>",
"  <!-- basicsTopicMinWidth -->",
" </div>",
" <!-- topicContent -->",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.3 - C21.34",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Morehouse School of Medicine",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1004-110.124.11.8-587BC34546-S473950.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f24_40_25218=[""].join("\n");
var outline_f24_40_25218=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H26738979\">",
"      What is an anal fissure?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H26738995\">",
"      What causes anal fissures?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H26739012\">",
"      What are the symptoms of an anal fissure?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H26739029\">",
"      Should I see my doctor or nurse?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H26739046\">",
"      Are there tests I should have?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H26739063\">",
"      What can I do on my own to help an anal fissure?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H26739080\">",
"      How are anal fissures treated?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H26739163\">",
"      More on this topic",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"PI/82909\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li>",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?14/56/15236\">",
"      Anal sphincter",
"     </a>",
"     <li>",
"      <a class=\"graphic graphic_figure\" href=\"UTD.htm?18/52/19265\">",
"       Colonoscopy versus sigmoidoscopy",
"      </a>",
"      <li>",
"       <a class=\"graphic graphic_figure\" href=\"UTD.htm?41/38/42598\">",
"        Foods with fiber",
"       </a>",
"       <li>",
"        <a class=\"graphic graphic_figure\" href=\"UTD.htm?38/31/39413\">",
"         Nutrition label",
"        </a>",
"       </li>",
"      </li>",
"     </li>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?43/31/44529?source=related_link\">",
"      Patient information: Anal fissure (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?18/11/18611?source=related_link\">",
"      Patient information: Colonoscopy (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?20/59/21426?source=related_link\">",
"      Patient information: Constipation in adults (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?34/51/35634?source=related_link\">",
"      Patient information: High-fiber diet (The Basics)",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f24_40_25219="Pilocarpine (ophthalmic): Pediatric drug information";
var content_f24_40_25219=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"14\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"drugTitle\">",
"   Pilocarpine (ophthalmic): Pediatric drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   (For additional information",
"   <a class=\"drug drug_general\" href=\"UTD.htm?4/28/4548?source=see_link\">",
"    see \"Pilocarpine (ophthalmic): Drug information\"",
"   </a>",
"   and",
"   <a class=\"drug drug_patient\" href=\"UTD.htm?18/3/18484?source=see_link\">",
"    see \"Pilocarpine (ophthalmic): Patient drug information\"",
"   </a>",
"   )",
"   <br/>",
"   For abbreviations and symbols that may be used in Lexicomp (",
"   <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\">",
"    show table",
"   </a>",
"   )",
"   <div class=\"list ubnlist drugH1Div drugBrandNames\" id=\"F9505057\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: U.S.",
"    </span>",
"    <ul>",
"     <li>",
"      Isopto&reg; Carpine;",
"     </li>",
"     <li>",
"      Pilopine HS&reg;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"list cbnlist drugH1Div drugBrandNames\" id=\"F9505058\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: Canada",
"    </span>",
"    <ul>",
"     <li>",
"      Diocarpine;",
"     </li>",
"     <li>",
"      Isopto&reg; Carpine;",
"     </li>",
"     <li>",
"      Pilopine HS&reg;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"list_set htclist drugH1Div drugBrandNames\" id=\"F10512786\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Therapeutic Category",
"    </span>",
"    <ul>",
"     <li>",
"      <span class=\"list-set-name\">",
"       Cholinergic Agent",
"      </span>",
"     </li>",
"     <li>",
"      <span class=\"list-set-name\">",
"       Cholinergic Agent, Ophthalmic",
"      </span>",
"     </li>",
"     <li>",
"      <span class=\"list-set-name\">",
"       Ophthalmic Agent, Miotic",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block dos drugH1Div\" id=\"F10512890\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Usual",
"    </span>",
"    <p>",
"     (For additional information",
"     <a class=\"drug drug_general\" href=\"UTD.htm?4/28/4548?source=see_link\">",
"      see \"Pilocarpine (ophthalmic): Drug information\"",
"     </a>",
"     )",
"    </p>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Children and Adults:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Gel: 0.5\" (1.3 cm) ribbon applied to lower conjunctival sac once daily at bedtime; adjust dosage as required to control elevated intraocular pressure",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Solution: Instill 1-2 drops up to 6 times/day; adjust the concentration and frequency as required to control elevated intraocular pressure",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     To counteract the mydriatic effects of sympathomimetic agents: Instill 1 drop of a 1% solution in the affected eye",
"    </p>",
"   </div>",
"   <div class=\"block foc drugH1Div\" id=\"F9505257\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosage Forms: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;text-align:justify;display:inline\">",
"     Excipient information presented when available (limited, particularly for generics); consult specific product labeling.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Gel, ophthalmic, as hydrochloride:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Pilopine HS&reg;: 4% (4 g) [contains benzalkonium chloride]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Solution, ophthalmic, as hydrochloride [drops]: 1% (15 mL); 2% (15 mL); 4% (15 mL)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Isopto&reg; Carpine: 1% (15 mL); 2% (15 mL); 4% (15 mL) [contains benzalkonium chloride]",
"    </p>",
"   </div>",
"   <div class=\"block geq drugH1Div\" id=\"F9505060\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Generic Equivalent Available: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Yes: Excludes gel",
"    </p>",
"   </div>",
"   <div class=\"block adm drugH1Div\" id=\"F10512924\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Administration",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Gel: Instill gel into affected eye(s); close the eye for 1-2 minutes and instruct patient to roll the eyeball in all directions; avoid contact of bottle tip with eye or skin",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Solution: Shake well before use; instill into affected eye(s); apply finger pressure to lacrimal sac during and for 1-2 minutes after instillation to decrease drainage into the nose and throat and minimize possible systemic absorption",
"    </p>",
"   </div>",
"   <div class=\"block use drugH1Div\" id=\"F10512787\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Use",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Management of chronic simple glaucoma, chronic and acute angle-closure glaucoma; counter effects of cycloplegics",
"    </p>",
"   </div>",
"   <div class=\"block mst drugH1Div\" id=\"F9505047\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Medication Safety Issues",
"    </span>",
"    <div class=\"collapsible\">",
"     <span class=\"collapsible-title\">",
"      Sound-alike/look-alike issues:",
"     </span>",
"     <div class=\"collapsible-wrap\">",
"      <p style=\"text-indent:-2em;margin-left:4em;\">",
"       Isopto&reg; Carpine may be confused with Isopto&reg; Carbachol",
"      </p>",
"     </div>",
"    </div>",
"   </div>",
"   <div class=\"block arm drugH1Div\" id=\"F9505081\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Adverse Reactions",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Cardiovascular: Hypertension, tachycardia",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Dermatologic: Diaphoresis",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Gastrointestinal: Diarrhea, nausea, salivation, vomiting",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Ocular: Burning, ciliary spasm, conjunctival vascular congestion, corneal granularity, lacrimation, lens opacity, myopia, retinal detachment, supraorbital or temporal headache, visual acuity decreased",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Respiratory: Bronchial spasm, pulmonary edema",
"    </p>",
"   </div>",
"   <div class=\"block coi drugH1Div\" id=\"F10512788\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Contraindications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Hypersensitivity to pilocarpine or any component; when cholinergic effects such as constriction are undesirable, eg, acute inflammatory disease of anterior chamber, acute iritis",
"    </p>",
"   </div>",
"   <div class=\"block pre drugH1Div\" id=\"F10512789\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Precautions",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Use with caution in patients with pre-existing retinal disease, corneal abrasion, or those predisposed to retinal tears; may occasionally precipitate angle closure by increased resistance to aqueous flow from the posterior to anterior eye chamber",
"    </p>",
"   </div>",
"   <div class=\"block cyt drugH1Div\" id=\"F9505084\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Metabolism/Transport Effects",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     <b>",
"      Inhibits",
"     </b>",
"     CYP2A6 (weak), CYP2E1 (weak), CYP3A4 (weak)",
"    </p>",
"   </div>",
"   <div class=\"block dri drugH1Div\" id=\"F9505087\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Drug Interactions",
"    </span>",
"    <br/>",
"    <br/>",
"    <div class=\"lexi\" id=\"lexiInteractAddInfo\">",
"     (For additional information:",
"     <a class=\"dip\" href=\"./drug-interaction\" target=\"_blank\">",
"      Launch Lexi-Interact&trade; Drug Interactions Program",
"     </a>",
"     )",
"    </div>",
"    <div class=\"lexi\" id=\"lexiInteractImgB\">",
"     <img border=\"0\" height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"    </div>",
"    <div class=\"clear\">",
"    </div>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Acetylcholinesterase Inhibitors: May enhance the adverse/toxic effect of Cholinergic Agonists.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     ARIPiprazole: CYP3A4 Inhibitors (Weak) may increase the serum concentration of ARIPiprazole.  Management: Monitor for increased aripiprazole pharmacologic effects. Aripiprazole dose adjustments may or may not be required based on concomitant therapy and/or indication. Consult full interaction monograph for specific recommendations.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Beta-Blockers: May enhance the adverse/toxic effect of Cholinergic Agonists. Of particular concern are the potential for cardiac conduction abnormalities and bronchoconstriction. Management: Administer these agents in combination with caution, and monitor for conduction disturbances.  Avoid methacholine with any beta blocker due to the potential for additive bronchoconstriction.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Lomitapide: CYP3A4 Inhibitors (Weak) may increase the serum concentration of Lomitapide.  Management: Limit the maximum adult dose of lomitapide to 30 mg daily when used in combination with any weak CYP3A4 inhibitor.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Pimozide: CYP3A4 Inhibitors (Weak) may increase the serum concentration of Pimozide.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"   </div>",
"   <div class=\"block prf drugH1Div\" id=\"F9505069\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Risk Factor",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     C (",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?16/42/17068\">",
"      show table",
"     </a>",
"     )",
"    </p>",
"   </div>",
"   <div class=\"block pri drugH1Div\" id=\"F9887312\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Implications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Animal reproduction studies have not been conducted.",
"    </p>",
"   </div>",
"   <div class=\"block mop drugH1Div\" id=\"F10512932\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Monitoring Parameters",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Intraocular pressure, funduscopic exam, visual field testing",
"    </p>",
"   </div>",
"   <div class=\"block pha drugH1Div\" id=\"F10512864\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Mechanism of Action",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Directly stimulates cholinergic receptors in the eye causing miosis (by contraction of the iris sphincter), loss of accommodation (by constriction of ciliary muscle), and lowering of intraocular pressure (with decreased resistance to aqueous humor outflow)",
"    </p>",
"   </div>",
"   <div class=\"block phd drugH1Div\" id=\"F10512884\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacodynamics",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Ophthalmic solution instillation: Miosis:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Onset of action: Within 10-30 minutes",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Duration: 4-8 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Intraocular pressure reduction:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Onset of action: 1 hour",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Duration: 4-12 hours",
"    </p>",
"   </div>",
"   <div class=\"block pai drugH1Div\" id=\"F10512933\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Patient Information",
"    </span>",
"    <p>",
"     (For additional information",
"     <a class=\"drug drug_patient\" href=\"UTD.htm?18/3/18484?source=see_link\">",
"      see \"Pilocarpine (ophthalmic): Patient drug information\"",
"     </a>",
"     )",
"    </p>",
"    <p style=\"text-indent:0em;display:inline\">",
"     May sting on instillation; notify physician of sweating, urinary retention; usually causes difficulty in dark adaptation; use caution when driving at night or doing hazardous activities in poor light",
"    </p>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 16042 Version 20.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0604-115.66.252.144-4F9416D058-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f24_40_25219=[""].join("\n");
var outline_f24_40_25219=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F9505057\">",
"      Brand Names: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F9505058\">",
"      Brand Names: Canada",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10512786\">",
"      Therapeutic Category",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10512890\">",
"      Dosing: Usual",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F9505257\">",
"      Dosage Forms: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F9505060\">",
"      Generic Equivalent Available: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10512924\">",
"      Administration",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10512787\">",
"      Use",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F9505047\">",
"      Medication Safety Issues",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F9505081\">",
"      Adverse Reactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10512788\">",
"      Contraindications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10512789\">",
"      Precautions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F9505084\">",
"      Metabolism/Transport Effects",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F9505087\">",
"      Drug Interactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F9505069\">",
"      Pregnancy Risk Factor",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F9887312\">",
"      Pregnancy Implications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10512932\">",
"      Monitoring Parameters",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10512864\">",
"      Mechanism of Action",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10512884\">",
"      Pharmacodynamics",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10512933\">",
"      Patient Information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"DRUG_PED/16042\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"DRUG_PED/16042|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\" title=\"Lexicomp clinical abbreviations\">",
"      Lexicomp clinical abbreviations",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_general\" href=\"UTD.htm?4/28/4548?source=related_link\">",
"      Pilocarpine (ophthalmic): Drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_patient\" href=\"UTD.htm?18/3/18484?source=related_link\">",
"      Pilocarpine (ophthalmic): Patient drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_general\" href=\"UTD.htm?32/55/33652?source=related_link\">",
"      Pilocarpine (systemic): Drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_patient\" href=\"UTD.htm?27/52/28484?source=related_link\">",
"      Pilocarpine (systemic): Patient drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_pediatric\" href=\"UTD.htm?7/44/7876?source=related_link\">",
"      Pilocarpine (systemic): Pediatric drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f24_40_25220="Low cytokeratin stain";
var content_f24_40_25220=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=GAST%2F81586&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=GAST%2F81586&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Idiopathic adulthood ductopenia",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 432px; height: 298px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    This is a low power view of a liver biopsy using a CK7 cytokeratin immunostain specific for biliary epitheium from a patient with idiopathic adulthood ductopenia. The central vein is in the center of the slide with portal triads visible at the periphery. There is no well defined bile duct present. The brown staining in the area of the portal triads represents focal ductular proliferation.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of John Hart, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f24_40_25220=[""].join("\n");
var outline_f24_40_25220=null;
var title_f24_40_25221="Insertion of pulmonary artery catheters";
var content_f24_40_25221=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"1\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Insertion of pulmonary artery catheters",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?24/40/25221/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?24/40/25221/contributors\">",
"     Gerald L Weinhouse, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?24/40/25221/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?24/40/25221/contributors\">",
"     Polly E Parsons, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?24/40/25221/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?24/40/25221/contributors\">",
"     Geraldine Finlay, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?24/40/25221/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Oct 25, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Flow-directed pulmonary artery catheters (also called Swan-Ganz catheters) can perform many functions including the following [",
"    <a class=\"abstract\" href=\"UTD.htm?24/40/25221/abstract/1\">",
"     1",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Direct measurement of the right atrial pressure, right ventricular pressure, and pulmonary arterial pressure",
"     </li>",
"     <li>",
"      Indirect assessment of the left atrial pressure via measurement of the pulmonary artery occlusion pressure (also called the pulmonary capillary wedge pressure)",
"     </li>",
"     <li>",
"      Sampling of mixed venous blood",
"     </li>",
"     <li>",
"      Automated thermodilution analysis, which is used to calculate hemodynamic variables such as cardiac output, pulmonary vascular resistance, and systemic vascular resistance.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The insertion of pulmonary artery catheters is reviewed here. Normal hemodynamic values and interpretation of the measurements are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?35/60/36807?source=see_link\">",
"     \"Cardiac catheterization techniques: Normal hemodynamics\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?43/10/44199?source=see_link\">",
"     \"Pulmonary artery catheterization: Interpretation of tracings\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     INDICATIONS",
"    </span>",
"    &nbsp;&mdash;&nbsp;There are no universally accepted indications for pulmonary artery catheterization because pulmonary artery catheters have not been shown to improve outcomes. However, situations in which pulmonary artery catheterization may be helpful have been determined by clinical experience and are described elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?26/31/27128?source=see_link\">",
"     \"Pulmonary artery catheterization: Indications and complications\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h1\">",
"     PREPARATION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Once the decision has been made to insert a pulmonary artery catheter, an adequate number of personnel need to be recruited. This includes a clinician to insert the catheter, nursing support to monitor and care for the patient, and additional clinicians to tend to the other patients in the intensive care unit.",
"   </p>",
"   <p>",
"    The additional clinicians are necessary because insertion of a pulmonary artery catheter can be time-consuming. In a study of 120 insertions, the median duration from the decision to insert a pulmonary artery catheter to the initiation of catheter-based treatment was approximately two hours [",
"    <a class=\"abstract\" href=\"UTD.htm?24/40/25221/abstract/2\">",
"     2",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h2\">",
"     Equipment",
"    </span>",
"    &nbsp;&mdash;&nbsp;In addition to the necessary personnel, the following items should be gathered and placed in the patient's room prior to beginning the insertion procedure:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      All equipment needed for catheter insertion and pressure monitoring (",
"      <a class=\"graphic graphic_table graphicRef54646 \" href=\"UTD.htm?26/30/27115\">",
"       table 1",
"      </a>",
"      ). The catheter should be flushed through all ports and the balloon should be inflated to test for leaks. The pressure lines and transducers should be set up, calibrated, and zero-balanced. Pressure transducer function can be confirmed by waving the distal catheter tip gently, which should result in a sinusoidal waveform on the monitor. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?43/10/44199?source=see_link&amp;anchor=H2#H2\">",
"       \"Pulmonary artery catheterization: Interpretation of tracings\", section on 'Zeroing and referencing'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      An ultrasound device, if ultrasound-guided insertion is planned. Ultrasonography is being used increasingly to guide the insertion of many types of vascular access devices, including conventional central venous catheters, peripherally inserted central venous catheters, and pulmonary artery catheters. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?0/1/29?source=see_link&amp;anchor=H1498481372#H1498481372\">",
"       \"Complications of central venous catheters and their prevention\", section on 'Ultrasound guidance'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Resuscitation equipment. Arrhythmias and vascular complications can occur during insertion, which may require emergent resuscitation. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?26/31/27128?source=see_link\">",
"       \"Pulmonary artery catheterization: Indications and complications\"",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?13/33/13850?source=see_link\">",
"       \"Advanced cardiac life support (ACLS) in adults\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      An external pacing device, if the patient has a preexisting left bundle branch block.",
"     </li>",
"     <li>",
"      Fluoroscopic equipment, if fluoroscopic-guided insertion is planned. Fluoroscopy should be considered in patients who have marked right atrial enlargement, right ventricular dilatation, severe tricuspid regurgitation, or a left bundle branch block. Portable fluoroscopic equipment may not be available at some institutions, in which case insertion in either the cardiac catheterization laboratory or radiology department may be considered.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h2\">",
"     Selecting the site",
"    </span>",
"    &nbsp;&mdash;&nbsp;The choice of an insertion site should be based upon the risks and benefits of each location (",
"    <a class=\"graphic graphic_table graphicRef56392 \" href=\"UTD.htm?35/13/36060\">",
"     table 2",
"    </a>",
"    ). Possibilities include a subclavian, internal jugular, femoral, or antecubital (basilic or brachial) vein [",
"    <a class=\"abstract\" href=\"UTD.htm?24/40/25221/abstract/3,4\">",
"     3,4",
"    </a>",
"    ]. Using the left subclavian or right internal jugular vein probably facilitates passage of the catheter into the pulmonary artery, while the femoral veins should be avoided. (See",
"    <a class=\"local\" href=\"#H7\">",
"     'Sterilizing the field'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    Visualization of the target vessel using hand-held ultrasound device may help determine the optimal insertion site by allowing the clinician to see the size, configuration, and position of the blood vessels. Fluoroscopic guidance should be considered if placement via a femoral or brachial approach is chosen.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h2\">",
"     Patient positioning",
"    </span>",
"    &nbsp;&mdash;&nbsp;Correct patient positioning is vital for successful insertion. The clinician should be able to observe and palpate the relevant anatomical landmarks for the selected site. The bed should be placed at a height that is comfortable for the clinician throughout the procedure.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h2\">",
"     Sterilizing the field",
"    </span>",
"    &nbsp;&mdash;&nbsp;A wide procedural field should be prepared with strict adherence to an aseptic technique. This is crucial for reducing infectious complications. Components of an aseptic technique include hand washing with antiseptic-containing soap or alcohol-based gels or foams, full barrier precautions (sterile gloves, long-sleeved surgical gown, a surgical mask, a surgical cap, a large sterile sheet drape), skin disinfection with 2 percent",
"    <a class=\"drug drug_general\" href=\"UTD.htm?12/36/12870?source=see_link\">",
"     chlorhexidine",
"    </a>",
"    , avoidance of the femoral insertion site, and use of a sterile sleeve to protect the catheter during insertion [",
"    <a class=\"abstract\" href=\"UTD.htm?24/40/25221/abstract/5\">",
"     5",
"    </a>",
"    ]. Preparation of the insertion site is discussed in detail separately [",
"    <a class=\"abstract\" href=\"UTD.htm?24/40/25221/abstract/5,6\">",
"     5,6",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?30/53/31578?source=see_link&amp;anchor=H20#H20\">",
"     \"Prevention of intravascular catheter-related infections\", section on 'Insertion site preparation'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h2\">",
"     Analgesia and sedation",
"    </span>",
"    &nbsp;&mdash;&nbsp;The insertion site should be infiltrated with a local anesthetic (eg, 1 or 2 percent",
"    <a class=\"drug drug_general\" href=\"UTD.htm?34/34/35360?source=see_link\">",
"     lidocaine",
"    </a>",
"    ), including the superficial and deep structures of the puncture site and the anticipated needle tract. Anesthetize the periosteum of the clavicle as well for subclavian approaches. A low dose of a short-acting benzodiazepine (eg,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?3/60/4042?source=see_link\">",
"     midazolam",
"    </a>",
"    ) may facilitate the procedure for patients who are awake and anxious.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h1\">",
"     VASCULAR ACCESS",
"    </span>",
"    &nbsp;&mdash;&nbsp;An introducer is a large central venous catheter through which the pulmonary artery catheter is placed. Insertion of the introducer is nearly identical to the insertion of other central venous catheters. It is generally accomplished using the modified Seldinger's technique, which is described in detail elsewhere (",
"    <a class=\"graphic graphic_figure graphicRef74780 \" href=\"UTD.htm?42/12/43206\">",
"     figure 1",
"    </a>",
"    ). (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?43/32/44553?source=see_link&amp;anchor=H3103752#H3103752\">",
"     \"Overview of central venous access\", section on 'Central catheters and devices'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h1\">",
"     INSERTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;The pulmonary artery catheter can be placed once the introducer has been inserted into the target blood vessel. First, the catheter is oriented so that its curve facilitates passage through the cardiac chambers (",
"    <a class=\"graphic graphic_figure graphicRef54333 \" href=\"UTD.htm?17/62/18415\">",
"     figure 2",
"    </a>",
"    ) and then the catheter is advanced through the introducer while the pressure at its tip is transduced.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h2\">",
"     Using the balloon",
"    </span>",
"    &nbsp;&mdash;&nbsp;The balloon may be inflated once the pressure tracing indicates that the tip of the catheter is in the right atrium. Estimated distances from the various insertion sites to the right atrium are shown in the table (",
"    <a class=\"graphic graphic_table graphicRef56392 \" href=\"UTD.htm?35/13/36060\">",
"     table 2",
"    </a>",
"    ).",
"   </p>",
"   <p>",
"    The balloon has a maximal volume of 1.5 mL. Inflation is normally met with a small amount of resistance. Excessive resistance usually indicates malposition of the catheter tip, which should prompt repositioning before another attempt to inflate the balloon. Little resistance suggests rupture of the balloon, in which case the catheter should be removed and the integrity of the balloon checked.",
"   </p>",
"   <p>",
"    The balloon should be fully inflated whenever the catheter is advanced and completely deflated whenever the catheter is withdrawn. Having the balloon fully inflated when the catheter is advanced minimizes the possibility that the catheter tip will cause myocardial or valvular injury (",
"    <a class=\"graphic graphic_figure graphicRef59475 \" href=\"UTD.htm?32/1/32799\">",
"     figure 3",
"    </a>",
"    ).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h2\">",
"     Advancing the catheter",
"    </span>",
"    &nbsp;&mdash;&nbsp;The operator must have an unobstructed view of the hemodynamic monitor during the entire procedure because the pressure tracing monitors the location of the catheter tip (",
"    <a class=\"graphic graphic_figure graphicRef75601 \" href=\"UTD.htm?8/48/8965\">",
"     figure 4",
"    </a>",
"    ). While advancing the catheter, it is useful to keep in mind the \"rule of 10s,\" which says that anatomic and hemodynamic changes occur at approximately 10 cm intervals. As an example, when the insertion site is an internal jugular or subclavian vein, the right atrium (RA) is generally entered after inserting the catheter 20 cm, the right ventricle (RV) after inserting 30 cm, the pulmonary artery (PA) after inserting 40 cm, and the pulmonary capillary wedge pressure (PCWP) after inserting 50 cm (",
"    <a class=\"graphic graphic_table graphicRef54646 \" href=\"UTD.htm?26/30/27115\">",
"     table 1",
"    </a>",
"    ). (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?35/60/36807?source=see_link\">",
"     \"Cardiac catheterization techniques: Normal hemodynamics\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    When the catheter tip is advanced across the tricuspid valve (from the RA to the RV), the pressure waveform changes and the systolic pressure increases (",
"    <a class=\"graphic graphic_figure graphicRef75601 \" href=\"UTD.htm?8/48/8965\">",
"     figure 4",
"    </a>",
"    ). The risk of arrhythmia is greatest while the catheter tip is in the RV. Thus, the catheter should be advanced from the RV to the PA without delay.",
"   </p>",
"   <p>",
"    When the catheter tip passes across the pulmonic valve (from the RV to the PA), the diastolic pressure increases and a characteristic dicrotic notch appears in the waveform (",
"    <a class=\"graphic graphic_figure graphicRef75601 \" href=\"UTD.htm?8/48/8965\">",
"     figure 4",
"    </a>",
"    ). If more than 30 cm of the catheter has been inserted (assuming that the insertion site is an internal jugular or subclavian vein) and the pressure tracing still indicates that the tip is within the RV, then the catheter is probably coiling in the RV. In this situation, the balloon should be deflated and then the catheter should be withdrawn until the RA waveform appears. Then, the balloon can be reinflated and another attempt can be made to advance the catheter through the RV and into the PA.",
"   </p>",
"   <p>",
"    Once the catheter tip has reached the PA, it should be advanced until the pulmonary capillary wedge pressure (PCWP) is identified by a decrease in the pressure combined with a change in the waveform (",
"    <a class=\"graphic graphic_figure graphicRef75601 \" href=\"UTD.htm?8/48/8965\">",
"     figure 4",
"    </a>",
"    ). The balloon should then be deflated and the PA tracing should reappear. If the PCWP tracing persists or there is any uncertainty about whether the tracing is a PCWP or PA tracing, then the catheter should be withdrawn until a definitive PA tracing is identified.",
"   </p>",
"   <p>",
"    Occasionally, the uncertainty persists despite withdrawing the catheter. In this situation, simultaneous pressure and electrocardiographic tracings may be helpful. The peak systolic pressure in the PA occurs just prior to the electrocardiographic T wave, whereas the peak V wave of a PCWP tracing occurs after the electrocardiographic T wave. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?43/10/44199?source=see_link\">",
"     \"Pulmonary artery catheterization: Interpretation of tracings\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h2\">",
"     Final position",
"    </span>",
"    &nbsp;&mdash;&nbsp;The final position of the catheter within the PA must be such that a PCWP tracing is obtained whenever 75 to 100 percent of the 1.5 mL maximum volume of the balloon is insufflated (",
"    <a class=\"graphic graphic_figure graphicRef59475 \" href=\"UTD.htm?32/1/32799\">",
"     figure 3",
"    </a>",
"    ).",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      If less than 1 mL is required to obtain a PCWP tracing, the tip of the catheter is probably in the distal PA and further inflation may lead to vessel rupture. In this situation, the catheter should be withdrawn incrementally, until the optimal position is found.",
"     </li>",
"     <li>",
"      If maximal balloon inflation fails to result in a PCWP tracing, or does so only after a 2 to 3 second delay, the catheter is probably too proximal. This means that it could slip back into the RV, increasing the risk of arrhythmia and intracardiac damage. In this situation, the catheter should be advanced in small increments, until the optimal position is located.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Once the desired position is reached, it is essential that the catheter be secured to prevent migration. This can be accomplished by suturing or taping the catheter to the skin or locking the introducer hub. In addition, a secure antiseptic dressing should be applied. The length of the catheter that was passed (indicated by marks on the catheter at 10 cm intervals) should be documented in the patient's medical record.",
"   </p>",
"   <p>",
"    Finally, a chest radiograph should be obtained to confirm the position of the catheter. The tip of the catheter should be no more than 3 to 5 cm from the midline. Daily chest radiographs are often obtained to monitor for migration of the catheter tip and other complications associated with prolonged use. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?26/31/27128?source=see_link\">",
"     \"Pulmonary artery catheterization: Indications and complications\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h1\">",
"     COMPLICATIONS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Complications associated with insertion of a pulmonary artery catheter include trauma to the vessels and heart, valvular damage, and arrhythmias. These adverse consequences are discussed in detail elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?26/31/27128?source=see_link\">",
"     \"Pulmonary artery catheterization: Indications and complications\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      There are no universally accepted indications for pulmonary artery catheterization. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?26/31/27128?source=see_link\">",
"       \"Pulmonary artery catheterization: Indications and complications\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Once the decision has been made to insert a pulmonary artery catheter, preparation consists of recruiting an adequate number of personnel, gathering the necessary equipment, selecting the insertion site, positioning the patient, sterilizing the procedural field, and giving analgesia and sedation if necessary. (See",
"      <a class=\"local\" href=\"#H3\">",
"       'Preparation'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      An introducer (also called a cordis) is a large central venous catheter through which the pulmonary artery catheter is placed. Insertion of an introducer is similar to the insertion of other central venous catheters. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?43/32/44553?source=see_link&amp;anchor=H3103752#H3103752\">",
"       \"Overview of central venous access\", section on 'Central catheters and devices'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Once the introducer has been inserted into the target blood vessel, the pulmonary artery catheter can be placed. The catheter is advanced through the introducer while the pressure at its tip is transduced. The balloon may be inflated once the pressure tracing indicates that the tip of the catheter is in the right atrium. The balloon should be fully inflated whenever the catheter is advanced and completely deflated whenever the catheter is withdrawn. (See",
"      <a class=\"local\" href=\"#H10\">",
"       'Insertion'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H11\">",
"       'Using the balloon'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      When the catheter tip passes from the right atrium into the right ventricle, the pressure waveform changes and the systolic pressure increases (",
"      <a class=\"graphic graphic_figure graphicRef75601 \" href=\"UTD.htm?8/48/8965\">",
"       figure 4",
"      </a>",
"      ). The catheter tip should be advanced into the pulmonary artery without delay because the risk of an arrhythmia is high while then catheter tip is in the right ventricle. Entry in the pulmonary artery is easily recognized because the diastolic pressure increases and a dicrotic notch appears. Once the catheter tip reaches the pulmonary artery, it should be advanced until the pulmonary capillary wedge pressure is identified by a decrease in the pressure combined with a change in the waveform. (See",
"      <a class=\"local\" href=\"#H12\">",
"       'Advancing the catheter'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The final position of the catheter must be such that a pulmonary capillary wedge pressure tracing is obtained whenever 75 to 100 percent of the 1.5 mL maximum volume of the balloon is insufflated. Once the desired position is reached, it is essential that the catheter be secured to prevent migration. Finally, a chest radiograph should be obtained to confirm the position of the catheter. (See",
"      <a class=\"local\" href=\"#H13\">",
"       'Final position'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Complications associated with insertion of a pulmonary artery catheter include trauma to the vessels and heart, valvular damage, and arrhythmias. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?26/31/27128?source=see_link\">",
"       \"Pulmonary artery catheterization: Indications and complications\"",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/40/25221/abstract/1\">",
"      Swan HJ, Ganz W, Forrester J, et al. Catheterization of the heart in man with use of a flow-directed balloon-tipped catheter. N Engl J Med 1970; 283:447.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/40/25221/abstract/2\">",
"      Lefrant JY, Muller L, Bruelle P, et al. Insertion time of the pulmonary artery catheter in critically ill patients. Crit Care Med 2000; 28:355.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/40/25221/abstract/3\">",
"      Summerhill EM, Baram M. Principles of pulmonary artery catheterization in the critically ill. Lung 2005; 183:209.",
"     </a>",
"    </li>",
"    <li>",
"     American Heart Association. Textbook of Advanced Cardiac Life Support, Cummins RO (Ed), American Heart Association, 1994.",
"    </li>",
"    <li>",
"     Healthcare infection control practices advisory committee (HICPAC). 2011 Guidelines for the prevention of intravascular catherter-related infections. file://www.cdc.gov/hicpac/BSI/05-bsi-background-info-2011.html (Accessed on October 25, 2012).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/40/25221/abstract/6\">",
"      Mermel LA. Prevention of intravascular catheter-related infections. Ann Intern Med 2000; 132:391.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 1658 Version 6.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0504-203.80.222.8-1A4E1675F2-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f24_40_25221=[""].join("\n");
var outline_f24_40_25221=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H15\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      INDICATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      PREPARATION",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      Equipment",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      Selecting the site",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      Patient positioning",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      Sterilizing the field",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      Analgesia and sedation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      VASCULAR ACCESS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      INSERTION",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      Using the balloon",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      Advancing the catheter",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      Final position",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      COMPLICATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"PULM/1658\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"PULM/1658|FIG\">",
"      <a href=\"#\" title=\"FIGURES\">",
"       FIGURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?42/12/43206\" title=\"figure 1\">",
"      Modified Seldinger tech",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?17/62/18415\" title=\"figure 2\">",
"      Insertion of Swan Ganz catheter",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?32/1/32799\" title=\"figure 3\">",
"      Swan Ganz balloon inflation",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?8/48/8965\" title=\"figure 4\">",
"      Waveforms Swan Ganz tip",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"PULM/1658|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?26/30/27115\" title=\"table 1\">",
"      Central line equipment",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?35/13/36060\" title=\"table 2\">",
"      PA catheter insertion sites",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?13/33/13850?source=related_link\">",
"      Advanced cardiac life support (ACLS) in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?35/60/36807?source=related_link\">",
"      Cardiac catheterization techniques: Normal hemodynamics",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?0/1/29?source=related_link\">",
"      Complications of central venous catheters and their prevention",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?43/32/44553?source=related_link\">",
"      Overview of central venous access",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?30/53/31578?source=related_link\">",
"      Prevention of intravascular catheter-related infections",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?26/31/27128?source=related_link\">",
"      Pulmonary artery catheterization: Indications and complications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?43/10/44199?source=related_link\">",
"      Pulmonary artery catheterization: Interpretation of tracings",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f24_40_25222="Intermediate case 15";
var content_f24_40_25222=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=CARD%2F76503&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=CARD%2F76503&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic2\" style=\"width: 1130px;\">",
"  <div class=\"figure\" style=\"width: 560px\">",
"   <div class=\"ttl\">",
"    Intermediate case 15",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 540px; height: 98px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
"  <div class=\"figure\" style=\"width: 450px\">",
"   <div class=\"ttl\">",
"    Normal rhythm strip",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 432px; height: 165px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Normal rhythm strip in lead II. The PR interval is 0.15 sec and the QRS duration is 0.08 sec. Both the P and T waves are upright.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Morton F Arnsdorf, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f24_40_25222=[""].join("\n");
var outline_f24_40_25222=null;
var title_f24_40_25223="Allopurinol: Drug information";
var content_f24_40_25223=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"drugTitle\">",
"   Allopurinol: Drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   (For additional information",
"   <a class=\"drug drug_patient\" href=\"UTD.htm?2/14/2277?source=see_link\">",
"    see \"Allopurinol: Patient drug information\"",
"   </a>",
"   and",
"   <a class=\"drug drug_pediatric\" href=\"UTD.htm?24/3/24629?source=see_link\">",
"    see \"Allopurinol: Pediatric drug information\"",
"   </a>",
"   )",
"   <br/>",
"   For abbreviations and symbols that may be used in Lexicomp (",
"   <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\">",
"    show table",
"   </a>",
"   )",
"   <div class=\"list ubnlist drugH1Div drugBrandNames\" id=\"F131745\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: U.S.",
"    </span>",
"    <ul>",
"     <li>",
"      Aloprim&reg;;",
"     </li>",
"     <li>",
"      Zyloprim&reg;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"list cbnlist drugH1Div drugBrandNames\" id=\"F131746\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: Canada",
"    </span>",
"    <ul>",
"     <li>",
"      Alloprin&reg;;",
"     </li>",
"     <li>",
"      Novo-Purol;",
"     </li>",
"     <li>",
"      Zyloprim&reg;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ex_sect_xr thclist drugH1Div drugBrandNames\" id=\"F131796\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacologic Category",
"    </span>",
"    <ul>",
"     <li>",
"      Antigout Agent;",
"     </li>",
"     <li>",
"      Xanthine Oxidase Inhibitor",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block doa drugH1Div\" id=\"F131750\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Adult",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     <b>",
"      Note:",
"     </b>",
"     Oral doses &gt;300 mg should be given in divided doses.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Gout (chronic):",
"     </b>",
"     Oral:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     <i>",
"      Manufacturer&rsquo;s labeling:",
"     </i>",
"     Mild: 200-300 mg/day; Severe: 400-600 mg/day; to reduce the possibility of acute gouty attacks, initiate dose at 100 mg/day and increase weekly to recommended dosage, also consider using low-dose colchicine or an NSAID to reduce the risk of a gouty attack. Maximum daily dose: 800 mg/day.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     <i>",
"      Alternative recommendations (unlabeled dosing):",
"     </i>",
"     Initial: 100 mg/day, increasing the dose gradually every 4 weeks, while monitoring plasma  uric acid levels to achieve a goal of &lt;6 mg/dL; dosages of 600 mg/day and rarely, 900 mg/day may be required (McGill, 2010)",
"     <b>",
"      or",
"     </b>",
"     Initial: 100 mg/day, increasing the dose by 100 mg/day  at 2-4 weeks intervals as required to achieve desired uric acid level  of &le;6 mg/dL (EULAR gout guidelines; Zhang, 2006).",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;margin-top:0em;text-align:justify;\">",
"     <b>",
"      Management of hyperuricemia associated with chemotherapy:",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Oral:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     <i>",
"      Manufacturer&rsquo;s labeling:",
"     </i>",
"     600-800 mg/day in 2-3 divided doses",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     <i>",
"      Alternative recommendations",
"     </i>",
"     (unlabeled dosing; intermediate-risk for tumor lysis syndrome): Intermediate-risk for tumor lysis syndrome: 10 mg/kg/day (maximum dose/day: 800 mg) in 3 divided doses",
"     <b>",
"      or",
"     </b>",
"     50-100 mg/m",
"     <sup>",
"      2",
"     </sup>",
"     every 8 hours (maximum dose: 300 mg/m",
"     <sup>",
"      2",
"     </sup>",
"     /day), begin 1-2 days before initiation of induction chemotherapy; may continue for 3-7 days after chemotherapy (Coiffier, 2008)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     I.V.:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     <i>",
"      Manufacturer&rsquo;s labeling:",
"     </i>",
"     200-400 mg/m",
"     <sup>",
"      2",
"     </sup>",
"     /day (maximum: 600 mg/day) beginning 1-2 days before chemotherapy",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     <i>",
"      Alternative recommendations",
"     </i>",
"     (unlabeled dosing; intermediate-risk for tumor lysis syndrome): 200-400 mg/m",
"     <sup>",
"      2",
"     </sup>",
"     /day (maximum dose/day: 600 mg) in 1-3 divided doses beginning 1-2 days before the start of induction chemotherapy; may continue for 3-7 days after chemotherapy (Coiffier, 2008)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     <b>",
"      Note:",
"     </b>",
"     Intravenous daily dose can be given as a single infusion or in equally divided doses at 6-, 8-, or 12-hour intervals. A fluid intake sufficient to yield a daily urinary output of at least 2 L in adults is desirable.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Recurrent calcium oxalate stones:",
"     </b>",
"     Oral: 200-300 mg/day in single or divided doses",
"    </p>",
"   </div>",
"   <div class=\"block dop drugH1Div\" id=\"F131774\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Pediatric",
"    </span>",
"    <p>",
"     (For additional information",
"     <a class=\"drug drug_pediatric\" href=\"UTD.htm?24/3/24629?source=see_link\">",
"      see \"Allopurinol: Pediatric drug information\"",
"     </a>",
"     )",
"    </p>",
"    <p style=\"text-indent:0em;margin-left:0em;\">",
"     <b>",
"      Management of hyperuricemia associated with chemotherapy:",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Oral:",
"     <b>",
"      Note:",
"     </b>",
"     Oral doses &gt;300 mg should be given in divided doses.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     <i>",
"      Manufacturer&rsquo;s labeling:",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     Children &lt;6 years: 150 mg/day",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     Children 6-10 years: 300 mg/day",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     Children &gt;10 years: Refer to adult dosing.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     <i>",
"      Alternative recommendations",
"     </i>",
"     (unlabeled dosing; intermediate-risk for tumor lysis syndrome): Intermediate-risk for tumor lysis syndrome: 10 mg/kg/day (maximum dose/day: 800 mg) in 3 divided doses",
"     <b>",
"      or",
"     </b>",
"     50-100 mg/m",
"     <sup>",
"      2",
"     </sup>",
"     every 8 hours (maximum dose: 300 mg/m",
"     <sup>",
"      2",
"     </sup>",
"     /day), begin 1-2 days before initiation of induction chemotherapy; may continue for 3-7 days after chemotherapy (Coiffier, 2008)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     I.V.:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     <i>",
"      Manufacturer&rsquo;s labeling:",
"     </i>",
"     Starting dose: 200 mg/m",
"     <sup>",
"      2",
"     </sup>",
"     /day  beginning 1-2 days before chemotherapy",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     <i>",
"      Alternative recommendations",
"     </i>",
"     (unlabeled dosing; intermediate-risk for tumor lysis syndrome) 200-400 mg/m",
"     <sup>",
"      2",
"     </sup>",
"     /day (maximum dose/day: 600 mg) in 1-3 divided doses beginning 1-2 days before the start of induction chemotherapy; may continue for 3-7 days after chemotherapy (Coiffier, 2008)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     <b>",
"      Note:",
"     </b>",
"     Adequate fluid intake is desirable.",
"    </p>",
"   </div>",
"   <div class=\"block doe drugH1Div\" id=\"F131751\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Geriatric",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Refer to adult dosing.",
"    </p>",
"   </div>",
"   <div class=\"block dor drugH1Div\" id=\"F131752\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Renal Impairment",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;margin-top:0em;text-align:justify;\">",
"     <i>",
"      Manufacturer&rsquo;s labeling:",
"     </i>",
"     Oral, I.V.: Lower doses are required in renal impairment due to potential for accumulation of allopurinol and metabolites.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;margin-top:0em;text-align:justify;\">",
"     Cl",
"     <sub>",
"      cr",
"     </sub>",
"     10-20 mL/minute: 200 mg/day",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;margin-top:0em;text-align:justify;\">",
"     Cl",
"     <sub>",
"      cr",
"     </sub>",
"     3-10 mL/minute: &le;100 mg/day",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;margin-top:0em;text-align:justify;\">",
"     Cl",
"     <sub>",
"      cr",
"     </sub>",
"     &lt;3 mL/minute: 100 mg/dose at extended intervals",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;margin-top:0em;text-align:justify;\">",
"     <i>",
"      Alternative recommendations (unlabeled dosing):",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;margin-top:0em;text-align:justify;\">",
"     Management of hyperuricemia associated with chemotherapy: Dosage reduction of 50% is recommended in renal impairment (Coiffier, 2008)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;margin-top:0em;text-align:justify;\">",
"     Gout: Oral:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;margin-top:0em;text-align:justify;\">",
"     Initiate therapy with 50-100 mg daily, and gradually increase to a maintenance dose to achieve a serum uric acid level of &le;6 mg/dL  (with close monitoring of serum uric acid levels and for hypersensitivity) (Dalbeth, 2007).",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;margin-top:0em;text-align:justify;\">",
"     Hemodialysis: Initial: 100 mg alternate days given postdialysis, increase cautiously to 300 mg based on response. If dialysis is on a daily basis, an additional 50% of the dose may be required postdialysis (Dalbeth, 2007)",
"    </p>",
"   </div>",
"   <div class=\"block foc drugH1Div\" id=\"F131716\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosage Forms: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;text-align:justify;display:inline\">",
"     Excipient information presented when available (limited, particularly for generics); consult specific product labeling.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Injection, powder for reconstitution, as sodium [strength expressed as base]: 500 mg",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Aloprim&reg;: 500 mg",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Tablet, oral: 100 mg, 300 mg",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Zyloprim&reg;: 100 mg, 300 mg [scored]",
"    </p>",
"   </div>",
"   <div class=\"block geq drugH1Div\" id=\"F131701\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Generic Equivalent Available: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Yes",
"    </p>",
"   </div>",
"   <div class=\"block adm drugH1Div\" id=\"F131721\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Administration",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Oral: Do not initiate or discontinue allopurinol during an acute gout attack. Should administer oral forms after meals with plenty of fluid.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     I.V.: The rate of infusion depends on the volume of the infusion; infuse maximum single daily doses (600 mg/day) over &ge;30 minutes. Whenever possible, therapy should be initiated at 24-48 hours before the start of chemotherapy known to cause tumor lysis (including adrenocorticosteroids). I.V. daily dose can be administered as a single infusion or in equally divided doses at 6-, 8-, or 12-hour interval.",
"    </p>",
"   </div>",
"   <div class=\"block scp drugH1Div\" id=\"F131802\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Compatibility",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Stable in D",
"     <sub>",
"      5",
"     </sub>",
"     W, NS, sterile water for injection.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Y-site administration: Compatible:",
"     </b>",
"     Acyclovir, aminophylline, ampicillin, aztreonam, bleomycin, bumetanide, buprenorphine, butorphanol, calcium gluconate, carboplatin, cefazolin, cefotetan, ceftazidime, cefuroxime, cisplatin, cyclophosphamide, dactinomycin, dexamethasone sodium phosphate, doxorubicin liposome, enalaprilat, etoposide, famotidine, filgrastim, fluconazole, fludarabine, fluorouracil, furosemide, gallium nitrate, ganciclovir, granisetron, heparin, hydrocortisone sodium phosphate, hydrocortisone sodium succinate, hydromorphone, ifosfamide, lorazepam, mannitol, melphalan, mesna, methotrexate, metronidazole, mitomycin, mitoxantrone, morphine, oxaliplatin, piperacillin, potassium chloride, ranitidine, sulfamethoxazole and trimethoprim, teniposide, thiotepa, ticarcillin/clavulanate, vancomycin, vinblastine, vincristine, zidovudine.",
"     <b>",
"      Incompatible:",
"     </b>",
"     Amikacin, amphotericin B, carmustine, cefotaxime, chlorpromazine, cimetidine, clindamycin, cytarabine, dacarbazine, daunorubicin, diphenhydramine, doxorubicin, doxycycline, droperidol, floxuridine, gentamicin, haloperidol, hydroxyzine, idarubicin, imipenem/cilastatin, mechlorethamine, meperidine, methylprednisolone sodium succinate, metoclopramide, minocycline, nalbuphine, ondansetron, prochlorperazine edisylate, promethazine, sodium bicarbonate, streptozocin, tobramycin, vinorelbine.",
"     <b>",
"      Variable (consult detailed reference):",
"     </b>",
"     Ceftriaxone.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Compatibility in  syringe: Incompatible:",
"     </b>",
"     Ceftriaxone",
"    </p>",
"   </div>",
"   <div class=\"block use drugH1Div\" id=\"F131720\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Use",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Oral: Management of primary or secondary gout (acute attack, tophi, joint destruction, uric acid lithiasis, and/or nephropathy); management of hyperuricemia associated with cancer treatment for leukemia, lymphoma, or solid tumor malignancies; management of recurrent calcium oxalate calculi (with uric acid excretion &gt;800 mg/day in men and &gt;750 mg/day in women)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     I.V.: Management of hyperuricemia associated with cancer treatment for leukemia, lymphoma, or solid tumor malignancies",
"    </p>",
"   </div>",
"   <div class=\"block mst drugH1Div\" id=\"F131804\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Medication Safety Issues",
"    </span>",
"    <div class=\"collapsible\">",
"     <span class=\"collapsible-title\">",
"      Sound-alike/look-alike issues:",
"     </span>",
"     <div class=\"collapsible-wrap\">",
"      <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"       Allopurinol may be confused with Apresoline",
"      </p>",
"      <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"       Zyloprim&reg; may be confused with ZORprin&reg;, Zovirax&reg;",
"      </p>",
"     </div>",
"    </div>",
"   </div>",
"   <div class=\"block ars drugH1Div\" id=\"F131794\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Adverse Reactions Significant",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Dermatologic: Rash",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Endocrine &amp; metabolic: Gout (acute)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Gastrointestinal: Diarrhea, nausea",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Hepatic: Alkaline phosphatase increased, liver enzymes increased",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     &lt;1% (Limited to important or life-threatening): Abdominal pain, agranulocytosis, alopecia, angioedema, aplastic anemia, arthralgia, bronchospasm, cataracts, cholestatic jaundice, dermatitis (eczematoid, exfoliative, vascular bullous), dyspepsia, ecchymosis, eosinophilia, epistaxis, fever, gastritis, granuloma annulare, hepatitis, gynecomastia, headache, hepatic necrosis, hepatomegaly, hyperbilirubinemia, hypersensitivity reactions, leukocytosis, leukopenia, lichen planus, loss of taste perception, macular retinitis, myopathy, necrotizing angiitis, nephritis, neuritis, neuropathy, onycholysis, pancreatitis, paresthesia, purpura, pruritus, renal failure, somnolence, Stevens-Johnson syndrome, taste perversion, thrombocytopenia, toxic epidermal necrolysis, toxic pustuloderma, uremia, vasculitis, vomiting",
"    </p>",
"   </div>",
"   <div class=\"block coi drugH1Div\" id=\"F131725\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Contraindications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Hypersensitivity to allopurinol or any component of the formulation",
"    </p>",
"   </div>",
"   <div class=\"block war drugH1Div\" id=\"F131705\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Warnings/Precautions",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Concerns related to adverse effects:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Allergic reaction: Has been associated with a number of hypersensitivity reactions, including severe reactions (vasculitis and Stevens-Johnson syndrome); discontinue at first sign of rash.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Bone marrow suppression: Has been reported; use caution with other drugs causing myelosuppression.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Hepatotoxicity: Reversible hepatotoxicity has been reported; use with caution in patients with pre-existing hepatic impairment.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Disease-related concerns:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Asymptomatic hyperuricemia: Do not use to treat asymptomatic hyperuricemia.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Renal impairment: Use with caution in patients with renal impairment; may be at increased risk for hypersensitivity reactions. Dosage adjustments needed.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Concurrent drug therapy issues:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; ACE inhibitors: The risk of hypersensitivity may be increased in patients receiving ACE inhibitors.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Amoxicillin/ampicillin: Risk of skin rash may be increased in patients receiving amoxicillin or ampicillin.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Azathioprine/mercaptopurine: Use with caution in patients taking mercaptopurine or azathioprine; dosage adjustment necessary.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Diuretics: Use with caution in patients taking diuretics concurrently. The risk of hypersensitivity may be increased in patients receiving thiazides.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Other warnings/precautions:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Appropriate use: Full effect on serum uric acid levels in chronic gout may take several weeks to become evident; gradual titration is recommended.",
"    </p>",
"   </div>",
"   <div class=\"block cyt drugH1Div\" id=\"F13298712\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Metabolism/Transport Effects",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     None known.",
"    </p>",
"   </div>",
"   <div class=\"block dri drugH1Div\" id=\"F131710\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Drug Interactions",
"    </span>",
"    <br/>",
"    <br/>",
"    <div class=\"lexi\" id=\"lexiInteractAddInfo\">",
"     (For additional information:",
"     <a class=\"dip\" href=\"./drug-interaction\" target=\"_blank\">",
"      Launch Lexi-Interact&trade; Drug Interactions Program",
"     </a>",
"     )",
"    </div>",
"    <div class=\"lexi\" id=\"lexiInteractImgB\">",
"     <img border=\"0\" height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"    </div>",
"    <div class=\"clear\">",
"    </div>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     ACE Inhibitors: May enhance the potential for allergic or hypersensitivity reactions to Allopurinol.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Amoxicillin: Allopurinol may enhance the potential for allergic or hypersensitivity reactions to Amoxicillin.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Ampicillin: Allopurinol may enhance the potential for allergic or hypersensitivity reactions to Ampicillin.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Antacids: May decrease the absorption of Allopurinol.",
"     <b>",
"      Exceptions:",
"     </b>",
"     Sodium Bicarbonate.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Anticonvulsants (Hydantoin): Allopurinol may increase the serum concentration of Anticonvulsants (Hydantoin).",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     AzaTHIOprine: Allopurinol may decrease the metabolism of AzaTHIOprine.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Bendamustine: Allopurinol may enhance the adverse/toxic effect of Bendamustine. Specifically, the risk of severe skin reactions may be enhanced.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     CarBAMazepine: Allopurinol may increase the serum concentration of CarBAMazepine.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     ChlorproPAMIDE: Allopurinol may increase the serum concentration of ChlorproPAMIDE.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Cyclophosphamide: Allopurinol may enhance the adverse/toxic effect of Cyclophosphamide. Specifically, bone marrow suppression.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Didanosine: Allopurinol may increase the serum concentration of Didanosine.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Loop Diuretics: May enhance the adverse/toxic effect of Allopurinol. Loop Diuretics may increase the serum concentration of Allopurinol. Specifically, Loop Diuretics may increase the concentration of Oxypurinol, an active metabolite of Allopurinol.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Mercaptopurine: Allopurinol may decrease the metabolism of Mercaptopurine.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Pegloticase: Allopurinol may enhance the adverse/toxic effect of Pegloticase. Specifically, Allopurinol may blunt increases in serum urate that would signal an increased risk of anaphylaxis and infusion reactions.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Theophylline Derivatives: Allopurinol may increase the serum concentration of Theophylline Derivatives.",
"     <b>",
"      Exceptions:",
"     </b>",
"     Dyphylline.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Thiazide Diuretics: May enhance the potential for allergic or hypersensitivity reactions to Allopurinol. Thiazide Diuretics may increase the serum concentration of Allopurinol. Specifically, Thiazide Diuretics may increase the concentration of Oxypurinol, an active metabolite of Allopurinol.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Vitamin K Antagonists (eg, warfarin): Allopurinol may enhance the anticoagulant effect of Vitamin K Antagonists.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"   </div>",
"   <div class=\"block foi drugH1Div\" id=\"F131742\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Ethanol/Nutrition/Herb Interactions",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Ethanol: May decrease effectiveness.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Iron supplements: Hepatic iron uptake may be increased.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Vitamin C: Large amounts of vitamin C may acidify urine and increase kidney stone formation.",
"    </p>",
"   </div>",
"   <div class=\"block prf drugH1Div\" id=\"F131712\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Risk Factor",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     C (",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?16/42/17068\">",
"      show table",
"     </a>",
"     )",
"    </p>",
"   </div>",
"   <div class=\"block pri drugH1Div\" id=\"F131728\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Implications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     There are few reports describing the use of allopurinol during pregnancy; no adverse fetal outcomes attributable to allopurinol have been reported in humans; use only if potential benefit outweighs the potential risk to the fetus.",
"    </p>",
"   </div>",
"   <div class=\"block lac drugH1Div\" id=\"F131759\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Lactation",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Enters breast milk/use caution (AAP rates &ldquo;compatible&rdquo;; AAP 2001 update pending)",
"    </p>",
"   </div>",
"   <div class=\"block dic drugH1Div\" id=\"F131729\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dietary Considerations",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Should take oral forms after meals with plenty of fluid. Fluid intake should be administered to yield neutral or slightly alkaline urine and an output of ~2 L (in adults).",
"    </p>",
"   </div>",
"   <div class=\"block fee drugH1Div\" id=\"F131727\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pricing: U.S. (Medi-Span&reg;)",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Solution (reconstituted)",
"     </b>",
"     (Allopurinol Sodium Intravenous)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     500 mg (1): $583.14",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Solution (reconstituted)",
"     </b>",
"     (Aloprim Intravenous)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     500 mg (1): $512.50",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Tablets",
"     </b>",
"     (Allopurinol Oral)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     100 mg (100): $24.25",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     300 mg (100): $60.81",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Tablets",
"     </b>",
"     (Zyloprim Oral)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     100 mg (100): $159.44",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     300 mg (100): $436.70",
"    </p>",
"   </div>",
"   <div class=\"block mop drugH1Div\" id=\"F131714\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Monitoring Parameters",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     CBC, serum uric acid levels, I &amp; O, hepatic and renal function, especially at start of therapy; signs and symptoms of hypersensitivity",
"    </p>",
"   </div>",
"   <div class=\"block rer drugH1Div\" id=\"F131717\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Reference Range",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Uric acid, serum: An increase occurs during childhood",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Adults:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Males: 3.4-7 mg/dL or slightly more",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Females: 2.4-6 mg/dL or slightly more",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Target: &le;6 mg/dL",
"    </p>",
"    <p style=\"text-indent:0em;margin-top:2em;text-align:justify;\">",
"     Values &gt;7 mg/dL are sometimes arbitrarily regarded as hyperuricemia, but there is no sharp line between normals on the one hand, and the serum uric acid of those with clinical gout. Normal ranges cannot be adjusted for purine ingestion, but high purine diet increases uric acid. Uric acid may be increased with body size, exercise, and stress.",
"    </p>",
"   </div>",
"   <div class=\"list fbnlist drugH1Div drugBrandNames\" id=\"F131730\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     International Brand Names",
"    </span>",
"    <ul>",
"     <li>",
"      Adenock (JP);",
"     </li>",
"     <li>",
"      AL (PH);",
"     </li>",
"     <li>",
"      Alinol (TH);",
"     </li>",
"     <li>",
"      Allo (CO);",
"     </li>",
"     <li>",
"      Allo-Puren (DE);",
"     </li>",
"     <li>",
"      Allogut (TR);",
"     </li>",
"     <li>",
"      Allohexal (NZ);",
"     </li>",
"     <li>",
"      Allopin (TH);",
"     </li>",
"     <li>",
"      Alloprim (PH);",
"     </li>",
"     <li>",
"      Allopur (CH, NO);",
"     </li>",
"     <li>",
"      Allopurinol-ratiopharm (LU);",
"     </li>",
"     <li>",
"      Alloric (TH);",
"     </li>",
"     <li>",
"      Alloril (IL);",
"     </li>",
"     <li>",
"      Allosig (AU);",
"     </li>",
"     <li>",
"      Allozym (JP);",
"     </li>",
"     <li>",
"      Allpargin (LU);",
"     </li>",
"     <li>",
"      Allurase (PH);",
"     </li>",
"     <li>",
"      Allurit (IT);",
"     </li>",
"     <li>",
"      Alopron (BB, BM, BS, GY, JM, SR, TT);",
"     </li>",
"     <li>",
"      Alopurinol (HR);",
"     </li>",
"     <li>",
"      Alositol (JP);",
"     </li>",
"     <li>",
"      Alpurase (PH);",
"     </li>",
"     <li>",
"      Alpuric (LU);",
"     </li>",
"     <li>",
"      Alpurin (PH);",
"     </li>",
"     <li>",
"      Alurin (BZ, GT);",
"     </li>",
"     <li>",
"      Aluron (VE);",
"     </li>",
"     <li>",
"      Anoprolin (JP);",
"     </li>",
"     <li>",
"      Anzief (JP);",
"     </li>",
"     <li>",
"      Aprinol (JP);",
"     </li>",
"     <li>",
"      Apronal (TH);",
"     </li>",
"     <li>",
"      Apurin (FI, GR, NL);",
"     </li>",
"     <li>",
"      Atisuril (MX);",
"     </li>",
"     <li>",
"      Benoxuric (ID);",
"     </li>",
"     <li>",
"      Bleminal (DE);",
"     </li>",
"     <li>",
"      Caplenal (GB);",
"     </li>",
"     <li>",
"      Cellidrin (DE);",
"     </li>",
"     <li>",
"      Clint (BF, BJ, CI, ET, GH, GM, GN, KE, LR, MA, ML, MR, MU, MW, NE, NG, SC, SD, SL, SN, TN, TW, TZ, UG, ZM, ZW);",
"     </li>",
"     <li>",
"      Etindrax (MX);",
"     </li>",
"     <li>",
"      Foligan (DE);",
"     </li>",
"     <li>",
"      Genozyl (MX);",
"     </li>",
"     <li>",
"      Gichtex (AT);",
"     </li>",
"     <li>",
"      Goutilex (TW);",
"     </li>",
"     <li>",
"      Hamarin (GB);",
"     </li>",
"     <li>",
"      Hexanurat (DK);",
"     </li>",
"     <li>",
"      Huma-Purol (HU);",
"     </li>",
"     <li>",
"      Isoric (ID);",
"     </li>",
"     <li>",
"      Ketanrift (JP);",
"     </li>",
"     <li>",
"      Ketobun-A (JP);",
"     </li>",
"     <li>",
"      Litinol (VE);",
"     </li>",
"     <li>",
"      Llanol (PH);",
"     </li>",
"     <li>",
"      Masaton (JP);",
"     </li>",
"     <li>",
"      Mephanol (AE, BF, BH, BJ, CH, CI, CY, EG, ET, GH, GM, GN, IQ, IR, JO, KE, KW, LB, LR, LY, MA, ML, MR, MU, MW, MY, NE, NG, OM, QA, SA, SC, SD, SL, SN, SY, TN, TZ, UG, YE, ZM, ZW);",
"     </li>",
"     <li>",
"      Milurit (BG, CZ, HN, HU);",
"     </li>",
"     <li>",
"      Miniplanor (JP);",
"     </li>",
"     <li>",
"      Neufan (JP);",
"     </li>",
"     <li>",
"      Nilapur (ID);",
"     </li>",
"     <li>",
"      Nipurol (VE);",
"     </li>",
"     <li>",
"      No-Uric (AE, BH, CY, EG, IQ, IR, JO, KW, LB, LY, OM, QA, SA, SY, YE);",
"     </li>",
"     <li>",
"      Nor-Purinol (NI, SV);",
"     </li>",
"     <li>",
"      Pritanol (ID);",
"     </li>",
"     <li>",
"      Progout (AU, HK, SG);",
"     </li>",
"     <li>",
"      Proxuric (ID);",
"     </li>",
"     <li>",
"      Puribel 300 (MX);",
"     </li>",
"     <li>",
"      Puricemia (ID);",
"     </li>",
"     <li>",
"      Puricos (ZA);",
"     </li>",
"     <li>",
"      Purinol (MY, RU);",
"     </li>",
"     <li>",
"      Remid (DE);",
"     </li>",
"     <li>",
"      Riball (JP);",
"     </li>",
"     <li>",
"      Ridonra (TW);",
"     </li>",
"     <li>",
"      Rinolic (ID);",
"     </li>",
"     <li>",
"      Ripunin (TW);",
"     </li>",
"     <li>",
"      Salterprim (ZA);",
"     </li>",
"     <li>",
"      Sinoric (ID);",
"     </li>",
"     <li>",
"      Takanarumin (JP);",
"     </li>",
"     <li>",
"      Tylonic (ID);",
"     </li>",
"     <li>",
"      Unizuric 300 (MX);",
"     </li>",
"     <li>",
"      Uric (JP);",
"     </li>",
"     <li>",
"      Uricad (TH);",
"     </li>",
"     <li>",
"      Uriconorm (CH);",
"     </li>",
"     <li>",
"      Urinol (MY);",
"     </li>",
"     <li>",
"      Urocuad (CO);",
"     </li>",
"     <li>",
"      Urogquad (AR);",
"     </li>",
"     <li>",
"      Uroquad (BB, BF, BJ, BM, BS, CI, ET, GH, GM, GN, GY, JM, KE, LR, MA, ML, MR, MU, MW, NE, NG, SC, SD, SL, SN, SR, TN, TT, TZ, UG, ZM, ZW);",
"     </li>",
"     <li>",
"      Urosin (AT, DE, EC, LU);",
"     </li>",
"     <li>",
"      Valeric (CL);",
"     </li>",
"     <li>",
"      Xandase (TH);",
"     </li>",
"     <li>",
"      Xanol (TH);",
"     </li>",
"     <li>",
"      Xanurace (PH);",
"     </li>",
"     <li>",
"      Zylapour (GR);",
"     </li>",
"     <li>",
"      Zyloprim (AU, BB, BM, BS, CR, DO, GY, JM, MX, PA, PH, PR, PY, SR, TT);",
"     </li>",
"     <li>",
"      Zyloric (AE, BE, BF, BH, BJ, BR, CH, CI, CN, CY, DE, EE, EG, ES, ET, FI, FR, GB, GH, GM, GN, ID, IE, IN, IQ, IR, IT, JO, KE, KP, KW, LB, LR, LU, LY, MA, ML, MR, MT, MU, MW, MY, NE, NG, NL, NO, OM, PK, PL, PT, QA, RU, SA, SC, SD, SE, SG, SK, SL, SN, SY, TH, TN, TZ, UG, UY, VE, YE, ZM, ZW);",
"     </li>",
"     <li>",
"      Zyngot (PE);",
"     </li>",
"     <li>",
"      Zyroric (KP)",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block pha drugH1Div\" id=\"F131704\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Mechanism of Action",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Allopurinol inhibits xanthine oxidase, the enzyme responsible for the conversion of hypoxanthine to xanthine to uric acid. Allopurinol is metabolized to oxypurinol which is also an inhibitor of xanthine oxidase; allopurinol acts on purine catabolism, reducing the production of uric acid without disrupting the biosynthesis of vital purines.",
"    </p>",
"   </div>",
"   <div class=\"block phk drugH1Div\" id=\"F131724\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacodynamics/Kinetics",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Onset of action: Peak effect: 1-2 weeks",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Absorption: Oral: ~80%; Rectal: Poor and erratic",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Distribution: V",
"     <sub>",
"      d",
"     </sub>",
"     : ~1.6 L/kg; V",
"     <sub>",
"      ss",
"     </sub>",
"     : 0.84-0.87 L/kg; enters breast milk",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Protein binding: &lt;1%",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Metabolism: ~75% to active metabolites, chiefly oxypurinol",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Bioavailability: 49% to 53%",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Half-life elimination:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Normal renal function: Parent drug: 1-3 hours; Oxypurinol: 18-30 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     End-stage renal disease: Prolonged",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Time to peak, plasma: Oral: 30-120 minutes",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Excretion: Urine (76% as oxypurinol, 12% as unchanged drug)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Allopurinol and oxypurinol are dialyzable",
"    </p>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <div class=\"reference\">",
"      Allen LV and Erickson MA 3d, &ldquo;Stability of Acetazolamide, Allopurinol, Azathioprine, Clonazepam, and Flucytosine in Extemporaneously Compounded Oral Liquids,&rdquo;",
"      <i>",
"       Am J Health Syst Pharm",
"      </i>",
"      , 1996, 53(16):1944-9.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?24/40/25223/abstract-text/8862208/pubmed\" id=\"8862208\" target=\"_blank\">",
"        8862208",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      American Academy of Pediatrics Committee on Drugs, \"Transfer of Drugs and Other Chemicals Into Human Milk,\"",
"      <i>",
"       Pediatrics",
"      </i>",
"      , 2001, 108(3):776-89.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?24/40/25223/abstract-text/11533352/pubmed\" id=\"11533352\" target=\"_blank\">",
"        11533352",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Appelbaum SJ, Mayersohn M, Dorr RT, et al, &ldquo;Allopurinol Kinetics and Bioavailability. Intravenous, Oral and Rectal Administration,&rdquo;",
"      <i>",
"       Cancer Chemother Pharmacol",
"      </i>",
"      , 1982, 8(1):93-8.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?24/40/25223/abstract-text/7094203/pubmed\" id=\"7094203\" target=\"_blank\">",
"        7094203",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Coiffier B, Altman A, Pui CH, et al, &ldquo;Guidelines for the Management of Pediatric and Adult Tumor Lysis Syndrome: An Evidence-Based Review,&rdquo;",
"      <i>",
"       J Clin Oncol",
"      </i>",
"      , 2008, 26(16):2767-78.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?24/40/25223/abstract-text/18509186/pubmed\" id=\"18509186\" target=\"_blank\">",
"        18509186",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Dalbeth N and Stamp L, &ldquo;Allopurinol Dosing in Renal Impairment: Walking the Tightrope Between Adequate Urate Lowering and Adverse Events,&rdquo;",
"      <i>",
"       Semin Dial",
"      </i>",
"      , 2007, 20(5):391-5.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?24/40/25223/abstract-text/17897242/pubmed\" id=\"17897242\" target=\"_blank\">",
"        17897242",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Day RO, Graham GG, Hicks M, et al, &ldquo;Clinical Pharmacokinetics and Pharmacodynamics of Allopurinol and Oxypurinol,&rdquo;",
"      <i>",
"       Clin Pharmacokinet",
"      </i>",
"      , 2007, 46(8):623-44.",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Elasy T, Kaminsky D, Tracy M, et al, &ldquo;Allopurinol Hypersensitivity Syndrome Revisited,&rdquo;",
"      <i>",
"       West J Med",
"      </i>",
"      , 1995, 162(4):360-1.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?24/40/25223/abstract-text/7747507/pubmed\" id=\"7747507\" target=\"_blank\">",
"        7747507",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      El-Zawawy H and Mandell BF, &ldquo;Managing Gout: How is it Different in Patients With Chronic Kidney Disease?&rdquo;",
"      <i>",
"       Cleve Clin J Med",
"      </i>",
"      , 2010, 77(12):919-28.",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Emmerson BT, &ldquo;The Management of Gout,&rdquo;",
"      <i>",
"       N Engl J Med",
"      </i>",
"      , 1996, 334(7):445-51.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?24/40/25223/abstract-text/8552148/pubmed\" id=\"8552148\" target=\"_blank\">",
"        8552148",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Fravel MA and Ernst ME, &ldquo;Management of Gout in the Older Adult,&rdquo;",
"      <i>",
"       Am J Geriatr Pharmacother",
"      </i>",
"      , 2011, 9(5):271-85.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?24/40/25223/abstract-text/21849262/pubmed\" id=\"21849262\" target=\"_blank\">",
"        21849262",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Gahart BL and Nazareno AR,",
"      <i>",
"       2012 Intravenous Medications: A Handbook for Nurses and Health Professionals",
"      </i>",
"      , 28th ed, St Louis, MO: Elsevier/Mosby, 2012, 58-9.",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Hande KR, Noone RM, and Stone WJ, &ldquo;Severe Allopurinol Toxicity,&rdquo;",
"      <i>",
"       Am J Med",
"      </i>",
"      , 1984, 76(1):47-56.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?24/40/25223/abstract-text/6691361/pubmed\" id=\"6691361\" target=\"_blank\">",
"        6691361",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      McGill NW, &ldquo;Management of Gout: Beyond Allopurinol,&rdquo;",
"      <i>",
"       Int Med J",
"      </i>",
"      , 2010, 40(8):545-53.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?24/40/25223/abstract-text/20561096/pubmed\" id=\"20561096\" target=\"_blank\">",
"        20561096",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Murrell GA and Rapeport WG, &ldquo;Clinical Pharmacokinetics of Allopurinol,&rdquo;",
"      <i>",
"       Clin Pharmacokinet",
"      </i>",
"      , 1986, 11(5):343-53.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?24/40/25223/abstract-text/3536254/pubmed\" id=\"3536254\" target=\"_blank\">",
"        3536254",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Parra E, Gota R, Gamen A, et al, &ldquo;Granulomatous Interstitial Nephritis Secondary to Allopurinol Treatment,&rdquo;",
"      <i>",
"       Clin Nephrol",
"      </i>",
"      , 1995, 43(5):350.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?24/40/25223/abstract-text/7634557/pubmed\" id=\"7634557\" target=\"_blank\">",
"        7634557",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Stamp LK, O&rsquo;Donnell JL, Zhang M, et al, &ldquo;Using Allopurinol Above the Dose Based on Creatinine Clearance Is Effective and Safe in Patients With Chronic gout, Including Those With Renal Impairment,&rdquo;",
"      <i>",
"       Arthritis Rheum",
"      </i>",
"      , 2011, 63(2):412-21.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?24/40/25223/abstract-text/21279998/pubmed\" id=\"21279998\" target=\"_blank\">",
"        21279998",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Zhang W, Doherty M, Bardin T, et al, &ldquo;EULAR Evidence Based Recommendations for Gout. Part II: Management. Report of a Task Force of the EULAR Standing Committee for International Clinical Studies Including Therapeutics (ESCISIT),&rdquo;",
"      <i>",
"       Ann Rheum Dis",
"      </i>",
"      , 2006, 65(10):1312-24.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?24/40/25223/abstract-text/16707532/pubmed\" id=\"16707532\" target=\"_blank\">",
"        16707532",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 8439 Version 43.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1105-83.177.194.223-D60132E406-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f24_40_25223=[""].join("\n");
var outline_f24_40_25223=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F131745\">",
"      Brand Names: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F131746\">",
"      Brand Names: Canada",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F131796\">",
"      Pharmacologic Category",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F131750\">",
"      Dosing: Adult",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F131774\">",
"      Dosing: Pediatric",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F131751\">",
"      Dosing: Geriatric",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F131752\">",
"      Dosing: Renal Impairment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F131716\">",
"      Dosage Forms: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F131701\">",
"      Generic Equivalent Available: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F131721\">",
"      Administration",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F131802\">",
"      Compatibility",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F131720\">",
"      Use",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F131804\">",
"      Medication Safety Issues",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F131794\">",
"      Adverse Reactions Significant",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F131725\">",
"      Contraindications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F131705\">",
"      Warnings/Precautions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13298712\">",
"      Metabolism/Transport Effects",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F131710\">",
"      Drug Interactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F131742\">",
"      Ethanol/Nutrition/Herb Interactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F131712\">",
"      Pregnancy Risk Factor",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F131728\">",
"      Pregnancy Implications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F131759\">",
"      Lactation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F131729\">",
"      Dietary Considerations",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F131727\">",
"      Pricing: U.S. (Medi-Span&reg;)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F131714\">",
"      Monitoring Parameters",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F131717\">",
"      Reference Range",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F131730\">",
"      International Brand Names",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F131704\">",
"      Mechanism of Action",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F131724\">",
"      Pharmacodynamics/Kinetics",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"DRUG_GEN/8439\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"DRUG_GEN/8439|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\" title=\"Lexicomp clinical abbreviations\">",
"      Lexicomp clinical abbreviations",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_patient\" href=\"UTD.htm?2/14/2277?source=related_link\">",
"      Allopurinol: Patient drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_pediatric\" href=\"UTD.htm?24/3/24629?source=related_link\">",
"      Allopurinol: Pediatric drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f24_40_25224="Renin-angiotensin system inhibition in the treatment of hypertension";
var content_f24_40_25224=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"0\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Renin-angiotensin system inhibition in the treatment of hypertension",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?24/40/25224/contributors\">",
"     Authors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?24/40/25224/contributors\">",
"     Johannes FE Mann, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?24/40/25224/contributors\">",
"     Karl F Hilgers, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?24/40/25224/contributors\">",
"     Section Editors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?24/40/25224/contributors\">",
"     George L Bakris, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?24/40/25224/contributors\">",
"     Norman M Kaplan, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?24/40/25224/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?24/40/25224/contributors\">",
"     John P Forman, MD, MSc",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?24/40/25224/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Sep 5, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Inhibitors of the renin-angiotensin system (RAS), including angiotensin-converting enzyme (ACE) inhibitors, angiotensin II receptor blockers (ARBs), and direct renin inhibitors are commonly used in the treatment of hypertension. The role of the RAS in hypertension and the use of specific inhibitors of this system to treat hypertension will be reviewed here.",
"   </p>",
"   <p>",
"    The use of RAS inhibitors in patients with kidney disease and diabetes are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?35/29/36314?source=see_link\">",
"     \"Choice of therapy in primary (essential) hypertension: Recommendations\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?40/10/41130?source=see_link\">",
"     \"Antihypertensive therapy and progression of nondiabetic chronic kidney disease in adults\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?20/45/21210?source=see_link\">",
"     \"Treatment of hypertension in patients with diabetes mellitus\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?39/48/40714?source=see_link\">",
"     \"Treatment of diabetic nephropathy\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The importance of local (ie, tissue) RAS activity in low renin hypertension and the effects of angiotensin II on the heart are presented elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?35/60/36804?source=see_link\">",
"     \"Low-renin essential (primary) hypertension\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?35/61/36825?source=see_link\">",
"     \"Actions of angiotensin II on the heart\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h1\">",
"     ANGIOTENSIN-CONVERTING ENZYME INHIBITORS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Since the introduction of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?8/59/9145?source=see_link\">",
"     captopril",
"    </a>",
"    in 1977 [",
"    <a class=\"abstract\" href=\"UTD.htm?24/40/25224/abstract/1\">",
"     1",
"    </a>",
"    ], angiotensin-converting enzyme (ACE) inhibitors have become widely used for the treatment of hypertension and three of its major complications: acute myocardial infarction [",
"    <a class=\"abstract\" href=\"UTD.htm?24/40/25224/abstract/2\">",
"     2",
"    </a>",
"    ], congestive heart failure [",
"    <a class=\"abstract\" href=\"UTD.htm?24/40/25224/abstract/3\">",
"     3",
"    </a>",
"    ], and chronic kidney disease. Fifty to 60 percent of Caucasian patients have a good response to monotherapy with ACE inhibitors, a response rate similar to other first-line antihypertensive drugs [",
"    <a class=\"abstract\" href=\"UTD.htm?24/40/25224/abstract/4\">",
"     4",
"    </a>",
"    ]. ACE inhibitors have the additional advantages of having a more favorable side effect profile than sympathetic blockers, beta blockers, and diuretics [",
"    <a class=\"abstract\" href=\"UTD.htm?24/40/25224/abstract/5\">",
"     5",
"    </a>",
"    ], and of producing more regression of left ventricular hypertrophy than beta blockers [",
"    <a class=\"abstract\" href=\"UTD.htm?24/40/25224/abstract/6\">",
"     6",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?17/34/17959?source=see_link&amp;anchor=H5#H5\">",
"     \"Clinical implications and treatment of left ventricular hypertrophy in hypertension\", section on 'Choice of drugs'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Guidelines issued in 2009 by the European Society of Hypertension [",
"    <a class=\"abstract\" href=\"UTD.htm?24/40/25224/abstract/7\">",
"     7",
"    </a>",
"    ], and in 2011 by NICE (National Institute for Health and Clinical Excellence of Great Britain) [",
"    <a class=\"abstract\" href=\"UTD.htm?24/40/25224/abstract/8\">",
"     8",
"    </a>",
"    ], recommend the use of an ACE inhibitor or ARB in younger and non-black patients [",
"    <a class=\"abstract\" href=\"UTD.htm?24/40/25224/abstract/9\">",
"     9",
"    </a>",
"    ]. However, this recommendation is based upon relatively small cross-over trials [",
"    <a class=\"abstract\" href=\"UTD.htm?24/40/25224/abstract/10\">",
"     10",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h2\">",
"     Specific indications for use",
"    </span>",
"    &nbsp;&mdash;&nbsp;There are a number of settings in which ACE inhibitors are the antihypertensive drugs of choice because of possible benefits in addition to lowering the blood pressure. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?35/29/36314?source=see_link&amp;anchor=H17#H17\">",
"     \"Choice of therapy in primary (essential) hypertension: Recommendations\", section on 'Indications for specific drugs'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    These include:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Heart failure due to systolic dysfunction [",
"      <a class=\"abstract\" href=\"UTD.htm?24/40/25224/abstract/3\">",
"       3",
"      </a>",
"      ]. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?15/45/16090?source=see_link\">",
"       \"ACE inhibitors in heart failure due to systolic dysfunction: Therapeutic use\"",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?12/38/12905?source=see_link\">",
"       \"Use of beta blockers in heart failure due to systolic dysfunction\"",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?3/55/3962?source=see_link\">",
"       \"Use of diuretics in patients with heart failure\"",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?27/54/28521?source=see_link\">",
"       \"Use of aldosterone antagonists in heart failure\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Proteinuric chronic kidney disease, both diabetic and nondiabetic [",
"      <a class=\"abstract\" href=\"UTD.htm?24/40/25224/abstract/11\">",
"       11",
"      </a>",
"      ]. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?40/10/41130?source=see_link\">",
"       \"Antihypertensive therapy and progression of nondiabetic chronic kidney disease in adults\"",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?41/49/42777?source=see_link\">",
"       \"Microalbuminuria in type 1 diabetes mellitus\"",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?38/33/39449?source=see_link\">",
"       \"Microalbuminuria in type 2 diabetes mellitus\"",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?20/45/21210?source=see_link\">",
"       \"Treatment of hypertension in patients with diabetes mellitus\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      After a myocardial infarction in most patients, particularly those with heart failure or reduced systolic function [",
"      <a class=\"abstract\" href=\"UTD.htm?24/40/25224/abstract/2\">",
"       2",
"      </a>",
"      ]. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?12/55/13175?source=see_link\">",
"       \"Angiotensin converting enzyme inhibitors and receptor blockers in acute myocardial infarction: Recommendations for use\"",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h2\">",
"     Antihypertensive response",
"    </span>",
"    &nbsp;&mdash;&nbsp;The decline in blood pressure seen with ACE inhibitors appears to be primarily due to decreased formation of angiotensin II, but decreased degradation of kinins could contribute by both direct vasodilation and increasing the production of vasodilator prostaglandins [",
"    <a class=\"abstract\" href=\"UTD.htm?24/40/25224/abstract/12\">",
"     12",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Black patients may be less sensitive than white patients to ACE inhibitors as monotherapy for hypertension (",
"    <a class=\"graphic graphic_figure graphicRef65117 \" href=\"UTD.htm?37/22/38253\">",
"     figure 1",
"    </a>",
"    )&nbsp;[",
"    <a class=\"abstract\" href=\"UTD.htm?24/40/25224/abstract/13\">",
"     13",
"    </a>",
"    ]. Although ACE inhibitors are relatively ineffective as monotherapy in blacks, the addition of even a low dose of a thiazide diuretic to an ACE inhibitor leads to a fall in BP that is comparable to that seen in white patients [",
"    <a class=\"abstract\" href=\"UTD.htm?24/40/25224/abstract/14\">",
"     14",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?15/14/15592?source=see_link\">",
"     \"Treatment of hypertension in blacks\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The utility of ACE inhibitors with diuretics is not limited to black patients, since these drugs have a synergistic effect, attaining goal BP in up to 85 percent of patients with mild hypertension [",
"    <a class=\"abstract\" href=\"UTD.htm?24/40/25224/abstract/14\">",
"     14",
"    </a>",
"    ]. The antihypertensive response to diuretics is often limited by the hypovolemia-induced increase in renin release and subsequent angiotensin II production [",
"    <a class=\"abstract\" href=\"UTD.htm?24/40/25224/abstract/15\">",
"     15",
"    </a>",
"    ]; this effect is prevented by converting enzyme inhibition, leading to a more prominent reduction in BP. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?14/63/15350?source=see_link\">",
"     \"Use of thiazide diuretics in patients with primary hypertension\"",
"    </a>",
"    .) For similar reasons, dietary sodium restriction can also enhance the response to an ACE inhibitor [",
"    <a class=\"abstract\" href=\"UTD.htm?24/40/25224/abstract/16\">",
"     16",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?23/35/24120?source=see_link&amp;anchor=H12#H12\">",
"     \"Salt intake, salt restriction, and essential hypertension\", section on 'Response to antihypertensive drugs'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    ACE inhibitors minimize some of the metabolic changes induced by diuretic therapy. Hypokalemia, for example, is less prominent because the reduction in angiotensin II formation induced by the ACE inhibitor leads to decreased secretion of aldosterone. ACE inhibitors also do not induce glucose intolerance, hyperlipidemia, or hyperuricemia, may increase insulin sensitivity, and may minimize or prevent diuretic-induced elevations in serum glucose, cholesterol and uric acid levels [",
"    <a class=\"abstract\" href=\"UTD.htm?24/40/25224/abstract/17\">",
"     17",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Apart from diuretics, calcium channel blockers can be used effectively with ACE inhibitors, and, as shown in the ACCOMPLISH trial, may have clinical advantages over diuretics when achieved blood pressure is similar. Combination of an ACE inhibitor with a beta blocker may be less useful because of inferior antihypertensive activity compared with other ACE inhibitor combinations [",
"    <a class=\"abstract\" href=\"UTD.htm?24/40/25224/abstract/18\">",
"     18",
"    </a>",
"    ]. This relative lack of efficacy may be due in part to similar mechanisms of action, as angiotensin II formation and renin secretion are respectively reduced. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?35/29/36314?source=see_link&amp;anchor=H9#H9\">",
"     \"Choice of therapy in primary (essential) hypertension: Recommendations\", section on 'ACCOMPLISH trial'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h2\">",
"     Dosage",
"    </span>",
"    &nbsp;&mdash;&nbsp;As with other antihypertensive agents, proper dosage can minimize the incidence of side effects (",
"    <a class=\"graphic graphic_table graphicRef64770 \" href=\"UTD.htm?40/63/41981\">",
"     table 1",
"    </a>",
"    ). To minimize the risk of first dose hypotension due to an abrupt decline in angiotensin II levels, the patient should not be volume depleted. The initial dose can be reduced by one-half in elderly patients or those with heart failure who are at higher risk for hypotension. Side effects other than those related to hypotension can occur with ACE inhibitors, the most common being cough [",
"    <a class=\"abstract\" href=\"UTD.htm?24/40/25224/abstract/19\">",
"     19",
"    </a>",
"    ], less commonly hyperkalemia, and rarely angioedema [",
"    <a class=\"abstract\" href=\"UTD.htm?24/40/25224/abstract/20\">",
"     20",
"    </a>",
"    ]. ACE inhibitors are",
"    <strong>",
"     contraindicated",
"    </strong>",
"    during pregnancy [",
"    <a class=\"abstract\" href=\"UTD.htm?24/40/25224/abstract/21\">",
"     21",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?18/2/18473?source=see_link\">",
"     \"Major side effects of angiotensin converting enzyme inhibitors and angiotensin II receptor blockers\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The duration of action varies with different ACE inhibitors. Some ACE inhibitors can be given once daily (eg,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?12/41/12952?source=see_link\">",
"     trandolapril",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?0/58/937?source=see_link\">",
"     lisinopril",
"    </a>",
"    , and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?16/19/16696?source=see_link\">",
"     benazepril",
"    </a>",
"    ). The use of longer-acting agents once daily should improve patient compliance, reduce costs, maintain smoother control, and ensure that the abrupt rise in pressure upon awakening in the early morning is blunted, hopefully thereby reducing the incidence of serious cardiovascular events at this time.",
"   </p>",
"   <p>",
"    After the initiation of therapy, the patient should be reexamined in a few weeks to allow the full antihypertensive effect to occur. If there is no or little fall in blood pressure with an adequate dose, the drug can be stopped and different class of drug started, a concept called \"sequential monotherapy\". Alternatively, another drug may be added, such as a calcium channel blocker. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?35/29/36314?source=see_link&amp;anchor=H15#H15\">",
"     \"Choice of therapy in primary (essential) hypertension: Recommendations\", section on 'Sequential monotherapy'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    If the patient's blood pressure is reduced by the ACE inhibitor but the goal pressure is not achieved, the dose can be gradually increased to the maximum levels noted in the table (",
"    <a class=\"graphic graphic_table graphicRef64770 \" href=\"UTD.htm?40/63/41981\">",
"     table 1",
"    </a>",
"    ). However, the addition of a second drug from a different class will provide much greater antihypertensive effect [",
"    <a class=\"abstract\" href=\"UTD.htm?24/40/25224/abstract/22\">",
"     22",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    In patients with extensive atherosclerosis or renal insufficiency who are more likely to have renovascular stenoses, a repeat plasma creatinine concentration should be obtained within one to two weeks to ensure that renal perfusion has been maintained. However, a modest and non-progressive increase in the plasma creatinine in such patients should",
"    <strong>",
"     not",
"    </strong>",
"    prompt discontinuation of therapy. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?18/60/19398?source=see_link&amp;anchor=H5#H5\">",
"     \"Renal effects of ACE inhibitors in hypertension\", section on 'Renovascular hypertension'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h1\">",
"     ANGIOTENSIN II RECEPTOR BLOCKERS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Angiotensin II receptor blockers (ARBs) interfere with the renin-angiotensin system by impairing the binding of angiotensin II to the AT1 receptor on the cell membrane, thereby inhibiting the action of angiotensin II [",
"    <a class=\"abstract\" href=\"UTD.htm?24/40/25224/abstract/23\">",
"     23",
"    </a>",
"    ]. Blockade of the action of angiotensin II leads to elevations in plasma levels of renin, angiotensin I, and angiotensin II. However, this build-up of precursors does not overwhelm the receptor blockade, as evidenced by a persistent fall in both blood pressure and plasma aldosterone levels [",
"    <a class=\"abstract\" href=\"UTD.htm?24/40/25224/abstract/24\">",
"     24",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h2\">",
"     Differences between ACE inhibitors and ARBs",
"    </span>",
"    &nbsp;&mdash;&nbsp;There are substantial pharmacological differences in the actions of ACE inhibitors and ARBs but few clinical differences have been documented. At least three factors may contribute to the pharmacological differences (",
"    <a class=\"graphic graphic_figure graphicRef55726 \" href=\"UTD.htm?9/23/9597\">",
"     figure 2",
"    </a>",
"    ):",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Angiotensin-converting enzyme is a",
"      <strong>",
"       kininase",
"      </strong>",
"      . Thus, inhibiting this enzyme, which normally degrades bradykinin, with an ACE inhibitor leads to increased kinin levels, an effect not seen with an ARB. This is likely responsible for the cough that may be seen with ACE inhibitors (but not with ARBs), although high bradykinin levels may also provide additional vasodilation and other benefits not observed with ARBs.",
"     </li>",
"     <li>",
"      By decreasing angiotensin II production, ACE inhibitors reduce the effect of both AT1 and AT2 receptors; only the former are inhibited by the ARBs.",
"     </li>",
"     <li>",
"      In the heart, kidney, and perhaps the blood vessels, the production of angiotensin II may be catalyzed by enzymes other than angiotensin-converting enzyme, such as chymase [",
"      <a class=\"abstract\" href=\"UTD.htm?24/40/25224/abstract/25\">",
"       25",
"      </a>",
"      ]. The effect of the angiotensin II produced by this reaction can be inhibited by the ARBs but not by ACE inhibitors.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h2\">",
"     Efficacy and dose",
"    </span>",
"    &nbsp;&mdash;&nbsp;The ARBs have an effect similar to that seen with monotherapy with other antihypertensive drugs (",
"    <a class=\"graphic graphic_table graphicRef64770 \" href=\"UTD.htm?40/63/41981\">",
"     table 1",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?24/40/25224/abstract/26\">",
"     26",
"    </a>",
"    ]. However, several studies have shown that",
"    <a class=\"drug drug_general\" href=\"UTD.htm?25/35/26168?source=see_link\">",
"     losartan",
"    </a>",
"    , when given once daily, does not control blood pressure to the same magnitude as other ARBs (",
"    <a class=\"drug drug_general\" href=\"UTD.htm?20/37/21079?source=see_link\">",
"     irbesartan",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?26/38/27239?source=see_link\">",
"     telmisartan",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?37/48/38663?source=see_link\">",
"     candesartan",
"    </a>",
"    , and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?31/4/31815?source=see_link\">",
"     valsartan",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?24/40/25224/abstract/27-30\">",
"     27-30",
"    </a>",
"    ]. On the other hand, losartan produces a slight fall in plasma uric acid that does not occur with the other ARBs, an effect that is due to enhanced uric acid excretion [",
"    <a class=\"abstract\" href=\"UTD.htm?24/40/25224/abstract/31\">",
"     31",
"    </a>",
"    ]. This appears to be mediated at least in part by direct inhibition of the proximal urate-anion exchanger that is responsible for urate reabsorption [",
"    <a class=\"abstract\" href=\"UTD.htm?24/40/25224/abstract/32\">",
"     32",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The antihypertensive efficacy of ARBs appears to be roughly equivalent to that of the ACE inhibitors. A meta-analysis of 61 studies that directly compared angiotensin II receptor blockers and ACE inhibitors reported no difference in the antihypertensive effects of these agents [",
"    <a class=\"abstract\" href=\"UTD.htm?24/40/25224/abstract/26\">",
"     26",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    In addition, the effects of ARBs and ACE inhibitors on cardiovascular events appear similar. The ONTARGET trial compared",
"    <a class=\"drug drug_general\" href=\"UTD.htm?26/38/27239?source=see_link\">",
"     telmisartan",
"    </a>",
"    (80",
"    <span class=\"nowrap\">",
"     mg/d),",
"    </span>",
"    <a class=\"drug drug_general\" href=\"UTD.htm?23/37/24152?source=see_link\">",
"     ramipril",
"    </a>",
"    (10",
"    <span class=\"nowrap\">",
"     mg/d),",
"    </span>",
"    and combination therapy (80 + 10",
"    <span class=\"nowrap\">",
"     mg/d)",
"    </span>",
"    with both agents in 25,620 patients with vascular disease or diabetes [",
"    <a class=\"abstract\" href=\"UTD.htm?24/40/25224/abstract/33\">",
"     33",
"    </a>",
"    ]. The primary outcome was death from cardiovascular causes, myocardial infarction, stroke, or hospitalization for heart failure. Achieved mean blood pressure was lower in patients who received telmisartan compared with ramipril (by",
"    <span class=\"nowrap\">",
"     0.9/0.6",
"    </span>",
"    mmHg) and in patients who received both agents compared with ramipril",
"    <span class=\"nowrap\">",
"     (2.4/1.4",
"    </span>",
"    mmHg). The cardiovascular outcomes were similar in all three groups, while cough was more common with ramipril and both hyperkalemia and acute kidney injury were more common with combined therapy. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?18/2/18473?source=see_link\">",
"     \"Major side effects of angiotensin converting enzyme inhibitors and angiotensin II receptor blockers\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    As with other agents that inhibit the renin angiotensin system, the efficacy of ARBs is enhanced by concomitant administration of low doses of a diuretic [",
"    <a class=\"abstract\" href=\"UTD.htm?24/40/25224/abstract/34\">",
"     34",
"    </a>",
"    ], and by a reduction in dietary sodium intake. As with ACE inhibitors, ARBs appear to minimize the hypokalemia and hyperuricemia induced by diuretic therapy [",
"    <a class=\"abstract\" href=\"UTD.htm?24/40/25224/abstract/34\">",
"     34",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?23/35/24120?source=see_link&amp;anchor=H12#H12\">",
"     \"Salt intake, salt restriction, and essential hypertension\", section on 'Response to antihypertensive drugs'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h1\">",
"     SIDE EFFECTS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Both ACE inhibitors and ARBs are generally well tolerated. Cough and angioedema are less common with ARBs [",
"    <a class=\"abstract\" href=\"UTD.htm?24/40/25224/abstract/33\">",
"     33",
"    </a>",
"    ]. Both ACE inhibitors and ARBs are contraindicated in pregnancy. These issues are discussed in detail separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?18/2/18473?source=see_link\">",
"     \"Major side effects of angiotensin converting enzyme inhibitors and angiotensin II receptor blockers\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?1/32/1543?source=see_link\">",
"     \"Angiotensin converting enzyme inhibitors and receptor blockers in pregnancy\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h2\">",
"     ACE inhibitors plus ARBs",
"    </span>",
"    &nbsp;&mdash;&nbsp;A separate issue is the side effects associated with combined ACE",
"    <span class=\"nowrap\">",
"     inhibitor/ARB",
"    </span>",
"    therapy compared with either drug alone. The ONTARGET trial cited above of high risk patients [",
"    <a class=\"abstract\" href=\"UTD.htm?24/40/25224/abstract/33,35\">",
"     33,35",
"    </a>",
"    ] found a significant increase in adverse effects (including a possible increase in mortality) with combined therapy compared with an ACE inhibitor alone. As a result, combined therapy is",
"    <strong>",
"     not",
"    </strong>",
"    recommended for the treatment of hypertension.",
"   </p>",
"   <p>",
"    The data supporting adverse effects and the possible role of combined therapy to slow progression in patients with proteinuric chronic kidney disease are discussed elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?18/2/18473?source=see_link&amp;anchor=H18#H18\">",
"     \"Major side effects of angiotensin converting enzyme inhibitors and angiotensin II receptor blockers\", section on 'Combination of ACE inhibitors and ARBs'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?40/10/41130?source=see_link&amp;anchor=H21#H21\">",
"     \"Antihypertensive therapy and progression of nondiabetic chronic kidney disease in adults\", section on 'Combination of ACE inhibitors and ARBs'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h1\">",
"     DIRECT RENIN INHIBITORS",
"    </span>",
"    &nbsp;&mdash;&nbsp;The first effective oral direct renin inhibitor,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?8/59/9142?source=see_link\">",
"     aliskiren",
"    </a>",
"    , became available in the United States in March 2007. Aliskiren lowers blood pressure to a degree comparable to most other agents [",
"    <a class=\"abstract\" href=\"UTD.htm?24/40/25224/abstract/36\">",
"     36",
"    </a>",
"    ]. A number of studies have evaluated the blood pressure lowering effect of aliskiren in combination with other antihypertensive drugs [",
"    <a class=\"abstract\" href=\"UTD.htm?24/40/25224/abstract/36-39\">",
"     36-39",
"    </a>",
"    ]. In one report, the combination of maximum doses of aliskiren and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?31/4/31815?source=see_link\">",
"     valsartan",
"    </a>",
"    decreased blood pressure more than maximum doses of either agent alone but not more than would be expected with dual therapy using drugs from different classes [",
"    <a class=\"abstract\" href=\"UTD.htm?24/40/25224/abstract/40\">",
"     40",
"    </a>",
"    ]. Aliskiren, as with other inhibitors of the renin-angiotensin system, should",
"    <strong>",
"     not",
"    </strong>",
"    be used in pregnancy.",
"   </p>",
"   <p>",
"    In the AVOID trial,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?8/59/9142?source=see_link\">",
"     aliskiren",
"    </a>",
"    plus",
"    <a class=\"drug drug_general\" href=\"UTD.htm?25/35/26168?source=see_link\">",
"     losartan",
"    </a>",
"    was associated with a significant 20 percent greater reduction in proteinuria compared with losartan alone in patients with type 2 diabetes and nephropathy, in the absence of a significantly greater effect on blood pressure [",
"    <a class=\"abstract\" href=\"UTD.htm?24/40/25224/abstract/41\">",
"     41",
"    </a>",
"    ]. However, this effect on proteinuria did",
"    <strong>",
"     not",
"    </strong>",
"    translate into a clinical benefit. In the ALTITUDE trial, 8600 patients with type 2 diabetes and kidney disease already taking either an ACE inhibitor or ARB were randomly assigned to additional therapy with aliskiren or placebo [",
"    <a class=\"abstract\" href=\"UTD.htm?24/40/25224/abstract/42\">",
"     42",
"    </a>",
"    ]. The ALTITUDE trial was stopped early because of futility (no benefit on the primary cardiovascular and renal outcomes) and because a preliminary analysis indicated that aliskiren therapy produced a higher rate of adverse events (ie, non-fatal stroke, hypotension, hyperkalemia) [",
"    <a class=\"abstract\" href=\"UTD.htm?24/40/25224/abstract/43\">",
"     43",
"    </a>",
"    ]. An increased risk of hyperkalemia when aliskiren is combined with ACE inhibitors or ARBs has also been described in other studies [",
"    <a class=\"abstract\" href=\"UTD.htm?24/40/25224/abstract/44\">",
"     44",
"    </a>",
"    ]. Thus, aliskiren should",
"    <strong>",
"     not",
"    </strong>",
"    be combined with ACE inhibitors or ARBs.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H983513\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Inhibitors of the renin-angiotensin system, including angiotensin-converting enzyme (ACE) inhibitors, angiotensin II receptor blockers (ARBs), and direct renin inhibitors are commonly used in the treatment of hypertension. (See",
"      <a class=\"local\" href=\"#H1\">",
"       'Introduction'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      There are a number of settings in which ACE inhibitors are the antihypertensive drugs of choice because of possible benefits in addition to lowering the blood pressure (see",
"      <a class=\"local\" href=\"#H4\">",
"       'Specific indications for use'",
"      </a>",
"      above):",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      Heart failure due to systolic dysfunction.",
"     </li>",
"     <li>",
"      Proteinuric chronic kidney disease, both diabetic and nondiabetic.",
"     </li>",
"     <li>",
"      After a myocardial infarction in most patients, particularly those with heart failure or reduced systolic function.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Proper dosage of ACE inhibitors can minimize the incidence of side effects (",
"      <a class=\"graphic graphic_table graphicRef64770 \" href=\"UTD.htm?40/63/41981\">",
"       table 1",
"      </a>",
"      ). The duration of action varies with different ACE inhibitors. Some ACE inhibitors can be given once daily (eg,",
"      <a class=\"drug drug_general\" href=\"UTD.htm?12/41/12952?source=see_link\">",
"       trandolapril",
"      </a>",
"      ,",
"      <a class=\"drug drug_general\" href=\"UTD.htm?0/58/937?source=see_link\">",
"       lisinopril",
"      </a>",
"      , and",
"      <a class=\"drug drug_general\" href=\"UTD.htm?16/19/16696?source=see_link\">",
"       benazepril",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H6\">",
"       'Dosage'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      There are pharmacological differences in the actions of ACE inhibitors and ARBs. Except for the cough associated with ACE inhibitors, these pharmacological differences are not associated with clinically meaningful differences in therapeutic effects. At least three factors may contribute to the pharmacological differences (",
"      <a class=\"graphic graphic_figure graphicRef55726 \" href=\"UTD.htm?9/23/9597\">",
"       figure 2",
"      </a>",
"      ) (see",
"      <a class=\"local\" href=\"#H9\">",
"       'Differences between ACE inhibitors and ARBs'",
"      </a>",
"      above):",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      Angiotensin-converting enzyme is a",
"      <strong>",
"       kininase",
"      </strong>",
"      . Thus, inhibiting this enzyme, which normally degrades bradykinin, with an ACE inhibitor leads to increased kinin levels, an effect not seen with an ARB. This is likely responsible for the cough that may be seen with ACE inhibitors (but not with ARBs), although high bradykinin levels may also provide additional vasodilation and other benefits not observed with ARBs.",
"     </li>",
"     <li>",
"      By decreasing angiotensin II production, ACE inhibitors reduce the effect of both AT1 and AT2 receptors; only the former are inhibited by the ARBs.",
"     </li>",
"     <li>",
"      In the heart, kidney, and perhaps the blood vessels, the production of angiotensin II may be catalyzed by enzymes other than angiotensin-converting enzyme, such as chymase. The effect of the angiotensin II produced by this reaction can be inhibited by the ARBs but not by ACE inhibitors.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      The ARBs have an effect similar to that seen with monotherapy with other antihypertensive drugs, including ACE inhibitors (",
"      <a class=\"graphic graphic_table graphicRef64770 \" href=\"UTD.htm?40/63/41981\">",
"       table 1",
"      </a>",
"      ).",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      The antihypertensive effect of both ACE inhibitors and ARBs is enhanced by concomitant administration of low doses of a diuretic, and by a reduction in dietary sodium intake. Both drugs also appear to minimize the hypokalemia and hyperuricemia induced by diuretic therapy. (See",
"      <a class=\"local\" href=\"#H6\">",
"       'Dosage'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H10\">",
"       'Efficacy and dose'",
"      </a>",
"      above and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?23/35/24120?source=see_link&amp;anchor=H12#H12\">",
"       \"Salt intake, salt restriction, and essential hypertension\", section on 'Response to antihypertensive drugs'",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Both ACE inhibitors and ARBs are generally well tolerated. Side effects other than those related to hypotension can occur with both drugs, including hyperkalemia and rarely angioedema, as well as acute kidney injury in patients with low effective arterial blood volume (eg, diarrhea, vomiting, heart failure). Cough is a common side effect of ACE inhibitors. ACE inhibitors and ARBs are",
"      <strong>",
"       contraindicated",
"      </strong>",
"      during pregnancy. (See",
"      <a class=\"local\" href=\"#H11\">",
"       'Side effects'",
"      </a>",
"      above and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?18/2/18473?source=see_link\">",
"       \"Major side effects of angiotensin converting enzyme inhibitors and angiotensin II receptor blockers\"",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Combined therapy with both an ACE inhibitor and ARB is",
"      <strong>",
"       not",
"      </strong>",
"      recommended for the treatment of hypertension. (See",
"      <a class=\"local\" href=\"#H12\">",
"       'ACE inhibitors plus ARBs'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      The first effective oral direct renin inhibitor,",
"      <a class=\"drug drug_general\" href=\"UTD.htm?8/59/9142?source=see_link\">",
"       aliskiren",
"      </a>",
"      , lowers blood pressure to a degree comparable to most other agents. In combination with an ACE inhibitor or ARB, aliskiren increases the risk of adverse effects and does not lower the risk of cardiovascular event. Thus, aliskiren should",
"      <strong>",
"       not",
"      </strong>",
"      be combined with ACE inhibitors or ARBs. (See",
"      <a class=\"local\" href=\"#H13\">",
"       'Direct renin inhibitors'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/40/25224/abstract/1\">",
"      Ondetti MA, Rubin B, Cushman DW. Design of specific inhibitors of angiotensin-converting enzyme: new class of orally active antihypertensive agents. Science 1977; 196:441.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/40/25224/abstract/2\">",
"      Pfeffer MA, Braunwald E, Moy&eacute; LA, et al. Effect of captopril on mortality and morbidity in patients with left ventricular dysfunction after myocardial infarction. Results of the survival and ventricular enlargement trial. The SAVE Investigators. N Engl J Med 1992; 327:669.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/40/25224/abstract/3\">",
"      Effect of enalapril on survival in patients with reduced left ventricular ejection fractions and congestive heart failure. The SOLVD Investigators. N Engl J Med 1991; 325:293.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/40/25224/abstract/4\">",
"      Neaton JD, Grimm RH Jr, Prineas RJ, et al. Treatment of Mild Hypertension Study. Final results. Treatment of Mild Hypertension Study Research Group. JAMA 1993; 270:713.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/40/25224/abstract/5\">",
"      Croog SH, Levine S, Testa MA, et al. The effects of antihypertensive therapy on the quality of life. N Engl J Med 1986; 314:1657.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/40/25224/abstract/6\">",
"      Klingbeil AU, Schneider M, Martus P, et al. A meta-analysis of the effects of treatment on left ventricular mass in essential hypertension. Am J Med 2003; 115:41.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/40/25224/abstract/7\">",
"      Mancia G, Laurent S, Agabiti-Rosei E, et al. Reappraisal of European guidelines on hypertension management: a European Society of Hypertension Task Force document. J Hypertens 2009; 27:2121.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/40/25224/abstract/8\">",
"      Krause T, Lovibond K, Caulfield M, et al. Management of hypertension: summary of NICE guidance. BMJ 2011; 343:d4891.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/40/25224/abstract/9\">",
"      Mancia G, De Backer G, Dominiczak A, et al. 2007 ESH-ESC Practice Guidelines for the Management of Arterial Hypertension: ESH-ESC Task Force on the Management of Arterial Hypertension. J Hypertens 2007; 25:1751.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/40/25224/abstract/10\">",
"      Dickerson JE, Hingorani AD, Ashby MJ, et al. Optimisation of antihypertensive treatment by crossover rotation of four major classes. Lancet 1999; 353:2008.",
"     </a>",
"    </li>",
"    <li>",
"     K/DOQI Clinical Practice Guidelines on Hypertension and Antihypertensive Agents in Chronic Kidney Disease. Am J Kidney Dis 2004; 43:5(Suppl 1):S1.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/40/25224/abstract/12\">",
"      Linz W, Wiemer G, Gohlke P, et al. Contribution of kinins to the cardiovascular actions of angiotensin-converting enzyme inhibitors. Pharmacol Rev 1995; 47:25.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/40/25224/abstract/13\">",
"      Materson BJ, Reda DJ, Cushman WC, et al. Single-drug therapy for hypertension in men. A comparison of six antihypertensive agents with placebo. The Department of Veterans Affairs Cooperative Study Group on Antihypertensive Agents. N Engl J Med 1993; 328:914.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/40/25224/abstract/14\">",
"      Townsend RR, Holland OB. Combination of converting enzyme inhibitor with diuretic for the treatment of hypertension. Arch Intern Med 1990; 150:1175.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/40/25224/abstract/15\">",
"      Vaughan ED Jr, Carey RM, Peach MJ, et al. The renin response to diuretic therapyl A limitation of antihypertensive potential. Circ Res 1978; 42:376.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/40/25224/abstract/16\">",
"      Slagman MC, Waanders F, Hemmelder MH, et al. Moderate dietary sodium restriction added to angiotensin converting enzyme inhibition compared with dual blockade in lowering proteinuria and blood pressure: randomised controlled trial. BMJ 2011; 343:d4366.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/40/25224/abstract/17\">",
"      Pollare T, Lithell H, Berne C. A comparison of the effects of hydrochlorothiazide and captopril on glucose and lipid metabolism in patients with hypertension. N Engl J Med 1989; 321:868.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/40/25224/abstract/18\">",
"      Pickering TG. The use of angiotensin converting enzyme inhibitors in combination with other antihypertensive agents. Am J Hypertens 1991; 4:73S.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/40/25224/abstract/19\">",
"      Bangalore S, Kumar S, Messerli FH. Angiotensin-converting enzyme inhibitor associated cough: deceptive information from the Physicians' Desk Reference. Am J Med 2010; 123:1016.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/40/25224/abstract/20\">",
"      Beltrami L, Zanichelli A, Zingale L, et al. Long-term follow-up of 111 patients with angiotensin-converting enzyme inhibitor-related angioedema. J Hypertens 2011; 29:2273.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/40/25224/abstract/21\">",
"      Li DK, Yang C, Andrade S, et al. Maternal exposure to angiotensin converting enzyme inhibitors in the first trimester and risk of malformations in offspring: a retrospective cohort study. BMJ 2011; 343:d5931.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/40/25224/abstract/22\">",
"      Wald DS, Law M, Morris JK, et al. Combination therapy versus monotherapy in reducing blood pressure: meta-analysis on 11,000 participants from 42 trials. Am J Med 2009; 122:290.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/40/25224/abstract/23\">",
"      Burnier M, Brunner HR. Angiotensin II receptor antagonists. Lancet 2000; 355:637.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/40/25224/abstract/24\">",
"      Grossman E, Peleg E, Carroll J, et al. Hemodynamic and humoral effects of the angiotensin II antagonist losartan in essential hypertension. Am J Hypertens 1994; 7:1041.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/40/25224/abstract/25\">",
"      Huang, XR, Chen, WY, Truong, LD, Lan, HY. Chymase is upregulated in diabetic nephropathy: Implications for an alternative pathway of angiotensin II-mediated diabetic renal and vascular disease. J Am Soc Nephrol 2003; 14:1952.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/40/25224/abstract/26\">",
"      Matchar DB, McCrory DC, Orlando LA, et al. Systematic review: comparative effectiveness of angiotensin-converting enzyme inhibitors and angiotensin II receptor blockers for treating essential hypertension. Ann Intern Med 2008; 148:16.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/40/25224/abstract/27\">",
"      Kassler-Taub K, Littlejohn T, Elliott W, et al. Comparative efficacy of two angiotensin II receptor antagonists, irbesartan and losartan in mild-to-moderate hypertension. Irbesartan/Losartan Study Investigators. Am J Hypertens 1998; 11:445.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/40/25224/abstract/28\">",
"      Mallion J, Siche J, Lacourci&egrave;re Y. ABPM comparison of the antihypertensive profiles of the selective angiotensin II receptor antagonists telmisartan and losartan in patients with mild-to-moderate hypertension. J Hum Hypertens 1999; 13:657.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/40/25224/abstract/29\">",
"      Andersson OK, Neldam S. The antihypertensive effect and tolerability of candesartan cilexetil, a new generation angiotensin II antagonist, in comparison with losartan. Blood Press 1998; 7:53.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/40/25224/abstract/30\">",
"      Hedner T, Oparil S, Rasmussen K, et al. A comparison of the angiotensin II antagonists valsartan and losartan in the treatment of essential hypertension. Am J Hypertens 1999; 12:414.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/40/25224/abstract/31\">",
"      Tikkanen I, Omvik P, Jensen HA. Comparison of the angiotensin II antagonist losartan with the angiotensin converting enzyme inhibitor enalapril in patients with essential hypertension. J Hypertens 1995; 13:1343.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/40/25224/abstract/32\">",
"      Enomoto A, Kimura H, Chairoungdua A, et al. Molecular identification of a renal urate anion exchanger that regulates blood urate levels. Nature 2002; 417:447.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/40/25224/abstract/33\">",
"      ONTARGET Investigators, Yusuf S, Teo KK, et al. Telmisartan, ramipril, or both in patients at high risk for vascular events. N Engl J Med 2008; 358:1547.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/40/25224/abstract/34\">",
"      Soffer BA, Wright JT Jr, Pratt JH, et al. Effects of losartan on a background of hydrochlorothiazide in patients with hypertension. Hypertension 1995; 26:112.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/40/25224/abstract/35\">",
"      Mann JF, Schmieder RE, McQueen M, et al. Renal outcomes with telmisartan, ramipril, or both, in people at high vascular risk (the ONTARGET study): a multicentre, randomised, double-blind, controlled trial. Lancet 2008; 372:547.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/40/25224/abstract/36\">",
"      Oh BH, Mitchell J, Herron JR, et al. Aliskiren, an oral renin inhibitor, provides dose-dependent efficacy and sustained 24-hour blood pressure control in patients with hypertension. J Am Coll Cardiol 2007; 49:1157.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/40/25224/abstract/37\">",
"      Pool JL, Schmieder RE, Azizi M, et al. Aliskiren, an orally effective renin inhibitor, provides antihypertensive efficacy alone and in combination with valsartan. Am J Hypertens 2007; 20:11.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/40/25224/abstract/38\">",
"      Villamil A, Chrysant SG, Calhoun D, et al. Renin inhibition with aliskiren provides additive antihypertensive efficacy when used in combination with hydrochlorothiazide. J Hypertens 2007; 25:217.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/40/25224/abstract/39\">",
"      Shafiq MM, Menon DV, Victor RG. Oral direct renin inhibition: premise, promise, and potential limitations of a new antihypertensive drug. Am J Med 2008; 121:265.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/40/25224/abstract/40\">",
"      Oparil S, Yarows SA, Patel S, et al. Efficacy and safety of combined use of aliskiren and valsartan in patients with hypertension: a randomised, double-blind trial. Lancet 2007; 370:221.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/40/25224/abstract/41\">",
"      Parving HH, Persson F, Lewis JB, et al. Aliskiren combined with losartan in type 2 diabetes and nephropathy. N Engl J Med 2008; 358:2433.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/40/25224/abstract/42\">",
"      Parving HH, Brenner BM, McMurray JJ, et al. Aliskiren Trial in Type 2 Diabetes Using Cardio-Renal Endpoints (ALTITUDE): rationale and study design. Nephrol Dial Transplant 2009; 24:1663.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/40/25224/abstract/43\">",
"      Azizi M, M&eacute;nard J. Renin inhibitors and cardiovascular and renal protection: an endless quest? Cardiovasc Drugs Ther 2013; 27:145.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/40/25224/abstract/44\">",
"      Harel Z, Gilbert C, Wald R, et al. The effect of combination treatment with aliskiren and blockers of the renin-angiotensin system on hyperkalaemia and acute kidney injury: systematic review and meta-analysis. BMJ 2012; 344:e42.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 3815 Version 6.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0604-183.166.191.243-1D72A0B336-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f24_40_25224=[""].join("\n");
var outline_f24_40_25224=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H983513\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      ANGIOTENSIN-CONVERTING ENZYME INHIBITORS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      Specific indications for use",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      Antihypertensive response",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      Dosage",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      ANGIOTENSIN II RECEPTOR BLOCKERS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      Differences between ACE inhibitors and ARBs",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      Efficacy and dose",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      SIDE EFFECTS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      ACE inhibitors plus ARBs",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      DIRECT RENIN INHIBITORS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H983513\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"NEPH/3815\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"NEPH/3815|FIG\">",
"      <a href=\"#\" title=\"FIGURES\">",
"       FIGURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?37/22/38253\" title=\"figure 1\">",
"      Response to antihypertensives in blacks",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?9/23/9597\" title=\"figure 2\">",
"      Comparison of the actions of ACE inhibitors and ARBs",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"NEPH/3815|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?40/63/41981\" title=\"table 1\">",
"      Dosing ACE inhib and ARBs",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?15/45/16090?source=related_link\">",
"      ACE inhibitors in heart failure due to systolic dysfunction: Therapeutic use",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?35/61/36825?source=related_link\">",
"      Actions of angiotensin II on the heart",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?12/55/13175?source=related_link\">",
"      Angiotensin converting enzyme inhibitors and receptor blockers in acute myocardial infarction: Recommendations for use",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?1/32/1543?source=related_link\">",
"      Angiotensin converting enzyme inhibitors and receptor blockers in pregnancy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?40/10/41130?source=related_link\">",
"      Antihypertensive therapy and progression of nondiabetic chronic kidney disease in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?35/29/36314?source=related_link\">",
"      Choice of therapy in primary (essential) hypertension: Recommendations",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?17/34/17959?source=related_link\">",
"      Clinical implications and treatment of left ventricular hypertrophy in hypertension",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?35/60/36804?source=related_link\">",
"      Low-renin essential (primary) hypertension",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?18/2/18473?source=related_link\">",
"      Major side effects of angiotensin converting enzyme inhibitors and angiotensin II receptor blockers",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?41/49/42777?source=related_link\">",
"      Microalbuminuria in type 1 diabetes mellitus",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?38/33/39449?source=related_link\">",
"      Microalbuminuria in type 2 diabetes mellitus",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?18/60/19398?source=related_link\">",
"      Renal effects of ACE inhibitors in hypertension",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?23/35/24120?source=related_link\">",
"      Salt intake, salt restriction, and essential hypertension",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?39/48/40714?source=related_link\">",
"      Treatment of diabetic nephropathy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?15/14/15592?source=related_link\">",
"      Treatment of hypertension in blacks",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?20/45/21210?source=related_link\">",
"      Treatment of hypertension in patients with diabetes mellitus",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?27/54/28521?source=related_link\">",
"      Use of aldosterone antagonists in heart failure",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?12/38/12905?source=related_link\">",
"      Use of beta blockers in heart failure due to systolic dysfunction",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?3/55/3962?source=related_link\">",
"      Use of diuretics in patients with heart failure",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?14/63/15350?source=related_link\">",
"      Use of thiazide diuretics in patients with primary hypertension",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f24_40_25225="Unruptured intracranial aneurysms";
var content_f24_40_25225=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/wk_utd-rgb.myextg\" width=\"220px\">",
"   </img>",
"  </div>",
"  <div id=\"printHeaderText\">",
"   Official reprint from  UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"   <a href=\"file://www.uptodate.com\">",
"    www.uptodate.com",
"   </a>",
"   <br>",
"    &copy;2013 UpToDate",
"    <sup>",
"     &reg;",
"    </sup>",
"   </br>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Unruptured intracranial aneurysms",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?24/40/25225/contributors\">",
"     Authors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?24/40/25225/contributors\">",
"     Robert J Singer, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?24/40/25225/contributors\">",
"     Christopher S Ogilvy, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?24/40/25225/contributors\">",
"     Guy Rordorf, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?24/40/25225/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?24/40/25225/contributors\">",
"     Jose Biller, MD, FACP, FAAN, FAHA",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?24/40/25225/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?24/40/25225/contributors\">",
"     Janet L Wilterdink, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?24/40/25225/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   May 3, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Most subarachnoid hemorrhages (SAH) are caused by ruptured intracranial saccular (berry) aneurysms. The epidemiology and pathogenesis of intracranial aneurysms and the management of unruptured aneurysms are discussed here. The epidemiology, etiology, clinical manifestations, diagnosis, and treatment of SAH, and issues related to screening for aneurysms are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?37/39/38522?source=see_link\">",
"     \"Etiology, clinical manifestations, and diagnosis of aneurysmal subarachnoid hemorrhage\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?36/54/37738?source=see_link\">",
"     \"Treatment of aneurysmal subarachnoid hemorrhage\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?3/43/3767?source=see_link\">",
"     \"Screening for intracranial aneurysm\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     EPIDEMIOLOGY",
"    </span>",
"    &nbsp;&mdash;&nbsp;The prevalence of intracranial saccular aneurysms by radiographic and autopsy series is estimated to be 3.2 percent in a population without comorbidity, a mean age of 50 years, and a 1:1 gender ratio [",
"    <a class=\"abstract\" href=\"UTD.htm?24/40/25225/abstract/1,2\">",
"     1,2",
"    </a>",
"    ],. Of patients with cerebral aneurysms, 20 to 30 percent have multiple aneurysms [",
"    <a class=\"abstract\" href=\"UTD.htm?24/40/25225/abstract/3\">",
"     3",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Aneurysmal SAH occurs at an estimated rate of 6 to 16 per 100,000 population [",
"    <a class=\"abstract\" href=\"UTD.htm?24/40/25225/abstract/4\">",
"     4",
"    </a>",
"    ]. In North America, this translates into approximately 30,000 affected persons per year. Thus, most aneurysms, particularly small aneurysms, do not rupture (see",
"    <a class=\"local\" href=\"#H13\">",
"     'Natural history of unruptured aneurysms'",
"    </a>",
"    below).",
"   </p>",
"   <p>",
"    Rupture of an intracranial aneurysm is believed to account for 0.4 to 0.6 percent of all deaths. Approximately 10 percent of patients die prior to reaching the hospital, and only one-third has a \"good result\" after treatment. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?36/54/37738?source=see_link\">",
"     \"Treatment of aneurysmal subarachnoid hemorrhage\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Most intracranial aneurysms (approximately 85 percent) are located in the anterior circulation, predominantly on the circle of Willis. Common sites include the junction of the anterior communicating artery with the anterior cerebral artery, the junction of the posterior communicating artery with the internal carotid artery, and the bifurcation of the middle cerebral artery. Posterior circulation sites often include the top of the basilar artery, the junction of the basilar artery and the superior or anterior inferior cerebellar arteries, and the junction of the vertebral artery and the posterior inferior cerebellar artery [",
"    <a class=\"abstract\" href=\"UTD.htm?24/40/25225/abstract/5\">",
"     5",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    There is a female preponderance for aneurysms ranging from 54 to 61 percent [",
"    <a class=\"abstract\" href=\"UTD.htm?24/40/25225/abstract/2,4\">",
"     2,4",
"    </a>",
"    ]. In populations older than 50 years, the increased prevalence in women may approach a 2 to 1 ratio or greater. (See",
"    <a class=\"local\" href=\"#H11\">",
"     'Estrogen deficiency'",
"    </a>",
"    below.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h1\">",
"     PATHOGENESIS AND RISK FACTORS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Saccular aneurysms are responsible for most SAHs, although fusiform and mycotic aneurysms can be identified in selected patients.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Saccular aneurysms are thin-walled protrusions from the intracranial arteries that are composed of a very thin or absent tunica media, and an absent or severely fragmented internal elastic lamina [",
"      <a class=\"abstract\" href=\"UTD.htm?24/40/25225/abstract/6\">",
"       6",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Fusiform aneurysms consist of enlargement or dilatation of the entire circumference of the involved vessel that may in part be formed due to atherosclerosis.",
"     </li>",
"     <li>",
"      Mycotic aneurysms usually result from infected emboli due to infective endocarditis [",
"      <a class=\"abstract\" href=\"UTD.htm?24/40/25225/abstract/7\">",
"       7",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h2\">",
"     Morphological factors",
"    </span>",
"    &nbsp;&mdash;&nbsp;The pathogenesis of saccular aneurysm formation is multifactorial [",
"    <a class=\"abstract\" href=\"UTD.htm?24/40/25225/abstract/8\">",
"     8",
"    </a>",
"    ]. Hemodynamic stress causes excessive wear and tear and breakdown of the internal elastic lamina. Turbulent blood flow produces vibrations that may coincide with the resonant frequency of the vessel wall, resulting in structural fatigue. Patients with hyperdynamic flow patterns as a result of anomalous collateral pathways or other high-flow states are predisposed to accelerated degenerative changes in the vessel wall and subsequent aneurysm development. Hypertension, cigarette smoking, and connective tissue disease probably play a contributory rather than causal role in this process (see",
"    <a class=\"local\" href=\"#H8\">",
"     'Other factors'",
"    </a>",
"    below).",
"   </p>",
"   <p>",
"    In a study that examined 66 saccular aneurysm samples (42 ruptured and 24 unruptured), four histological types of aneurysm walls were identified that may reflect consecutive stages of degeneration leading to rupture [",
"    <a class=\"abstract\" href=\"UTD.htm?24/40/25225/abstract/9\">",
"     9",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Endothelialized wall with linearly organized smooth muscle cells (Type A); 7 of 17 (41 percent) ruptured.",
"     </li>",
"     <li>",
"      Thickened wall with disorganized smooth muscle cells (Type B); 11 of 20 (55 percent) ruptured.",
"     </li>",
"     <li>",
"      Hypocellular wall with either intimal hyperplasia or organizing luminal thrombosis (Type C); 9 of 14 (64 percent) ruptured.",
"     </li>",
"     <li>",
"      Extremely thin thrombosis-lined hypocellular wall (Type D); all 15 (100 percent) ruptured.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Lack of elastic lamina was a common feature of both ruptured and unruptured aneurysms. Ruptured aneurysm walls were more likely to have complete absence of endothelial lining and evidence of inflammation, characterized by T cell and macrophage infiltration, compared with unruptured walls.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h2\">",
"     Genetic factors",
"    </span>",
"    &nbsp;&mdash;&nbsp;The role for genetic factors in the pathogenesis of intracranial aneurysm formation is supported by studies that have found an increased risk in patients with some known hereditary syndromes and by the occurrence of aneurysms in families.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h3\">",
"     Hereditary syndromes",
"    </span>",
"    &nbsp;&mdash;&nbsp;A known hereditary syndrome is often present when aneurysms are diagnosed in more than one family member. Heritable disorders associated with the presence of intracranial aneurysm include:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Connective tissue diseases such as Ehlers-Danlos syndrome and pseudoxanthoma elasticum are associated with intracranial aneurysms [",
"      <a class=\"abstract\" href=\"UTD.htm?24/40/25225/abstract/10,11\">",
"       10,11",
"      </a>",
"      ], but probably not Marfan syndrome [",
"      <a class=\"abstract\" href=\"UTD.htm?24/40/25225/abstract/12\">",
"       12",
"      </a>",
"      ]",
"     </li>",
"     <li>",
"      Autosomal dominant polycystic kidney disease is associated with a 6.9 times higher risk of intracranial aneurysm [",
"      <a class=\"abstract\" href=\"UTD.htm?24/40/25225/abstract/2\">",
"       2",
"      </a>",
"      ]. (see",
"      <a class=\"medical medical_review\" href=\"UTD.htm?29/33/30233?source=see_link\">",
"       \"Extrarenal manifestations of autosomal dominant polycystic kidney disease\"",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      Glucocorticoid-remediable aldosteronism (familial aldosteronism type I) (see",
"      <a class=\"medical medical_review\" href=\"UTD.htm?22/5/22615?source=see_link\">",
"       \"Familial hyperaldosteronism\"",
"      </a>",
"      )",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Moyamoya syndrome is also associated with an increased frequency of intracranial aneurysms; although most cases of moyamoya are sporadic, there is probably a genetic susceptibility underlying the disease, and familial occurrence is known to occur. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?3/44/3786?source=see_link\">",
"     \"Moyamoya disease: Etiology, clinical features, and diagnosis\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The mechanism by which connective tissue diseases predispose to aneurysm formation presumably involves an inherent weakness of the arterial wall exposed to the non-laminar flow pattern of blood, which is then exposed to shear stresses. Aneurysm formation in glucocorticoid-remediable hyperaldosteronism may result in part from congenital hypertension during the early stages of cerebrovascular development [",
"    <a class=\"abstract\" href=\"UTD.htm?24/40/25225/abstract/13\">",
"     13",
"    </a>",
"    ]. Concurrent hypertension also may contribute in polycystic kidney disease, although the precise mechanism is unclear.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h3\">",
"     Familial aneurysms",
"    </span>",
"    &nbsp;&mdash;&nbsp;Family members of patients with intracranial aneurysms are at increased risk of having an aneurysm, even in the absence of a known hereditary syndrome. In one study, for example, the age-adjusted prevalence of incidental aneurysms in first-degree relatives of patients with an aneurysm was 9 percent, a number significantly higher than the general population [",
"    <a class=\"abstract\" href=\"UTD.htm?24/40/25225/abstract/14\">",
"     14",
"    </a>",
"    ]. Only a small proportion of these families had an identifiable hereditary syndrome known to be associated with aneurysms. In a second report of patients with mostly sporadic SAH, intracranial aneurysms were found in 4 percent of first-degree relatives (approximately twice that of the general population) [",
"    <a class=\"abstract\" href=\"UTD.htm?24/40/25225/abstract/15\">",
"     15",
"    </a>",
"    ]. Other studies have estimated that a family history of aneurysm or subarachnoid hemorrhage confers a 3.6 times greater risk [",
"    <a class=\"abstract\" href=\"UTD.htm?24/40/25225/abstract/2\">",
"     2",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The mode of inheritance is variable, with autosomal dominant, recessive, and multifactorial transmission evident in different families [",
"    <a class=\"abstract\" href=\"UTD.htm?24/40/25225/abstract/16,17\">",
"     16,17",
"    </a>",
"    ]. Familial aneurysms have been linked to the 7q11 and to the 9p21 region in Japanese families [",
"    <a class=\"abstract\" href=\"UTD.htm?24/40/25225/abstract/18,19\">",
"     18,19",
"    </a>",
"    ] and to the 19q13.3 region in Finnish families [",
"    <a class=\"abstract\" href=\"UTD.htm?24/40/25225/abstract/17,20\">",
"     17,20",
"    </a>",
"    ]. Other chromosomal loci have been implicated in families in other geographic regions [",
"    <a class=\"abstract\" href=\"UTD.htm?24/40/25225/abstract/21\">",
"     21",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Familial aneurysms tend to rupture at a smaller size and younger age than sporadic aneurysms [",
"    <a class=\"abstract\" href=\"UTD.htm?24/40/25225/abstract/14,22,23\">",
"     14,22,23",
"    </a>",
"    ]. Siblings often experience rupture in the same decade of life [",
"    <a class=\"abstract\" href=\"UTD.htm?24/40/25225/abstract/22\">",
"     22",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h2\">",
"     Other factors",
"    </span>",
"    &nbsp;&mdash;&nbsp;Because intracranial aneurysms are the major etiology of SAH, risk factors for SAH may also be risk factors for intracranial aneurysms. Risk factors for SAH include hypertension, cigarette smoking, and alcohol consumption [",
"    <a class=\"abstract\" href=\"UTD.htm?24/40/25225/abstract/24-26\">",
"     24-26",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?37/39/38522?source=see_link\">",
"     \"Etiology, clinical manifestations, and diagnosis of aneurysmal subarachnoid hemorrhage\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Known and possible risk factors for aneurysm formation include:",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h3\">",
"     Cigarette smoking",
"    </span>",
"    &nbsp;&mdash;&nbsp;The importance of cigarette smoking was illustrated in a case-control analysis of 45 men and 70 women with SAH between the ages of 35 and 64 [",
"    <a class=\"abstract\" href=\"UTD.htm?24/40/25225/abstract/27\">",
"     27",
"    </a>",
"    ]. Cigarette smokers had a significantly increased risk of SAH compared with a control population; the relative risk for men and women was 3.0 and 4.7, respectively, and the risk increased with the number of cigarettes smoked. Those who both smoked and had hypertension had an almost 15-fold increase in risk of SAH compared with normotensive nonsmokers. In a study of familial intracranial aneurysms, the risk of intracranial aneurysm within affected families was increased by cigarette smoking [",
"    <a class=\"abstract\" href=\"UTD.htm?24/40/25225/abstract/21\">",
"     21",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The mechanism by which cigarette smoking predisposes to aneurysm formation may involve decreasing the effectiveness of alpha-1 antitrypsin, an important inhibitor of proteases such as elastase [",
"    <a class=\"abstract\" href=\"UTD.htm?24/40/25225/abstract/5\">",
"     5",
"    </a>",
"    ]. Support for this hypothesis is derived from studies, which suggest that patients with alpha-1 antitrypsin deficiency are at increased risk of aneurysm formation [",
"    <a class=\"abstract\" href=\"UTD.htm?24/40/25225/abstract/22\">",
"     22",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h3\">",
"     Hypertension",
"    </span>",
"    &nbsp;&mdash;&nbsp;The association between hypertension and aneurysm formation and rupture has been controversial, although the balance of evidence suggests that hypertension is a risk factor. One report, for example, compared 113 patients with SAH and angiographically verified aneurysms to 63 patients with SAH but no aneurysm [",
"    <a class=\"abstract\" href=\"UTD.htm?24/40/25225/abstract/28\">",
"     28",
"    </a>",
"    ]. Blood pressure greater than",
"    <span class=\"nowrap\">",
"     160/95",
"    </span>",
"    was present in 62 percent of patients with aneurysms compared with 37 percent without. In another study in which over 20,000 Medicare patients were followed, there was an increased prevalence of hypertension in patients with aneurysms compared with a control population (43 versus 35 percent) [",
"    <a class=\"abstract\" href=\"UTD.htm?24/40/25225/abstract/29\">",
"     29",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h3\">",
"     Estrogen deficiency",
"    </span>",
"    &nbsp;&mdash;&nbsp;There is a female preponderance for aneurysms ranging from 54 to 61 percent [",
"    <a class=\"abstract\" href=\"UTD.htm?24/40/25225/abstract/4\">",
"     4",
"    </a>",
"    ]. The estrogen deficiency of menopause causes a reduction in the collagen content of tissues. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?43/45/44761?source=see_link\">",
"     \"Clinical manifestations and diagnosis of menopause\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    This collagen wasting may contribute to aneurysm development in postmenopausal women, analogous to the situation in patients with connective tissue diseases. In one case-control study, premenopausal women without a history of smoking or hypertension were at reduced risk of SAH compared with age-matched postmenopausal women (odds ratio 0.24) [",
"    <a class=\"abstract\" href=\"UTD.htm?24/40/25225/abstract/30\">",
"     30",
"    </a>",
"    ]. Furthermore, the use of estrogen replacement therapy was associated with a reduced risk of SAH in postmenopausal women (odds ratio 0.47). This protective effect of estrogen replacement therapy has been seen in other studies as well [",
"    <a class=\"abstract\" href=\"UTD.htm?24/40/25225/abstract/31\">",
"     31",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h3\">",
"     Coarctation of the aorta",
"    </span>",
"    &nbsp;&mdash;&nbsp;Patients with coarctation of the aorta are at increased risk for aneurysm formation [",
"    <a class=\"abstract\" href=\"UTD.htm?24/40/25225/abstract/32,33\">",
"     32,33",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?22/53/23385?source=see_link\">",
"     \"Clinical manifestations and diagnosis of coarctation of the aorta\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h1\">",
"     NATURAL HISTORY OF UNRUPTURED ANEURYSMS",
"    </span>",
"    &nbsp;&mdash;&nbsp;The largest study of the natural history of unruptured intracranial aneurysms was the International Study of Unruptured Intracranial Aneurysms (ISUIA), which prospectively assessed 4060 patients in the United States, Canada, and Europe [",
"    <a class=\"abstract\" href=\"UTD.htm?24/40/25225/abstract/34\">",
"     34",
"    </a>",
"    ]. There were 1692 patients with 2686 unruptured intracranial aneurysms who did not have surgery or endovascular treatment. The results in these conservatively managed patients were noted over 6544 patient-years of follow-up (mean follow-up 4.1 years) and are described below according to aneurysm size (see",
"    <a class=\"local\" href=\"#H14\">",
"     'Size'",
"    </a>",
"    below) and site (see",
"    <a class=\"local\" href=\"#H16\">",
"     'Site'",
"    </a>",
"    below).",
"   </p>",
"   <p>",
"    In the ISUIA, the effect of patient's age and other putative risk factors for aneurysmal rupture were not significant predictors of SAH in a multivariate analysis [",
"    <a class=\"abstract\" href=\"UTD.htm?24/40/25225/abstract/34\">",
"     34",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h2\">",
"     Size",
"    </span>",
"    &nbsp;&mdash;&nbsp;The ISUIA confirmed results from previous studies showing that the rates of aneurysmal rupture were lower in smaller aneurysms [",
"    <a class=\"abstract\" href=\"UTD.htm?24/40/25225/abstract/34-37\">",
"     34-37",
"    </a>",
"    ]. The optimum size cutpoint in this study for defining low risk of rupture was 7 mm [",
"    <a class=\"abstract\" href=\"UTD.htm?24/40/25225/abstract/34\">",
"     34",
"    </a>",
"    ]. With increasing size over 7 mm, the risk of aneurysmal SAH increased correspondingly. For anterior circulation aneurysms 5-year rates of rupture for those 7 to 12mm was 2.6 percent; for those 13 to 24 mm, 14.5 percent; and for those &gt; 25 mm, 40 percent. Another prospective cohort study followed 374 patients with 448 aneurysms that were &lt;5 mm in size; the average annual rupture rate was 0.54 percent overall; 0.34 percent for single aneurysms and 0.95 for multiple aneurysms [",
"    <a class=\"abstract\" href=\"UTD.htm?24/40/25225/abstract/38\">",
"     38",
"    </a>",
"    ]. In this group, aneurysm rupture risk was also somewhat higher in those &lt;50 years of age and those with aneurysms &gt;4 mm in size.",
"   </p>",
"   <p>",
"    Aneurysm growth is more likely to occur in larger than smaller aneurysm [",
"    <a class=\"abstract\" href=\"UTD.htm?24/40/25225/abstract/39,40\">",
"     39,40",
"    </a>",
"    ]. Among 165 patients with 191 unruptured aneurysms, the frequency of enlargement over 47 months was 7, 25, and 83 percent for aneurysms &lt;8 mm, 8 to 12 mm, and &gt;13 mm, respectively [",
"    <a class=\"abstract\" href=\"UTD.htm?24/40/25225/abstract/40\">",
"     40",
"    </a>",
"    ]. One study also found that internal carotid and basilar artery aneurysms were more likely to grow than those located in other regions [",
"    <a class=\"abstract\" href=\"UTD.htm?24/40/25225/abstract/39\">",
"     39",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h3\">",
"     Hypothesis of growth and rupture",
"    </span>",
"    &nbsp;&mdash;&nbsp;There are some concerns about the data reported from studies of unruptured intracranial aneurysms showing a low rate of rupture for aneurysms 7 mm and smaller [",
"    <a class=\"abstract\" href=\"UTD.htm?24/40/25225/abstract/34-37\">",
"     34-37",
"    </a>",
"    ] because a large percentage of patients that present with SAH appear to have had rupture of aneurysms that were smaller than 10 mm in diameter [",
"    <a class=\"abstract\" href=\"UTD.htm?24/40/25225/abstract/41\">",
"     41",
"    </a>",
"    ], and a majority appear smaller than 7 mm in diameter [",
"    <a class=\"abstract\" href=\"UTD.htm?24/40/25225/abstract/42\">",
"     42",
"    </a>",
"    ]. Based on available clinical and natural history data, as well as pathophysiology, the following hypothesis of aneurysmal growth and rupture has been proposed as the explanation for this apparent discrepancy [",
"    <a class=\"abstract\" href=\"UTD.htm?24/40/25225/abstract/8,37,43\">",
"     8,37,43",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Intracranial saccular aneurysms are acquired lesions, not congenital.",
"     </li>",
"     <li>",
"      Most intracranial aneurysms develop over a short period of hours, days, or weeks, attaining a size allowed by the elasticity limits of the aneurysmal wall; at this point, the aneurysm either ruptures or undergoes stabilization and hardening.",
"     </li>",
"     <li>",
"      Those aneurysms that do not rupture gain significant tensile strength due to compensatory hardening with formation of excessive collagen. Therefore, the likelihood of rupture decreases unless the size of the aneurysm is fairly large at the time of initial stabilization.",
"     </li>",
"     <li>",
"      Aneurysms 1 cm or larger at initial stabilization are considerably more likely to undergo subsequent growth and rupture because wall stress increases with the square of the diameter (Laplace's law).",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    If this hypothesis is correct, it follows that the critical size for aneurysmal rupture is smaller for aneurysms that rupture soon after formation, as would appear to be true for the vast majority of small aneurysms that rupture [",
"    <a class=\"abstract\" href=\"UTD.htm?24/40/25225/abstract/8,43\">",
"     8,43",
"    </a>",
"    ]. This hypothesis is based on data derived from patients with unruptured aneurysms and no history of prior SAH, and it is probably not applicable to patients who have an unruptured aneurysm and prior SAH from another aneurysm.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16\">",
"    <span class=\"h2\">",
"     Site",
"    </span>",
"    &nbsp;&mdash;&nbsp;In the prospective ISUIA, three aneurysm site groupings were associated with different rates of rupture [",
"    <a class=\"abstract\" href=\"UTD.htm?24/40/25225/abstract/34\">",
"     34",
"    </a>",
"    ]. The three groupings of aneurysm site were based on the parent artery:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Cavernous carotid artery aneurysms had the lowest rates of rupture.",
"     </li>",
"     <li>",
"      Anterior circulation aneurysms, involving the anterior communicating, anterior cerebral or internal carotid arteries, had intermediate rates of rupture.",
"     </li>",
"     <li>",
"      Posterior circulation aneurysms, involving the vertebrobasilar, posterior cerebral arterial system, or posterior communicating arteries, had the highest rates of rupture.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The cumulative five-year rate of rupture according to aneurysm site and size at diagnosis were as follows:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      For 7 to 12 mm aneurysms, rupture rates for cavernous carotid, anterior circulation, and posterior circulation aneurysms were 0, 2.6, and 14.5 percent.",
"     </li>",
"     <li>",
"      For 13 to 24 mm aneurysms, rupture rates for cavernous carotid, anterior circulation, and posterior circulation aneurysms were 3.0, 14.5, and 18.4 percent.",
"     </li>",
"     <li>",
"      For 25 mm or larger aneurysms, rupture rates for cavernous carotid, anterior circulation, and posterior circulation aneurysms were 6.4, 40, and 50 percent.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17\">",
"    <span class=\"h2\">",
"     Racial differences",
"    </span>",
"    &nbsp;&mdash;&nbsp;It is unclear whether racial or genetic background has a substantial impact upon the natural history of unruptured intracranial aneurysms. The prospective ISUIA data were obtained primarily from white populations in North America and Europe, but no similar large prospective study has been published in other populations. However, predisposition to aneurysm formation is clearly influenced by genetic makeup (see",
"    <a class=\"local\" href=\"#H5\">",
"     'Genetic factors'",
"    </a>",
"    above), and there is epidemiologic evidence of wide variations in the rate of SAH worldwide [",
"    <a class=\"abstract\" href=\"UTD.htm?24/40/25225/abstract/44\">",
"     44",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Although not directly comparable, data from a systematic review of 13 retrospective studies of unruptured intracranial aneurysms in Japan [",
"    <a class=\"abstract\" href=\"UTD.htm?24/40/25225/abstract/45\">",
"     45",
"    </a>",
"    ] found a much higher overall rupture rate than that reported in the ISUIA study [",
"    <a class=\"abstract\" href=\"UTD.htm?24/40/25225/abstract/34\">",
"     34",
"    </a>",
"    ]. Similar to the ISUIA data, the risk of rupture in Japan was significantly increased for large, posterior circulation, and symptomatic aneurysms [",
"    <a class=\"abstract\" href=\"UTD.htm?24/40/25225/abstract/45\">",
"     45",
"    </a>",
"    ]. Most of the studies in the Japanese review included a mix of patients with and without prior SAH, populations that appear to have different risks in the prospective ISUIA study. Prospective studies underway in Japan may address these issues [",
"    <a class=\"abstract\" href=\"UTD.htm?24/40/25225/abstract/46,47\">",
"     46,47",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H18\">",
"    <span class=\"h2\">",
"     Prior hemorrhage",
"    </span>",
"    &nbsp;&mdash;&nbsp;If an individual has had a previous aneurysmal SAH, the risk of rupture of a separate aneurysm is probably higher than if the individual did not have that history. In the ISUIA, unruptured aneurysms less than 7 mm in a patient with a history of aneurysmal SAH ruptured at a rate of 0.5 percent per year compared 0.1 percent per year in those with no prior aneurysmal SAH [",
"    <a class=\"abstract\" href=\"UTD.htm?24/40/25225/abstract/34\">",
"     34",
"    </a>",
"    ]. A higher risk for those with prior SAH was not noted for larger aneurysm categories in the ISUIA, but the number of patients with large unruptured aneurysms and prior SAH were relatively small.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H19\">",
"    <span class=\"h2\">",
"     Family history",
"    </span>",
"    &nbsp;&mdash;&nbsp;Familial aneurysms tend to rupture at a smaller size and younger age than sporadic aneurysms [",
"    <a class=\"abstract\" href=\"UTD.htm?24/40/25225/abstract/14,22,23\">",
"     14,22,23",
"    </a>",
"    ]. In one study, the observed rupture rate of 1.2 percent per year was almost 17 times higher than the rupture rate of aneurysms matched for size and location in the ISUIA [",
"    <a class=\"abstract\" href=\"UTD.htm?24/40/25225/abstract/23\">",
"     23",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H20\">",
"    <span class=\"h1\">",
"     CLINICAL MANIFESTATIONS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Most intracranial aneurysms are asymptomatic unless they rupture, and so they are usually found either incidentally or when a patient presents with SAH. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?37/39/38522?source=see_link\">",
"     \"Etiology, clinical manifestations, and diagnosis of aneurysmal subarachnoid hemorrhage\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Some unruptured aneurysms can become symptomatic [",
"    <a class=\"abstract\" href=\"UTD.htm?24/40/25225/abstract/48,49\">",
"     48,49",
"    </a>",
"    ]. Symptoms include headache (which may be severe and comparable to the headache of SAH [",
"    <a class=\"abstract\" href=\"UTD.htm?24/40/25225/abstract/48\">",
"     48",
"    </a>",
"    ]), visual acuity loss, cranial neuropathies (particularly third nerve palsy), pyramidal tract dysfunction, and facial pain; they are felt to be due to the mass effect of the aneurysm. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?35/63/36856?source=see_link\">",
"     \"Third cranial nerve (oculomotor nerve) palsy in adults\"",
"    </a>",
"    .) Ischemia can occur as a result of emboli originating from within an aneurysm.",
"   </p>",
"   <p>",
"    Treatment of the aneurysm may lead to resolution of symptoms [",
"    <a class=\"abstract\" href=\"UTD.htm?24/40/25225/abstract/49\">",
"     49",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?36/54/37738?source=see_link\">",
"     \"Treatment of aneurysmal subarachnoid hemorrhage\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H21\">",
"    <span class=\"h1\">",
"     DIAGNOSIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;As mentioned above, most intracranial aneurysms present as SAH or are found incidentally or on screening. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?3/43/3767?source=see_link\">",
"     \"Screening for intracranial aneurysm\"",
"    </a>",
"    .) Because symptomatic unruptured aneurysms are unusual, there are little data on the best diagnostic strategy in the presence of symptoms that could be due to an aneurysm.",
"   </p>",
"   <p>",
"    Magnetic resonance angiography (MRA) and CT angiography (CTA) appear to be able to detect aneurysms 5 mm or larger; smaller aneurysms (down to 2 mm) are less reliably detected or may be seen in retrospect when compared with cerebral angiography [",
"    <a class=\"abstract\" href=\"UTD.htm?24/40/25225/abstract/50-53\">",
"     50-53",
"    </a>",
"    ]. A systematic review of studies of CTA concluded that the sensitivity of CTA ranged from 53 percent for 2 mm aneurysms to 95 percent for 7 mm aneurysms, and that specificity was also higher for larger aneurysms (",
"    <a class=\"graphic graphic_figure graphicRef81565 graphicRef69728 \" href=\"UTD.htm?19/35/20030\">",
"     figure 1A-B",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?24/40/25225/abstract/53\">",
"     53",
"    </a>",
"    ]. As technology improves, the sensitivity and specificity of noninvasive imaging is also likely to improve. A 2011 meta-analysis of CTA diagnosis of intracranial aneurysms found that, compared with single-detector CTA, use of multidetector CTA was associated with an overall improved sensitivity and specificity for aneurysm detection (both &gt;97 percent) as well as improved detection of smaller aneurysms &le;4 mm in diameter [",
"    <a class=\"abstract\" href=\"UTD.htm?24/40/25225/abstract/54\">",
"     54",
"    </a>",
"    ]. Another study examining 307 aneurysm in 246 patients found that three-dimensional time-of-flight MRA with volume rendering at 3.0 Tesla had a sensitivity and specificity of 99 and 97 percent that was irrespective of aneurysm size (range &lt;3 mm to &gt;10 mm) [",
"    <a class=\"abstract\" href=\"UTD.htm?24/40/25225/abstract/55\">",
"     55",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Pretest probability should affect the interpretations of CTA results: in the presence of SAH, an aneurysm is likely, and a positive CTA finding of any size can generally be trusted, while a negative result should lead to further testing; in the absence of SAH, a CTA finding of a large aneurysm (&gt;7 mm) can be trusted, but findings of small or medium aneurysms have a higher likelihood of being false positives and may require confirmation, if felt to be clinically important [",
"    <a class=\"abstract\" href=\"UTD.htm?24/40/25225/abstract/53\">",
"     53",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Angiography is a more invasive test that is associated with a higher risk of complications, and it should only be performed if there is a high clinical suspicion for an aneurysm despite negative noninvasive studies. Very small aneurysms (below the practical limit of detection of MRA and CTA) can occasionally present with symptoms such as third nerve palsy [",
"    <a class=\"abstract\" href=\"UTD.htm?24/40/25225/abstract/49\">",
"     49",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H22\">",
"    <span class=\"h1\">",
"     MANAGEMENT OF UNRUPTURED ANEURYSMS",
"    </span>",
"    &nbsp;&mdash;&nbsp;The management of unruptured intracranial aneurysms is controversial [",
"    <a class=\"abstract\" href=\"UTD.htm?24/40/25225/abstract/56\">",
"     56",
"    </a>",
"    ]. Decisions about therapy need to weigh the natural history of the aneurysm, the risks of intervention, and patient preferences.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H23\">",
"    <span class=\"h2\">",
"     Risk of intervention",
"    </span>",
"    &nbsp;&mdash;&nbsp;The risk of intervention was best illustrated in the second report from the International Study of Unruptured Intracranial Aneurysms (ISUIA), a prospective observational study in which 1917 patients underwent open surgical repair and 451 endovascular repair [",
"    <a class=\"abstract\" href=\"UTD.htm?24/40/25225/abstract/34\">",
"     34",
"    </a>",
"    ]. The following findings were noted:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Among 1591 patients who underwent surgery and had no prior history of aneurysm rupture, the rate of surgery-related death or poor neurologic outcome was 13.7 percent at 30 days and 12.6 percent at one year (the lower value at one year reflects neurologic recovery in some patients). Similar outcomes were noted in 326 patients who had a history of prior subarachnoid hemorrhage from a different site.",
"     </li>",
"     <li>",
"      Among 409 patients who underwent endovascular repair and had no prior history of aneurysm rupture, the rate of therapy-related death or poor neurologic outcomes was 9.3 percent at 30 days and 9.8 percent at one year.",
"     </li>",
"     <li>",
"      The risk of an adverse outcome after surgery was importantly affected by patient age, increasing progressively from about 6 percent between the ages of 40 and 49, to about 30 percent at age 70 or higher. Other risk factors identified on multivariate analysis included aneurysm size &gt;12 mm and location in the posterior circulation. These two risk factors, but not increasing age, were also important in patients undergoing endovascular repair.",
"     </li>",
"     <li>",
"      For many combinations of age, aneurysm location, and size, the likelihood of a poor post-procedure outcome was equal to or greater than the five-year likelihood of aneurysm rupture. (See",
"      <a class=\"local\" href=\"#H13\">",
"       'Natural history of unruptured aneurysms'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Another observational cohort study of 7236 patients found that endovascular repair of unruptured intracranial aneurysms was associated with lower mortality (1.6 versus 0.6) and lower perioperative ischemic or hemorrhagic stroke (4.3 versus 9.0 percent) compared with surgical clipping [",
"    <a class=\"abstract\" href=\"UTD.htm?24/40/25225/abstract/57\">",
"     57",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    In a separate study, similar to the results in the ISUIA, a multivariate analysis found that increasing aneurysm size, increasing patient age, and vertebrobasilar aneurysm location were independently associated with poor surgical outcomes [",
"    <a class=\"abstract\" href=\"UTD.htm?24/40/25225/abstract/58\">",
"     58",
"    </a>",
"    ]. The risk of a poor outcome was generally lower than in the ISUIA and was approximately 1 percent in young patients with small aneurysms in the anterior circulation; patients aged 70 and over with aneurysms &gt;10 mm had a risk of a poor outcome of 5 percent for anterior circulation and 15 percent for posterior circulation aneurysms. Another study found that the risk of endovascular intervention was similar in very small aneurysms (&le;3 mm) and for somewhat larger aneurysms (&gt;3mm) [",
"    <a class=\"abstract\" href=\"UTD.htm?24/40/25225/abstract/59\">",
"     59",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Age is a crucial element in deciding whether to treat an unruptured aneurysm [",
"    <a class=\"abstract\" href=\"UTD.htm?24/40/25225/abstract/8\">",
"     8",
"    </a>",
"    ]. Morbidity and mortality are increased with open surgery in patients 50 years and older and with endovascular procedures in patients 70 years and older. However, age has relatively little effect on the natural history of unruptured aneurysms.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H24\">",
"    <span class=\"h2\">",
"     Benefit of intervention",
"    </span>",
"    &nbsp;&mdash;&nbsp;The ISUIA investigators concluded that in patients without a history of previous SAH, it is unlikely that any therapy would be able to improve upon the untreated natural history of aneurysms that are smaller than 7 mm, and they also suggested that in patients with larger asymptomatic unruptured aneurysms, patient preference for immediate risk versus risk over time might determine the appropriate course of action.",
"   </p>",
"   <p>",
"    The investigators also point to specific groups from their data that appear to have the largest benefit from intervention, such as open surgery for patients younger than 50 years with aneurysms of the posterior communicating artery that are 7 to 24 mm. Although it may be appropriate to take these subgroup data into account when making recommendations for individual patients, it is important to recognize that such subgroup analyses are vulnerable to statistical problems and need to be confirmed prospectively.",
"   </p>",
"   <p>",
"    The management of unruptured intracranial aneurysms has also been evaluated by studies performing cost-effectiveness analyses. One such study, published prior to the prospective 2003 ISUIA report [",
"    <a class=\"abstract\" href=\"UTD.htm?24/40/25225/abstract/34\">",
"     34",
"    </a>",
"    ], found that treatment of asymptomatic aneurysms &lt;10 mm in diameter in patients with no history of SAH from another aneurysm worsened clinical outcomes; treatment of unruptured aneurysms that were larger, symptomatic, or in patients with a history of SAH was cost-effective [",
"    <a class=\"abstract\" href=\"UTD.htm?24/40/25225/abstract/60\">",
"     60",
"    </a>",
"    ]. Aneurysm location was not considered in this analysis.",
"   </p>",
"   <p>",
"    A later decision and cost-effectiveness analysis used the 2003 ISUIA data and compared surgical or endovascular treatment with no treatment for unruptured intracranial aneurysms [",
"    <a class=\"abstract\" href=\"UTD.htm?24/40/25225/abstract/61\">",
"     61",
"    </a>",
"    ]. The following observations were reported:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      For 50 year old patients, treatment was ineffective or not cost effective for aneurysms with the following characteristics:",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      Small (&lt;7 mm), due to the low risk of rupture",
"     </li>",
"     <li>",
"      Located in the cavernous carotid artery",
"     </li>",
"     <li>",
"      Large (&gt;25 mm) and located in the posterior circulation, due to the high risk of complications from treatment",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      For 40 year old patients, treatment was ineffective or not cost effective for aneurysms with the following characteristics:",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      Small (&lt;12 mm) or large (&gt;25 mm) and located in the cavernous carotid artery",
"     </li>",
"     <li>",
"      Small (&lt;7 mm) and located in the anterior circulation",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H25\">",
"    <span class=\"h2\">",
"     Special situations",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H26\">",
"    <span class=\"h3\">",
"     With AVM",
"    </span>",
"    &nbsp;&mdash;&nbsp;Rare patients have an intracranial aneurysm associated with an intracranial arteriovenous malformations (AVM). These aneurysms are more likely to be associated with growth and rupture than aneurysms in general [",
"    <a class=\"abstract\" href=\"UTD.htm?24/40/25225/abstract/62\">",
"     62",
"    </a>",
"    ]. Therefore, repairing the aneurysm prior to treating the AVM is recommended.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H27\">",
"    <span class=\"h3\">",
"     Carotid stenosis",
"    </span>",
"    &nbsp;&mdash;&nbsp;One study found that intracranial aneurysms appeared to be more common than expected in a population of patients with symptomatic carotid artery disease, perhaps because of shared risk factors [",
"    <a class=\"abstract\" href=\"UTD.htm?24/40/25225/abstract/63\">",
"     63",
"    </a>",
"    ]. Aneurysms distal to a symptomatic cervical internal carotid artery stenosis may be susceptible to sudden hemodynamic changes with carotid endarterectomy (CEA) that could lead to aneurysmal rupture [",
"    <a class=\"abstract\" href=\"UTD.htm?24/40/25225/abstract/8\">",
"     8",
"    </a>",
"    ]. On the other hand, surgical clipping of an aneurysm distal to a severe internal carotid stenosis may increase the risk of ischemic stroke.",
"   </p>",
"   <p>",
"    Unfortunately, data for this situation are too sparse to allow firm conclusions as to which problem should be tackled first. However, caution is advised if CEA is performed in this setting, especially if the unruptured ipsilateral aneurysm is 7 mm or larger in diameter or if there is a history of SAH from another aneurysm.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H28\">",
"    <span class=\"h3\">",
"     Use of antithrombotic therapy",
"    </span>",
"    &nbsp;&mdash;&nbsp;Patients with intracranial aneurysms may require antithrombotic therapy for the management of other conditions such as atrial fibrillation. The available data are limited, somewhat conflicting, and not sufficient to determine whether anticoagulant (eg,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?27/41/28314?source=see_link\">",
"     warfarin",
"    </a>",
"    ) or antiplatelet therapy increases the risk of aneurysm rupture. While other studies have suggested a higher associated risk, a trend of a protective effect of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?24/7/24698?source=see_link\">",
"     aspirin",
"    </a>",
"    use (&ge;3 times weekly) for the risk of aneurysm rupture was noted in a nested case-control study using the untreated cohort of patients in the ISUIA study (adjusted OR = 0.27; 95% CI 0.11 &ndash; 0.67) [",
"    <a class=\"abstract\" href=\"UTD.htm?24/40/25225/abstract/64\">",
"     64",
"    </a>",
"    ]. This finding requires confirmation in other studies.",
"   </p>",
"   <p>",
"    However, anticoagulant therapy does appear to increase the severity of rupture should it occur. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?32/36/33348?source=see_link\">",
"     \"Anticoagulant and antiplatelet therapy in patients with an unruptured intracranial aneurysm\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H29\">",
"    <span class=\"h1\">",
"     RECOMMENDATIONS",
"    </span>",
"    &nbsp;&mdash;&nbsp;The available studies emphasize the need to examine each case individually, considering factors such as comorbid medical illness, patient age, aneurysm size and location, and risks of treatment. The sum of these data support expectant management of very small saccular aneurysms, particularly when such aneurysms are located in the anterior circulation or when they are detected in older patients.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H30\">",
"    <span class=\"h2\">",
"     Whom to treat",
"    </span>",
"    &nbsp;&mdash;&nbsp;A task force of the Stroke Council of the American Heart Association published recommendations (also prior to the 2003 ISUIA data) for the management of patients with an unruptured intracranial aneurysm that are similar to the above recommendations [",
"    <a class=\"abstract\" href=\"UTD.htm?24/40/25225/abstract/65\">",
"     65",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The treatment of small incidental intracavernous internal carotid artery aneurysms is generally not indicated. For large symptomatic intracavernous aneurysms, treatment decisions should be individualized on the basis of patient age, severity and progression of symptoms, and treatment alternatives. The higher risk of treatment and shorter life expectancy in older individuals must be considered in all patients, and it favors observation in older patients with asymptomatic aneurysms.",
"     </li>",
"     <li>",
"      Symptomatic intradural aneurysms of all sizes should be considered for treatment with relative urgency.",
"     </li>",
"     <li>",
"      Coexisting or remaining aneurysms of all sizes in patients with a SAH due to another treated aneurysm warrant consideration for treatment. Aneurysms located at the basilar apex carry a relatively high risk of rupture. Treatment decisions must take into account the patient's age, existing medical and neurologic condition, and relative risks of repair. If a decision is made for observation, reevaluation on a periodic basis with",
"      <span class=\"nowrap\">",
"       CTA/MRA",
"      </span>",
"      or selective contrast angiography should be considered, with changes in aneurysmal size sought, although careful attention to technical factors will be required to optimize the reliability of these measures.",
"     </li>",
"     <li>",
"      Given the apparent low risk of hemorrhage from incidental, small (&lt;7 mm) aneurysms in patients without previous SAH, observation rather than intervention is generally advocated. However, special consideration for treatment should be given to young (&lt;50 years) patients in this group.",
"     </li>",
"     <li>",
"      Asymptomatic aneurysms &ge;7 to 10 mm in diameter warrant strong consideration for treatment, taking into account patient age, existing medical and neurologic conditions, and relative risks for treatment [",
"      <a class=\"abstract\" href=\"UTD.htm?24/40/25225/abstract/66\">",
"       66",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H48585018\">",
"    <span class=\"h2\">",
"     Choice of procedure",
"    </span>",
"    &nbsp;&mdash;&nbsp;Surgical treatment of unruptured aneurysms has been the most common procedure used in patients who undergo definitive therapy. In clinical studies, which are typically in centers with high case volumes, endovascular techniques appear to be associated with lower morbidity and mortality than surgical clipping and are playing an increasing role in the treatment of unruptured aneurysms [",
"    <a class=\"abstract\" href=\"UTD.htm?24/40/25225/abstract/67-70\">",
"     67-70",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?36/54/37738?source=see_link\">",
"     \"Treatment of aneurysmal subarachnoid hemorrhage\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H31\">",
"    <span class=\"h2\">",
"     Monitoring",
"    </span>",
"    &nbsp;&mdash;&nbsp;For patients with unruptured intracranial aneurysms that are not treated with open surgery or endovascular methods, the following recommendations are made for monitoring [",
"    <a class=\"abstract\" href=\"UTD.htm?24/40/25225/abstract/8\">",
"     8",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      We suggest that unruptured intracranial aneurysms be monitored with CTA or MRA annually for two to three years, and every two to five years thereafter if the aneurysm is clinically and radiographically stable [",
"      <a class=\"abstract\" href=\"UTD.htm?24/40/25225/abstract/8\">",
"       8",
"      </a>",
"      ]. However, it is not unreasonable to obtain the first reimaging study of newly detected small aneurysms at six months, since there is evidence that newly formed small aneurysms may be at higher risk of rupture than older more stable aneurysms (see",
"      <a class=\"local\" href=\"#H15\">",
"       'Hypothesis of growth and rupture'",
"      </a>",
"      above). Longer reimaging intervals are certainly appropriate if the six-month study shows no significant change.",
"     </li>",
"     <li>",
"      Patients should be instructed to avoid smoking, heavy alcohol consumption, stimulant medications, illicit drugs, and excessive straining and Valsalva maneuvers.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"PATIENT_INFORMATION\">",
"    <span class=\"h1\">",
"     INFORMATION FOR PATIENTS",
"    </span>",
"    &nbsp;&mdash;&nbsp;UpToDate offers two types of patient education materials, &ldquo;The Basics&rdquo; and &ldquo;Beyond the Basics.&rdquo; The Basics patient education pieces are written in plain language, at the 5",
"    <sup>",
"     th",
"    </sup>",
"    to 6",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10",
"    <sup>",
"     th",
"    </sup>",
"    to 12",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.",
"   </p>",
"   <p>",
"    Here are the patient education articles that are relevant to this topic. We encourage you to print or e-mail these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on &ldquo;patient info&rdquo; and the keyword(s) of interest.)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Basics topic (see",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?5/17/5394?source=see_link\">",
"       \"Patient information: Brain aneurysm (The Basics)\"",
"      </a>",
"      )",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/40/25225/abstract/1\">",
"      Vernooij MW, Ikram MA, Tanghe HL, et al. Incidental findings on brain MRI in the general population. N Engl J Med 2007; 357:1821.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/40/25225/abstract/2\">",
"      Vlak MH, Algra A, Brandenburg R, Rinkel GJ. Prevalence of unruptured intracranial aneurysms, with emphasis on sex, age, comorbidity, country, and time period: a systematic review and meta-analysis. Lancet Neurol 2011; 10:626.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/40/25225/abstract/3\">",
"      STEHBENS WE. ANEURYSMS AND ANATOMICAL VARIATION OF CEREBRAL ARTERIES. Arch Pathol 1963; 75:45.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/40/25225/abstract/4\">",
"      Sarti C, Tuomilehto J, Salomaa V, et al. Epidemiology of subarachnoid hemorrhage in Finland from 1983 to 1985. Stroke 1991; 22:848.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/40/25225/abstract/5\">",
"      Schievink WI. Intracranial aneurysms. N Engl J Med 1997; 336:28.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/40/25225/abstract/6\">",
"      Austin G, Fisher S, Dickson D, et al. The significance of the extracellular matrix in intracranial aneurysms. Ann Clin Lab Sci 1993; 23:97.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/40/25225/abstract/7\">",
"      Patel RL, Richards P, Chambers DJ, Venn G. Infective endocarditis complicated by ruptured cerebral mycotic aneurysm. J R Soc Med 1991; 84:746.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/40/25225/abstract/8\">",
"      Wiebers DO, Piepgras DG, Meyer FB, et al. Pathogenesis, natural history, and treatment of unruptured intracranial aneurysms. Mayo Clin Proc 2004; 79:1572.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/40/25225/abstract/9\">",
"      Fr&ouml;sen J, Piippo A, Paetau A, et al. Remodeling of saccular cerebral artery aneurysm wall is associated with rupture: histological analysis of 24 unruptured and 42 ruptured cases. Stroke 2004; 35:2287.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/40/25225/abstract/10\">",
"      Neil-Dwyer G, Bartlett JR, Nicholls AC, et al. Collagen deficiency and ruptured cerebral aneurysms. A clinical and biochemical study. J Neurosurg 1983; 59:16.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/40/25225/abstract/11\">",
"      Pepin M, Schwarze U, Superti-Furga A, Byers PH. Clinical and genetic features of Ehlers-Danlos syndrome type IV, the vascular type. N Engl J Med 2000; 342:673.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/40/25225/abstract/12\">",
"      Conway JE, Hutchins GM, Tamargo RJ. Marfan syndrome is not associated with intracranial aneurysms. Stroke 1999; 30:1632.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/40/25225/abstract/13\">",
"      Litchfield WR, Anderson BF, Weiss RJ, et al. Intracranial aneurysm and hemorrhagic stroke in glucocorticoid-remediable aldosteronism. Hypertension 1998; 31:445.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/40/25225/abstract/14\">",
"      Ronkainen A, Hernesniemi J, Puranen M, et al. Familial intracranial aneurysms. Lancet 1997; 349:380.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/40/25225/abstract/15\">",
"      Raaymakers TW. Aneurysms in relatives of patients with subarachnoid hemorrhage: frequency and risk factors. MARS Study Group. Magnetic Resonance Angiography in Relatives of patients with Subarachnoid hemorrhage. Neurology 1999; 53:982.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/40/25225/abstract/16\">",
"      Bromberg JE, Rinkel GJ, Algra A, et al. Familial subarachnoid hemorrhage: distinctive features and patterns of inheritance. Ann Neurol 1995; 38:929.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/40/25225/abstract/17\">",
"      Wills S, Ronkainen A, van der Voet M, et al. Familial intracranial aneurysms: an analysis of 346 multiplex Finnish families. Stroke 2003; 34:1370.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/40/25225/abstract/18\">",
"      Onda H, Kasuya H, Yoneyama T, et al. Genomewide-linkage and haplotype-association studies map intracranial aneurysm to chromosome 7q11. Am J Hum Genet 2001; 69:804.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/40/25225/abstract/19\">",
"      Hashikata H, Liu W, Inoue K, et al. Confirmation of an association of single-nucleotide polymorphism rs1333040 on 9p21 with familial and sporadic intracranial aneurysms in Japanese patients. Stroke 2010; 41:1138.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/40/25225/abstract/20\">",
"      van der Voet M, Olson JM, Kuivaniemi H, et al. Intracranial aneurysms in Finnish families: confirmation of linkage and refinement of the interval to chromosome 19q13.3. Am J Hum Genet 2004; 74:564.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/40/25225/abstract/21\">",
"      Deka R, Koller DL, Lai D, et al. The relationship between smoking and replicated sequence variants on chromosomes 8 and 9 with familial intracranial aneurysm. Stroke 2010; 41:1132.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/40/25225/abstract/22\">",
"      St Jean P, Hart B, Webster M, et al. Alpha-1-antitrypsin deficiency in aneurysmal disease. Hum Hered 1996; 46:92.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/40/25225/abstract/23\">",
"      Broderick JP, Brown RD Jr, Sauerbeck L, et al. Greater rupture risk for familial as compared to sporadic unruptured intracranial aneurysms. Stroke 2009; 40:1952.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/40/25225/abstract/24\">",
"      Teunissen LL, Rinkel GJ, Algra A, van Gijn J. Risk factors for subarachnoid hemorrhage: a systematic review. Stroke 1996; 27:544.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/40/25225/abstract/25\">",
"      Knekt P, Reunanen A, Aho K, et al. Risk factors for subarachnoid hemorrhage in a longitudinal population study. J Clin Epidemiol 1991; 44:933.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/40/25225/abstract/26\">",
"      Lepp&auml;l&auml; JM, Paunio M, Virtamo J, et al. Alcohol consumption and stroke incidence in male smokers. Circulation 1999; 100:1209.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/40/25225/abstract/27\">",
"      Bonita R. Cigarette smoking, hypertension and the risk of subarachnoid hemorrhage: a population-based case-control study. Stroke 1986; 17:831.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/40/25225/abstract/28\">",
"      Stober T, Sen S, Anst&auml;tt T, et al. Direct evidence of hypertension and the possible role of post-menopause oestrogen deficiency in the pathogenesis of berry aneurysms. J Neurol 1985; 232:67.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/40/25225/abstract/29\">",
"      Taylor CL, Yuan Z, Selman WR, et al. Cerebral arterial aneurysm formation and rupture in 20,767 elderly patients: hypertension and other risk factors. J Neurosurg 1995; 83:812.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/40/25225/abstract/30\">",
"      Longstreth WT, Nelson LM, Koepsell TD, van Belle G. Subarachnoid hemorrhage and hormonal factors in women. A population-based case-control study. Ann Intern Med 1994; 121:168.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/40/25225/abstract/31\">",
"      Mhurchu CN, Anderson C, Jamrozik K, et al. Hormonal factors and risk of aneurysmal subarachnoid hemorrhage: an international population-based, case-control study. Stroke 2001; 32:606.",
"     </a>",
"    </li>",
"    <li>",
"     Perloff JK. The Clinical Recognition of Congenital Heart Disease, 4th, WB Saunders, Philadelphia 1994.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/40/25225/abstract/33\">",
"      HODES HL, STEINFELD L, BLUMENTHAL S. Congenital cerebral aneurysms and coarctation of the aorta. Arch Pediatr 1959; 76:28.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/40/25225/abstract/34\">",
"      Wiebers DO, Whisnant JP, Huston J 3rd, et al. Unruptured intracranial aneurysms: natural history, clinical outcome, and risks of surgical and endovascular treatment. Lancet 2003; 362:103.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/40/25225/abstract/35\">",
"      Unruptured intracranial aneurysms--risk of rupture and risks of surgical intervention. International Study of Unruptured Intracranial Aneurysms Investigators. N Engl J Med 1998; 339:1725.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/40/25225/abstract/36\">",
"      Wiebers DO, Whisnant JP, O'Fallon WM. The natural history of unruptured intracranial aneurysms. N Engl J Med 1981; 304:696.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/40/25225/abstract/37\">",
"      Wiebers DO, Whisnant JP, Sundt TM Jr, O'Fallon WM. The significance of unruptured intracranial saccular aneurysms. J Neurosurg 1987; 66:23.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/40/25225/abstract/38\">",
"      Sonobe M, Yamazaki T, Yonekura M, Kikuchi H. Small unruptured intracranial aneurysm verification study: SUAVe study, Japan. Stroke 2010; 41:1969.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/40/25225/abstract/39\">",
"      Matsubara S, Hadeishi H, Suzuki A, et al. Incidence and risk factors for the growth of unruptured cerebral aneurysms: observation using serial computerized tomography angiography. J Neurosurg 2004; 101:908.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/40/25225/abstract/40\">",
"      Burns JD, Huston J 3rd, Layton KF, et al. Intracranial aneurysm enlargement on serial magnetic resonance angiography: frequency and risk factors. Stroke 2009; 40:406.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/40/25225/abstract/41\">",
"      Forget TR Jr, Benitez R, Veznedaroglu E, et al. A review of size and location of ruptured intracranial aneurysms. Neurosurgery 2001; 49:1322.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/40/25225/abstract/42\">",
"      White PM, Wardlaw J. Unruptured intracranial aneurysms: prospective data have arrived. Lancet 2003; 362:90.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/40/25225/abstract/43\">",
"      Sato K, Yoshimoto Y. Risk profile of intracranial aneurysms: rupture rate is not constant after formation. Stroke 2011; 42:3376.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/40/25225/abstract/44\">",
"      Ingall T, Asplund K, M&auml;h&ouml;nen M, Bonita R. A multinational comparison of subarachnoid hemorrhage epidemiology in the WHO MONICA stroke study. Stroke 2000; 31:1054.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/40/25225/abstract/45\">",
"      Morita A, Fujiwara S, Hashi K, et al. Risk of rupture associated with intact cerebral aneurysms in the Japanese population: a systematic review of the literature from Japan. J Neurosurg 2005; 102:601.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/40/25225/abstract/46\">",
"      Morita A. [On-line outcome study of unruptured cerebral aneurysm in Japan (UCAS Japan)]. Rinsho Shinkeigaku 2002; 42:1188.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/40/25225/abstract/47\">",
"      Yonekura M. Small unruptured aneurysm verification (SUAVe Study, Japan)--interim report. Neurol Med Chir (Tokyo) 2004; 44:213.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/40/25225/abstract/48\">",
"      Raps EC, Rogers JD, Galetta SL, et al. The clinical spectrum of unruptured intracranial aneurysms. Arch Neurol 1993; 50:265.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/40/25225/abstract/49\">",
"      Friedman JA, Piepgras DG, Pichelmann MA, et al. Small cerebral aneurysms presenting with symptoms other than rupture. Neurology 2001; 57:1212.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/40/25225/abstract/50\">",
"      Huston J 3rd, Nichols DA, Luetmer PH, et al. Blinded prospective evaluation of sensitivity of MR angiography to known intracranial aneurysms: importance of aneurysm size. AJNR Am J Neuroradiol 1994; 15:1607.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/40/25225/abstract/51\">",
"      Schwartz RB, Tice HM, Hooten SM, et al. Evaluation of cerebral aneurysms with helical CT: correlation with conventional angiography and MR angiography. Radiology 1994; 192:717.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/40/25225/abstract/52\">",
"      White PM, Teadsale E, Wardlaw JM, Easton V. What is the most sensitive non-invasive imaging strategy for the diagnosis of intracranial aneurysms? J Neurol Neurosurg Psychiatry 2001; 71:322.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/40/25225/abstract/53\">",
"      van Gelder JM. Computed tomographic angiography for detecting cerebral aneurysms: implications of aneurysm size distribution for the sensitivity, specificity, and likelihood ratios. Neurosurgery 2003; 53:597.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/40/25225/abstract/54\">",
"      Menke J, Larsen J, Kallenberg K. Diagnosing cerebral aneurysms by computed tomographic angiography: meta-analysis. Ann Neurol 2011; 69:646.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/40/25225/abstract/55\">",
"      Li MH, Li YD, Tan HQ, et al. Contrast-free MRA at 3.0 T for the detection of intracranial aneurysms. Neurology 2011; 77:667.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/40/25225/abstract/56\">",
"      Johnston SC, Wilson CB, Halbach VV, et al. Endovascular and surgical treatment of unruptured cerebral aneurysms: comparison of risks. Ann Neurol 2000; 48:11.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/40/25225/abstract/57\">",
"      Alshekhlee A, Mehta S, Edgell RC, et al. Hospital mortality and complications of electively clipped or coiled unruptured intracranial aneurysm. Stroke 2010; 41:1471.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/40/25225/abstract/58\">",
"      Ogilvy CS, Carter BS. Stratification of outcome for surgically treated unruptured intracranial aneurysms. Neurosurgery 2003; 52:82.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/40/25225/abstract/59\">",
"      Pierot L, Barbe C, Spelle L, ATENA investigators. Endovascular treatment of very small unruptured aneurysms: rate of procedural complications, clinical outcome, and anatomical results. Stroke 2010; 41:2855.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/40/25225/abstract/60\">",
"      Johnston SC, Gress DR, Kahn JG. Which unruptured cerebral aneurysms should be treated? A cost-utility analysis. Neurology 1999; 52:1806.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/40/25225/abstract/61\">",
"      Takao H, Nojo T. Treatment of unruptured intracranial aneurysms: decision and cost-effectiveness analysis. Radiology 2007; 244:755.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/40/25225/abstract/62\">",
"      Wiebers DO, Torres VE. Screening for unruptured intracranial aneurysms in autosomal dominant polycystic kidney disease. N Engl J Med 1992; 327:953.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/40/25225/abstract/63\">",
"      H&eacute;man LM, Jongen LM, van der Worp HB, et al. Incidental intracranial aneurysms in patients with internal carotid artery stenosis: a CT angiography study and a metaanalysis. Stroke 2009; 40:1341.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/40/25225/abstract/64\">",
"      Hasan DM, Mahaney KB, Brown RD Jr, et al. Aspirin as a promising agent for decreasing incidence of cerebral aneurysm rupture. Stroke 2011; 42:3156.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/40/25225/abstract/65\">",
"      Bederson JB, Awad IA, Wiebers DO, et al. Recommendations for the management of patients with unruptured intracranial aneurysms: A statement for healthcare professionals from the Stroke Council of the American Heart Association. Circulation 2000; 102:2300.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/40/25225/abstract/66\">",
"      Greving JP, Rinkel GJ, Buskens E, Algra A. Cost-effectiveness of preventive treatment of intracranial aneurysms: new data and uncertainties. Neurology 2009; 73:258.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/40/25225/abstract/67\">",
"      Johnston SC, Zhao S, Dudley RA, et al. Treatment of unruptured cerebral aneurysms in California. Stroke 2001; 32:597.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/40/25225/abstract/68\">",
"      Vallee JN, Aymard A, Vicaut E, et al. Endovascular treatment of basilar tip aneurysms with Guglielmi detachable coils: predictors of immediate and long-term results with multivariate analysis 6-year experience. Radiology 2003; 226:867.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/40/25225/abstract/69\">",
"      Raftopoulos C, Goffette P, Vaz G, et al. Surgical clipping may lead to better results than coil embolization: results from a series of 101 consecutive unruptured intracranial aneurysms. Neurosurgery 2003; 52:1280.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/40/25225/abstract/70\">",
"      Zacharia BE, Ducruet AF, Hickman ZL, et al. Technological advances in the management of unruptured intracranial aneurysms fail to improve outcome in New York state. Stroke 2011; 42:2844.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 1132 Version 12.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.3 - C21.34",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Morehouse School of Medicine",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1104-85.214.214.87-D5DBC4741A-S473950.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f24_40_25225=[""].join("\n");
var outline_f24_40_25225=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H29\" id=\"summRecButton\">",
"      <span>",
"       RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      EPIDEMIOLOGY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      PATHOGENESIS AND RISK FACTORS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      Morphological factors",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      Genetic factors",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      - Hereditary syndromes",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      - Familial aneurysms",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      Other factors",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      - Cigarette smoking",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      - Hypertension",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      - Estrogen deficiency",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      - Coarctation of the aorta",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      NATURAL HISTORY OF UNRUPTURED ANEURYSMS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      Size",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      - Hypothesis of growth and rupture",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H16\">",
"      Site",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H17\">",
"      Racial differences",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H18\">",
"      Prior hemorrhage",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H19\">",
"      Family history",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H20\">",
"      CLINICAL MANIFESTATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H21\">",
"      DIAGNOSIS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H22\">",
"      MANAGEMENT OF UNRUPTURED ANEURYSMS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H23\">",
"      Risk of intervention",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H24\">",
"      Benefit of intervention",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H25\">",
"      Special situations",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H26\">",
"      - With AVM",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H27\">",
"      - Carotid stenosis",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H28\">",
"      - Use of antithrombotic therapy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H29\">",
"      RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H30\">",
"      Whom to treat",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H48585018\">",
"      Choice of procedure",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H31\">",
"      Monitoring",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#PATIENT_INFORMATION\">",
"      INFORMATION FOR PATIENTS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"NEURO/1132\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"NEURO/1132|FIG\">",
"      <a href=\"#\" title=\"FIGURES\">",
"       FIGURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?14/0/14349\" title=\"figure 1A\">",
"      Sensitivity of CTA for intracranial aneurysm",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?4/56/5005\" title=\"figure 1B\">",
"      CTA false pos intracran aneurys",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?32/36/33348?source=related_link\">",
"      Anticoagulant and antiplatelet therapy in patients with an unruptured intracranial aneurysm",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?22/53/23385?source=related_link\">",
"      Clinical manifestations and diagnosis of coarctation of the aorta",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?43/45/44761?source=related_link\">",
"      Clinical manifestations and diagnosis of menopause",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?37/39/38522?source=related_link\">",
"      Etiology, clinical manifestations, and diagnosis of aneurysmal subarachnoid hemorrhage",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?29/33/30233?source=related_link\">",
"      Extrarenal manifestations of autosomal dominant polycystic kidney disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?22/5/22615?source=related_link\">",
"      Familial hyperaldosteronism",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?3/44/3786?source=related_link\">",
"      Moyamoya disease: Etiology, clinical features, and diagnosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?5/17/5394?source=related_link\">",
"      Patient information: Brain aneurysm (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?3/43/3767?source=related_link\">",
"      Screening for intracranial aneurysm",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?35/63/36856?source=related_link\">",
"      Third cranial nerve (oculomotor nerve) palsy in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?36/54/37738?source=related_link\">",
"      Treatment of aneurysmal subarachnoid hemorrhage",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f24_40_25226="Cardiac involvement in HIV-infected patients";
var content_f24_40_25226=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"4\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Cardiac involvement in HIV-infected patients",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?24/40/25226/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?24/40/25226/contributors\">",
"     Melvin D Cheitlin, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?24/40/25226/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?24/40/25226/contributors\">",
"     John G Bartlett, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?24/40/25226/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?24/40/25226/contributors\">",
"     Allyson Bloom, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?24/40/25226/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Nov 23, 2010.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Cardiac abnormalities were appreciated early in the epidemic of acquired immunodeficiency syndrome (AIDS), even before the etiologic agent, human immunodeficiency virus (HIV) was isolated and characterized. The etiology and pathogenesis of myocarditis and cardiomyopathy in association with HIV infection is still the subject of intense speculation [",
"    <a class=\"abstract\" href=\"UTD.htm?24/40/25226/abstract/1,2\">",
"     1,2",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    This topic is devoted to the spectrum of cardiac diseases seen in HIV-infected patients. Discussions related specifically to coronary artery disease and its management in HIV-infected patients is discussed elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?26/1/26650?source=see_link\">",
"     \"Epidemiology of cardiovascular disease and risk factors in HIV-infected patients\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?0/3/49?source=see_link\">",
"     \"Management of dyslipidemia and cardiovascular risk in the HIV-infected patient\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     TYPES OF CARDIAC DISEASE",
"    </span>",
"    &nbsp;&mdash;&nbsp;Patients with advanced HIV infection can have a variety of cardiovascular manifestations. The most common are:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Pericarditis",
"     </li>",
"     <li>",
"      Myocarditis",
"     </li>",
"     <li>",
"      Cardiomyopathy",
"     </li>",
"     <li>",
"      Pulmonary vascular disease and pulmonary hypertension",
"     </li>",
"     <li>",
"      Valvular disease",
"     </li>",
"     <li>",
"      An increased incidence of vascular disease including coronary artery disease",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h1\">",
"     EPIDEMIOLOGY",
"    </span>",
"    &nbsp;&mdash;&nbsp;Symptomatic cardiac disease was described first in children but is also seen in HIV-infected adults [",
"    <a class=\"abstract\" href=\"UTD.htm?24/40/25226/abstract/3,4\">",
"     3,4",
"    </a>",
"    ]. Patients with AIDS can have cardiac pathology related to opportunistic infections and tumors. In one small autopsy series, major cardiac pathology was noted in 24 percent of cases [",
"    <a class=\"abstract\" href=\"UTD.htm?24/40/25226/abstract/5\">",
"     5",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Many of the studies of cardiovascular disease in HIV-infected patients were performed before the availability of highly active antiretroviral therapy (HAART); thus, the applicability of some of the following observations to current practice is uncertain. With the introduction of HAART, patients are living longer and other comorbidities have surfaced, such as hypertension, metabolic abnormalities (hyperglycemia, hyperlipidemia, lipodystrophy), and accelerated atherosclerosis, including coronary artery disease [",
"    <a class=\"abstract\" href=\"UTD.htm?24/40/25226/abstract/6-8\">",
"     6-8",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?26/1/26650?source=see_link\">",
"     \"Epidemiology of cardiovascular disease and risk factors in HIV-infected patients\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    In Africa, the incidence of AIDS-related cardiac disease is very high compared to that seen in western developed countries. For instance, in the period from 1993 to 1999 in Burkina Faso, 79 percent of the AIDS patients exhibited heart involvement, including myocarditis and cardiomyopathy, whereas in an Italian study in the period from 1992 to 1995, the incidence of AIDS-related cardiac disease was 6.5 percent [",
"    <a class=\"abstract\" href=\"UTD.htm?24/40/25226/abstract/9\">",
"     9",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h1\">",
"     PERICARDITIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;The most frequent clinical manifestation of cardiovascular disease in patients with AIDS is pericardial disease. Echocardiographic studies have identified a pericardial effusion in approximately 20 percent (range 10 to 40 percent) of these patients, and the effusion is large in 4 percent [",
"    <a class=\"abstract\" href=\"UTD.htm?24/40/25226/abstract/10-15\">",
"     10-15",
"    </a>",
"    ]. Patients who develop a pericardial effusion generally have a poor prognosis (see below).",
"   </p>",
"   <p>",
"    One report, for example, summarized results of serial echocardiograms in 195 HIV-infected subjects (59 asymptomatic, 62 with early symptoms, and 74 with AIDS) [",
"    <a class=\"abstract\" href=\"UTD.htm?24/40/25226/abstract/14\">",
"     14",
"    </a>",
"    ]. Pericardial effusions were essentially limited to the patients with AIDS. They were present in 5 percent at study entry and developed during follow-up at a rate of 11 percent per year. Almost all of the effusions were small and asymptomatic; only two of the patients developed clinical pericarditis. In a review of the literature, in 15 autopsy and echocardiographic series involving 1139 patients with HIV infection, the average prevalence of pericardial disease is 21 percent. Most cases were asymptomatic and without an identifiable etiology. In the symptomatic patients, approximately two-thirds were caused by infection or neoplasm [",
"    <a class=\"abstract\" href=\"UTD.htm?24/40/25226/abstract/15\">",
"     15",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Among all patients who present with pericardial effusion, the proportion associated with HIV infection will vary markedly according to the type of hospital. Among hospitals in which HIV-infected patients are commonly seen, HIV infection has been found in 7 percent of all pericardial effusions [",
"    <a class=\"abstract\" href=\"UTD.htm?24/40/25226/abstract/16\">",
"     16",
"    </a>",
"    ] and 28 to 33 percent of clinically significant pericardial effusions [",
"    <a class=\"abstract\" href=\"UTD.htm?24/40/25226/abstract/17,18\">",
"     17,18",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The picture of clinical pericarditis is similar to that of pericarditis from etiologies other than HIV. Some patients are symptomatic with fever, pleuritic chest pain, and, in some cases, a pericardial friction rub. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?36/47/37625?source=see_link\">",
"     \"Clinical presentation and diagnostic evaluation of acute pericarditis\"",
"    </a>",
"    .) However, most patients present with an asymptomatic increase in the cardiac silhouette on chest x-ray. In the experience at San Francisco General Hospital, about one-third of the symptomatic patients present with or develop signs of pericardial tamponade. Similar findings have been noted by others [",
"    <a class=\"abstract\" href=\"UTD.htm?24/40/25226/abstract/18\">",
"     18",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The clinical spectrum of disease etiology in HIV-infected patients with pericardial effusions is broad [",
"    <a class=\"abstract\" href=\"UTD.htm?24/40/25226/abstract/8,16,18-21\">",
"     8,16,18-21",
"    </a>",
"    ]. Mycobacterium tuberculosis, atypical mycobacteria, fungi, Staphylococcus aureus, and Streptococcus pneumoniae have all been described, as well as more unusual pathogens such as Nocardia asteroides, Listeria monocytogenes, Rhodococcus equi, and Chlamydia trachomatis. Neoplasms, particularly lymphoma and Kaposi's sarcoma, also can cause pericardial effusion. In other studies, M. tuberculosis was seen to be a frequent etiology [",
"    <a class=\"abstract\" href=\"UTD.htm?24/40/25226/abstract/22-26\">",
"     22-26",
"    </a>",
"    ]. In sub-Saharan Africa, where tuberculosis is endemic and access to ART is limited, pericardial disease is one of the most common forms of heart disease seen in HIV-infected patients [",
"    <a class=\"abstract\" href=\"UTD.htm?24/40/25226/abstract/27\">",
"     27",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The relative frequency of these disorders can be illustrated by the following observations:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      In a report of 29 patients with AIDS who underwent a pericardial window for pericardial effusion, culture and biopsy specimens established a diagnosis in only seven (three with lymphoma, two with adenocarcinoma, and one each with tuberculosis and S. aureus) [",
"      <a class=\"abstract\" href=\"UTD.htm?24/40/25226/abstract/19\">",
"       19",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      In a review of 74 reported cases of cardiac tamponade in HIV-infected patients, the major causes were idiopathic (45 percent), mycobacteria (20 percent), bacteria (19 percent), lymphoma (7 percent), Kaposi's sarcoma (5 percent), viruses (3 percent), and fungi (1 percent) [",
"      <a class=\"abstract\" href=\"UTD.htm?24/40/25226/abstract/18\">",
"       18",
"      </a>",
"      ]. Therefore, more than one-half of the symptomatic patients with pericarditis have an identifiable, and possibly treatable, etiology.",
"     </li>",
"     <li>",
"      In a review of 185 cases of pericardial tamponade, mycobacterial infection was the most common etiology (42 percent), including M. tuberculosis, M. avium-intracellulare, and M. kansasii [",
"      <a class=\"abstract\" href=\"UTD.htm?24/40/25226/abstract/18\">",
"       18",
"      </a>",
"      ]. Other etiologies included Staphylococcus aureus (11 percent), neoplasms, including lymphoma and Kaposi's sarcoma (15 percent), and isolated cases of Cryptococcus, Nocardia, and Aspergillus species. In 26 percent, no etiology was identified [",
"      <a class=\"abstract\" href=\"UTD.htm?24/40/25226/abstract/28\">",
"       28",
"      </a>",
"      ].",
"      <br/>",
"      <br/>",
"      Tuberculous pericarditis may be difficult to diagnose in patients with AIDS. Cutaneous anergy is common in this setting (61 percent in one series) [",
"      <a class=\"abstract\" href=\"UTD.htm?24/40/25226/abstract/29\">",
"       29",
"      </a>",
"      ]; as a result, a negative",
"      <a class=\"drug drug_general\" href=\"UTD.htm?15/35/15924?source=see_link\">",
"       tuberculin skin test",
"      </a>",
"      does not exclude the diagnosis. Pericardial biopsy is more sensitive than smears and culture of pericardial fluid but may not be positive for caseating granulomata. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?2/36/2633?source=see_link\">",
"       \"Tuberculous pericarditis\"",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h2\">",
"     Treatment",
"    </span>",
"    &nbsp;&mdash;&nbsp;The evaluation and therapy of pericardial effusion in HIV-infected patients varies with the clinical setting. The majority of patients with a pericardial effusion have small effusions causing no symptoms. An asymptomatic, small pericardial effusion without tamponade often requires no further testing except for follow-up [",
"    <a class=\"abstract\" href=\"UTD.htm?24/40/25226/abstract/13,30\">",
"     13,30",
"    </a>",
"    ]. If, on the other hand, the patient is symptomatic and the effusion large, even without tamponade, pericardiocentesis is indicated to obtain cultures, cytology, and chemistries.",
"   </p>",
"   <p>",
"    If tamponade occurs, which, as noted above, occurs in as many as 33 to 40 percent of patients with clinical pericarditis [",
"    <a class=\"abstract\" href=\"UTD.htm?24/40/25226/abstract/18\">",
"     18",
"    </a>",
"    ], immediate drainage is necessary. A catheter is often left in the pericardial space to drain by underwater-seal suction for the next 48 hours. If the effusion returns, subxiphoid pericardiotomy with creation of a pericardial window can be performed [",
"    <a class=\"abstract\" href=\"UTD.htm?24/40/25226/abstract/19,21\">",
"     19,21",
"    </a>",
"    ]. An alternative with which there is much less experience is balloon pericardiotomy to rupture the pericardium into the left pleural cavity [",
"    <a class=\"abstract\" href=\"UTD.htm?24/40/25226/abstract/31,32\">",
"     31,32",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?18/52/19273?source=see_link\">",
"     \"Cardiac tamponade\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    It is generally recommended that patients with a large pericardial effusion in whom no etiology is established be treated empirically for M. tuberculosis. Patients with AIDS have responded successfully to conventional antituberculous therapy for tuberculous pericarditis [",
"    <a class=\"abstract\" href=\"UTD.htm?24/40/25226/abstract/33-35\">",
"     33-35",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Among all patients with tuberculous pericarditis, the addition of a one-month course of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?32/48/33536?source=see_link\">",
"     prednisolone",
"    </a>",
"    followed by a slow taper is associated with more rapid recovery, lower rates of mortality, and a decrease in surgical intervention. The administration of corticosteroid therapy as an adjunct to antituberculous therapy in patients with HIV infection and tuberculous pericarditis was given a class I recommendation by a 2004 task force of the European Society of Cardiology [",
"    <a class=\"abstract\" href=\"UTD.htm?24/40/25226/abstract/36\">",
"     36",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?2/36/2633?source=see_link\">",
"     \"Tuberculous pericarditis\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Other causes of pericarditis in patients with AIDS should also be treated when identified. Bacterial or fungal infection should be treated with appropriate drugs. Primary effusion lymphoma is a rare high-grade B-cell non-Hodgkin lymphoma associated with Kaposi sarcoma-associated",
"    <span class=\"nowrap\">",
"     herpesvirus/human",
"    </span>",
"    herpes virus 8 infection, mostly seen with HIV patients. Prognosis is poor with a median survival less than six months [",
"    <a class=\"abstract\" href=\"UTD.htm?24/40/25226/abstract/37\">",
"     37",
"    </a>",
"    ]. Pericarditis due to lymphoma has been treated with radiation therapy and chemotherapy [",
"    <a class=\"abstract\" href=\"UTD.htm?24/40/25226/abstract/38,39\">",
"     38,39",
"    </a>",
"    ]. However, responses are generally transient [",
"    <a class=\"abstract\" href=\"UTD.htm?24/40/25226/abstract/40\">",
"     40",
"    </a>",
"    ], and combination chemotherapy is associated with a significant risk of early death due to opportunistic infection [",
"    <a class=\"abstract\" href=\"UTD.htm?24/40/25226/abstract/38\">",
"     38",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h2\">",
"     Prognosis",
"    </span>",
"    &nbsp;&mdash;&nbsp;The development of pericardial effusion in a patient with AIDS is a bad prognostic sign, even if asymptomatic [",
"    <a class=\"abstract\" href=\"UTD.htm?24/40/25226/abstract/14,28,30,41\">",
"     14,28,30,41",
"    </a>",
"    ]. In the series of 195 patients described above, mortality in the patients with pericardial effusion was significantly higher than in the patients with AIDS who did not have an effusion (64 versus 7 percent at six months) [",
"    <a class=\"abstract\" href=\"UTD.htm?24/40/25226/abstract/14\">",
"     14",
"    </a>",
"    ]. The shortened survival remained significant (relative risk 2.2) after adjustment for lead time bias and risk factors. The pericardial effusions rarely directly contribute to mortality but rather serve as a marker of advanced HIV infection.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h1\">",
"     MYOCARDIAL DISEASE",
"    </span>",
"    &nbsp;&mdash;&nbsp;There are three major forms of myocardial disease in patients with AIDS:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Focal myocarditis, usually seen incidentally at autopsy",
"     </li>",
"     <li>",
"      Echocardiographic evidence of decreased left ventricular function",
"     </li>",
"     <li>",
"      Clinical cardiomyopathy",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h2\">",
"     Focal myocarditis",
"    </span>",
"    &nbsp;&mdash;&nbsp;The prevalence of focal myocarditis depends upon how it is determined. Autopsy studies have found myocarditis in 9 to 52 percent of HIV-infected patients (average 33 percent) [",
"    <a class=\"abstract\" href=\"UTD.htm?24/40/25226/abstract/20,42,43\">",
"     20,42,43",
"    </a>",
"    ]. Nearly all had focal collections of mononuclear cells with or without evidence of myocardial necrosis; ventricular dilatation was occasionally seen [",
"    <a class=\"abstract\" href=\"UTD.htm?24/40/25226/abstract/42\">",
"     42",
"    </a>",
"    ]. Most of these patients had had no cardiovascular signs or symptoms [",
"    <a class=\"abstract\" href=\"UTD.htm?24/40/25226/abstract/44\">",
"     44",
"    </a>",
"    ]; however, heart failure can occur.",
"   </p>",
"   <p>",
"    In a report from Rwanda [",
"    <a class=\"abstract\" href=\"UTD.htm?24/40/25226/abstract/45\">",
"     45",
"    </a>",
"    ], 416 HIV-positive patients without a history of previous cardiovascular disease, not receiving HAART, were enrolled from January to December 2005. By echocardiography, 71 (17.7 percent) had dilated cardiomyopathy. By multivariate analysis, low socio-economic status, duration of HIV infection, CD4 cell count, HIV-1 viral load, CDC Stage B and C of HIV disease, and low plasma level of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?13/37/13907?source=see_link\">",
"     selenium",
"    </a>",
"    were factors significantly associated with dilated cardiomyopathy.",
"   </p>",
"   <p>",
"    Among patients with myocarditis, opportunistic bacterial, fungal, and protozoan pathogens can be identified in 10 to 15 percent of cases. In one autopsy series, 12 percent of 182 patients had cardiac toxoplasmosis [",
"    <a class=\"abstract\" href=\"UTD.htm?24/40/25226/abstract/46\">",
"     46",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?22/28/22986?source=see_link\">",
"     \"Etiology and pathogenesis of myocarditis\"",
"    </a>",
"    .) However, symptomatic disease appears to be rare. A French survey estimated the prevalence of clinical extracerebral toxoplasmosis at 1.5 to 2 percent; only 3 percent of these patients had cardiac disease [",
"    <a class=\"abstract\" href=\"UTD.htm?24/40/25226/abstract/47\">",
"     47",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Cytomegalovirus is another common opportunistic infection in patients with late stage AIDS that can cause myocarditis in selected patients [",
"    <a class=\"abstract\" href=\"UTD.htm?24/40/25226/abstract/43,48\">",
"     43,48",
"    </a>",
"    ]. Coxsackievirus infection is another possible etiology [",
"    <a class=\"abstract\" href=\"UTD.htm?24/40/25226/abstract/43,49\">",
"     43,49",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Since the introduction of HAART regimens there has been a marked reduction in the incidence of myocarditis and opportunistic infections, which has led to a nearly 30 percent reduction in HIV-associated cardiomyopathy [",
"    <a class=\"abstract\" href=\"UTD.htm?24/40/25226/abstract/50\">",
"     50",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h3\">",
"     Role of direct HIV infection",
"    </span>",
"    &nbsp;&mdash;&nbsp;The cause of the 80 to 85 percent of cases of apparently idiopathic myocarditis is uncertain. HIV itself may be responsible but other cardiotropic viruses, such as cytomegalovirus, coxsackievirus, or Epstein-Barr virus, also may be important [",
"    <a class=\"abstract\" href=\"UTD.htm?24/40/25226/abstract/8,26\">",
"     8,26",
"    </a>",
"    ]. It is not clear if HIV-associated disease is due to direct myocardial infection, an autoimmune process induced by HIV or other cardiotropic viruses, or coexisting opportunistic infection. Since the myocardial cell lacks CD4 receptors, HIV is denied the usual mode of entrance into the cell. However, the organism could enter the cell if the cell was injured by another virus. In in vitro studies, for example, Epstein-Barr virus permitted the entrance and replication of HIV into CD4 receptor-negative myocardial cells [",
"    <a class=\"abstract\" href=\"UTD.htm?24/40/25226/abstract/51\">",
"     51",
"    </a>",
"    ]. In addition, HIV has been localized in or near the myocardial cell by immunocytochemical techniques [",
"    <a class=\"abstract\" href=\"UTD.htm?24/40/25226/abstract/52,53\">",
"     52,53",
"    </a>",
"    ] and in situ DNA hybridization [",
"    <a class=\"abstract\" href=\"UTD.htm?24/40/25226/abstract/43,54,55\">",
"     43,54,55",
"    </a>",
"    ]. In one study, HIV-1 was seen in 25 percent of samples by in situ hybridization, albeit in low signal level [",
"    <a class=\"abstract\" href=\"UTD.htm?24/40/25226/abstract/54\">",
"     54",
"    </a>",
"    ]. However, HIV sequences also can be identified in HIV-infected patients without apparent cardiac disease. Evidence from studies of simian immunodeficiency virus (SIV)-infected primates supports retroviral infection of cells other than myocytes, mainly monocytes, as being the major cell type in inflammatory heart disease in the simian model [",
"    <a class=\"abstract\" href=\"UTD.htm?24/40/25226/abstract/56\">",
"     56",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    In a prospective echocardiographic survey of 296 adults infected with HIV and conducted over four years, dilated CMP, isolated right ventricular dilatation and borderline LV dysfunction was seen in 4, 4, and 6 percent of patients, respectively. Dilated CMP was associated with a CD4 cell count of",
"    <span class=\"nowrap\">",
"     &lt;100/mm",
"    </span>",
"    [",
"    <a class=\"abstract\" href=\"UTD.htm?24/40/25226/abstract/57\">",
"     57",
"    </a>",
"    ]. During the study 12 of 13 patients with dilated CMP and 8 of 19 patients with LV dysfunction died of AIDS-related conditions. The median survival from the index echocardiogram was 101 days (95% CI 42-146) for those with CMP and 472 days (95% CI 383-560) for AIDS patients with normal hearts. Patients with LV dysfunction alone had a survival similar to those with normal hearts [",
"    <a class=\"abstract\" href=\"UTD.htm?24/40/25226/abstract/57\">",
"     57",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h2\">",
"     Subclinical and clinical dilated cardiomyopathy",
"    </span>",
"    &nbsp;&mdash;&nbsp;Echocardiographic studies have identified cardiac abnormalities in 10 to 40 percent of patients with AIDS, with asymptomatic pericardial effusion and left ventricular systolic dysfunction being the most common findings [",
"    <a class=\"abstract\" href=\"UTD.htm?24/40/25226/abstract/10-12,30,58\">",
"     10-12,30,58",
"    </a>",
"    ]. Others have found a high prevalence of left ventricular diastolic dysfunction [",
"    <a class=\"abstract\" href=\"UTD.htm?24/40/25226/abstract/59,60\">",
"     59,60",
"    </a>",
"    ]. Clinically important cardiomyopathy is less common, but has been reported in up to 10 percent of patients [",
"    <a class=\"abstract\" href=\"UTD.htm?24/40/25226/abstract/61-65\">",
"     61-65",
"    </a>",
"    ]. These functional abnormalities can be transient [",
"    <a class=\"abstract\" href=\"UTD.htm?24/40/25226/abstract/30,66-68\">",
"     30,66-68",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The variability in the prevalence of cardiomyopathy in different studies may depend in part upon whether the patient is seen in a primary-care center or a tertiary referral center. This variance also depends upon whether or not the patient is an injection drug user (IDU). The range of findings can be illustrated by the following observations:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      In one series in which serial echocardiography was performed, global left ventricular hypokinesis was found in 10 of 69 (14 percent) asymptomatic HIV-infected patients [",
"      <a class=\"abstract\" href=\"UTD.htm?24/40/25226/abstract/65\">",
"       65",
"      </a>",
"      ]. Of the 59 patients with initially normal echoes, 11 developed hypokinesis over mean follow-up of 11 months (1.5 percent per month). It was estimated that the crude annual rate for overt cardiomyopathy was 2.1 percent in a clinic population of almost 2000 patients who were actively followed.",
"     </li>",
"     <li>",
"      A much lower incidence of echocardiographic dilated cardiomyopathy was noted in the series of 952 asymptomatic patients described above (1.6 percent per year) [",
"      <a class=\"abstract\" href=\"UTD.htm?24/40/25226/abstract/69\">",
"       69",
"      </a>",
"      ], and in another study of 136 HIV-infected patients without clinical, electrocardiographic or echocardiographic evidence of cardiovascular dysfunction on admission who were prospectively studied with serial echocardiograms; 93 of the patients had AIDS [",
"      <a class=\"abstract\" href=\"UTD.htm?24/40/25226/abstract/62\">",
"       62",
"      </a>",
"      ]. During a mean follow-up period of 415 days, seven patients, all in the AIDS subgroup, developed clinical and echocardiographic findings of acute global left ventricular dysfunction; six of these seven patients died of heart failure. Necropsy findings in five of these patients revealed acute lymphocytic myocarditis in three, cryptococcal myocarditis in one, and interstitial edema and fibrosis in one.",
"     </li>",
"     <li>",
"      Predictors of myocardial dysfunction were examined in 181 patients at all stages of HIV infection. Using a backward logistic regression model to assess for variables to predict the presence of ventricular dysfunction, the presence of pulmonary infection (all etiologies mixed) was the only predictor of isolated right ventricular dysfunction (Odds ratio 4.1, p = 0.02). A history of previous opportunistic infections (all etiologies mixed) (Odds ratio 10.9, p = 0.003) and time since the diagnosis of AIDS &gt;12 months (Odds ratio 6.6, p = 0.03) were the only two independent predictors of left ventricular dysfunction [",
"      <a class=\"abstract\" href=\"UTD.htm?24/40/25226/abstract/59\">",
"       59",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Summarizing the longitudinal studies, clinical dilated cardiomyopathy is seen in approximately 1 to 3 percent of patients with AIDS for an annual rate of 1 to 2 percent [",
"    <a class=\"abstract\" href=\"UTD.htm?24/40/25226/abstract/43,57,59,65,69\">",
"     43,57,59,65,69",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h3\">",
"     Possible etiology",
"    </span>",
"    &nbsp;&mdash;&nbsp;Some patients with asymptomatic or overt left ventricular dysfunction have a known etiology such as toxoplasmosis, cryptococcosis, cocaine use, toxo-serology hypertrophic cardiomyopathy, alcoholic heart disease, or drug toxicity [",
"    <a class=\"abstract\" href=\"UTD.htm?24/40/25226/abstract/1,2,8,26\">",
"     1,2,8,26",
"    </a>",
"    ]. In addition to direct effects of cocaine on the heart as well as indirect effects through vasospasm, cocaine suppresses cellular immune response. In mice infected with Coxsackievirus B and LP-BM5 retrovirus; those given cocaine had greatly enhanced myocardial lesions compared to those not given cocaine [",
"    <a class=\"abstract\" href=\"UTD.htm?24/40/25226/abstract/70\">",
"     70",
"    </a>",
"    ]. The diagnostic evaluation should include Toxoplasma serology cryptococcus neoformins serum antigen assay and review of drugs. In addition, as noted in the section on focal myocarditis, HIV infection itself or infection with coxsackievirus, cytomegalovirus, and Epstein-Barr virus may be responsible in selected patients [",
"    <a class=\"abstract\" href=\"UTD.htm?24/40/25226/abstract/8,26,69\">",
"     8,26,69",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Methamphetamine, through the release of catecholamines, can cause CMP. An additional problem is its potential to enhance immunosuppression, suppressing mitogen-stimulated lymphocytes and stimulating secretion of pro-inflammatory cytokines. Concomitant methamphetamine use and HIV infection enhances immunosuppression and increases the risk of cardiac complications [",
"    <a class=\"abstract\" href=\"UTD.htm?24/40/25226/abstract/71\">",
"     71",
"    </a>",
"    ]. Methamphetamines have been shown to significantly increase HIV reverse transcriptase activity in human monocyte-derived macrophages by upregulating the expression of the HIV entry coreceptor CCR5 on macrophages. In this way, methamphetamines function as a cofactor in the immunopathogenesis of HIV infection [",
"    <a class=\"abstract\" href=\"UTD.htm?24/40/25226/abstract/72\">",
"     72",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    A variety of other factors may contribute to the development of myocardial dysfunction. These include:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Autoimmune disease, which can surface when immune competence is restored with introduction of antiretroviral therapy [",
"      <a class=\"abstract\" href=\"UTD.htm?24/40/25226/abstract/73,74\">",
"       73,74",
"      </a>",
"      ]. HIV-associated polyclonal B cell stimulation may be related to the formation of autoantibodies.",
"     </li>",
"     <li>",
"      Cachexia [",
"      <a class=\"abstract\" href=\"UTD.htm?24/40/25226/abstract/75,76\">",
"       75,76",
"      </a>",
"      ]",
"     </li>",
"     <li>",
"      <a class=\"drug drug_general\" href=\"UTD.htm?13/37/13907?source=see_link\">",
"       Selenium",
"      </a>",
"      deficiency [",
"      <a class=\"abstract\" href=\"UTD.htm?24/40/25226/abstract/77\">",
"       77",
"      </a>",
"      ] &mdash; In one pediatric patient, cardiomyopathy was reversed by supplementation with selenium [",
"      <a class=\"abstract\" href=\"UTD.htm?24/40/25226/abstract/77\">",
"       77",
"      </a>",
"      ]. Selenium supplementation may improve immune functioning, and in a randomized trial, selenium has been shown to mildly suppress the HIV-1 viral load [",
"      <a class=\"abstract\" href=\"UTD.htm?24/40/25226/abstract/78\">",
"       78",
"      </a>",
"      ], but there is no convincing evidence that either selenium deficiency causes cardiomyopathy or that selenium supplementation improves patients with clinical cardiomyopathy.",
"     </li>",
"     <li>",
"      Cardiotoxicity from therapeutic drugs such as",
"      <a class=\"drug drug_general\" href=\"UTD.htm?21/43/22199?source=see_link\">",
"       pentamidine",
"      </a>",
"      &nbsp;[",
"      <a class=\"abstract\" href=\"UTD.htm?24/40/25226/abstract/79\">",
"       79",
"      </a>",
"      ] and possibly",
"      <a class=\"drug drug_general\" href=\"UTD.htm?23/28/24008?source=see_link\">",
"       zidovudine",
"      </a>",
"      &nbsp;[",
"      <a class=\"abstract\" href=\"UTD.htm?24/40/25226/abstract/80\">",
"       80",
"      </a>",
"      ]. ZDV produces cardiomyopathy in mice with pathologic changes in the mitochondria [",
"      <a class=\"abstract\" href=\"UTD.htm?24/40/25226/abstract/1,81\">",
"       1,81",
"      </a>",
"      ]. AIDS patients with cardiomyopathy have been reported on myocardial biopsy to have similar ultrastructural changes in their mitochondria. In one case, reversal of the cardiac dysfunction was seen on discontinuation of the ZDV therapy [",
"      <a class=\"abstract\" href=\"UTD.htm?24/40/25226/abstract/82\">",
"       82",
"      </a>",
"      ].",
"      <br/>",
"      <br/>",
"      There is also evidence of cardiotoxicity of ZDV in children. A retrospective, echocardiographic study with review of clinical records and laboratory data was reported in 137 HIV-infected children receiving ZDV,",
"      <a class=\"drug drug_general\" href=\"UTD.htm?14/38/14952?source=see_link\">",
"       didanosine",
"      </a>",
"      , both, or no antiretroviral therapy. Despite correcting for age, CD4 cell count, time since onset, and mode of acquisition of HIV, children treated with ZDV had a lower average LV fractional shortening than those not treated with ZDV (p&lt;0.00001). There was a nonlinear relation between days on ZDV and decrease in fractional shortening, and the odds that dilated CMP would develop was 8.4 times greater in children who had previously used ZDV than in those who had not (95% CI 1.7-42). Didanosine was not associated with development of CMP [",
"      <a class=\"abstract\" href=\"UTD.htm?24/40/25226/abstract/82\">",
"       82",
"      </a>",
"      ].",
"      <br/>",
"      <br/>",
"      Although ZDV is associated with a myopathy in skeletal muscle that is mediated via mitochondrial toxicity, it is unclear if a similar mechanism may be playing a causative role in cardiac dysfunction [",
"      <a class=\"abstract\" href=\"UTD.htm?24/40/25226/abstract/83,84\">",
"       83,84",
"      </a>",
"      ]. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?29/40/30345?source=see_link\">",
"       \"Mitochondrial toxicity of HIV nucleoside reverse transcriptase inhibitors\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Cytokines, such as tumor necrosis factor-alpha (TNF), interleukin (IL)-1, IL-2, endothelin (ET-1), and alpha interferon [",
"      <a class=\"abstract\" href=\"UTD.htm?24/40/25226/abstract/85-87\">",
"       85-87",
"      </a>",
"      ] are proteins or large peptides released by HIV-infected macrophages. These cytokines increase the production of inducible nitric oxide synthase (iNOS) and nitric oxide, which are cytotoxic to myocardial cells; furthermore, TNF and reactive oxygen species may signal the onset of myocyte apoptosis leading to progressive loss of ventricular function [",
"      <a class=\"abstract\" href=\"UTD.htm?24/40/25226/abstract/88-91\">",
"       88-91",
"      </a>",
"      ]. Enhanced expression of iNOS is seen particularly in patients with low CD4 cell counts [",
"      <a class=\"abstract\" href=\"UTD.htm?24/40/25226/abstract/92\">",
"       92",
"      </a>",
"      ]. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?22/28/22986?source=see_link\">",
"       \"Etiology and pathogenesis of myocarditis\"",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?12/36/12872?source=see_link\">",
"       \"Nitric oxide, other hormones, cytokines, and chemokines in heart failure\"",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h1\">",
"     PULMONARY HYPERTENSION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Severe pulmonary hypertension, with and without cor pulmonale and right heart failure, have been described in patients with AIDS [",
"    <a class=\"abstract\" href=\"UTD.htm?24/40/25226/abstract/93-100\">",
"     93-100",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    In a prospective study of 7648 HIV-positive patients during the era of potent ART, the prevalence of pulmonary hypertension (mean resting pulmonary arterial pressure &le;25 mm Hg and pulmonary capillary wedge pressure &ge;15 mm Hg) was 0.46 percent [",
"    <a class=\"abstract\" href=\"UTD.htm?24/40/25226/abstract/100\">",
"     100",
"    </a>",
"    ]. A higher prevalence of 4.7 percent was documented in a cross-sectional study of 802 HIV-seropositive patients [",
"    <a class=\"abstract\" href=\"UTD.htm?24/40/25226/abstract/101\">",
"     101",
"    </a>",
"    ]; in addition 96 percent of the patients with elevated pulmonary artery pressure were taking ART.",
"   </p>",
"   <p>",
"    The etiology of this problem is not well understood. Many, but not all, of these patients have had multiple pulmonary infections, often with Pneumocystis carinii [",
"    <a class=\"abstract\" href=\"UTD.htm?24/40/25226/abstract/98\">",
"     98",
"    </a>",
"    ]; and many were IDUs. As a result, interstitial disease and vascular bed destruction by multiple pulmonary infections were thought to be important.",
"   </p>",
"   <p>",
"    However, some patients have never had a pulmonary infection, and the histology of the lung and the clinical pattern are similar to that seen in idiopathic pulmonary arterial hypertension [",
"    <a class=\"abstract\" href=\"UTD.htm?24/40/25226/abstract/94-97,99\">",
"     94-97,99",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?18/47/19193?source=see_link\">",
"     \"Overview of pulmonary hypertension in adults\"",
"    </a>",
"    .) In a review of 88 reported cases, for example, lung tissue was evaluated microscopically in 33; 28 were of the plexogenic variant of idiopathic pulmonary arterial hypertension; three had thrombotic pulmonary arteriopathy (one due to recurrent thromboembolism, and two to in situ thrombosis); and two had pulmonary venoocclusive disease [",
"    <a class=\"abstract\" href=\"UTD.htm?24/40/25226/abstract/94\">",
"     94",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The mechanism by which idiopathic pulmonary arterial hypertension might occur in HIV-infected patients is not known. However, hyperplasia of vascular smooth muscle cells in the small pulmonary arteries occurs in HIV infection. The changes are not due to direct HIV infection but may involve release of cytokines. There is an homology between a receptor-active region of the envelope protein gp120 of HIV virus and neuropeptide Y (NPY). NPY is mitogenic for vascular smooth muscle cells and in an in vitro preparation, the gp 120 protein was a more potent mitogen than NPY [",
"    <a class=\"abstract\" href=\"UTD.htm?24/40/25226/abstract/102\">",
"     102",
"    </a>",
"    ]. Gp120 is a viral protein necessary for the binding and entrance of HIV into macrophages and has been shown to target human lung endothelial cells, increase markers of apoptosis, and stimulate the secretion of endothelin-1 [",
"    <a class=\"abstract\" href=\"UTD.htm?24/40/25226/abstract/103\">",
"     103",
"    </a>",
"    ]. Only a small percentage of patients with HIV infection develop pulmonary hypertension, suggesting the existence of genetic predisposition to the development of vascular disease [",
"    <a class=\"abstract\" href=\"UTD.htm?24/40/25226/abstract/104\">",
"     104",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Affected patients may present with several months of easy fatiguability and shortness of breath, or with frank right ventricular failure. The diagnosis is made by Doppler echocardiography, which shows an enlarged and hypertrophied right ventricle and a possibly enlarged right atrium in the presence of a normal left ventricle [",
"    <a class=\"abstract\" href=\"UTD.htm?24/40/25226/abstract/98\">",
"     98",
"    </a>",
"    ]. The pulmonary artery systolic pressure can be estimated from the tricuspid regurgitation jet. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?18/47/19193?source=see_link\">",
"     \"Overview of pulmonary hypertension in adults\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The HIV-infected patient with pulmonary hypertension has a poor prognosis. Patients have the worst survival when they are in NYHA Class III-IV. In one report, survival was 73 percent, 60 percent, and 47 percent at one, two, and three years, respectively [",
"    <a class=\"abstract\" href=\"UTD.htm?24/40/25226/abstract/105\">",
"     105",
"    </a>",
"    ]. Multi-drug antiretroviral therapy benefit can result in a marked drop in pulmonary artery pressure and possibly prolong survival [",
"    <a class=\"abstract\" href=\"UTD.htm?24/40/25226/abstract/99,106\">",
"     99,106",
"    </a>",
"    ]. The prostacyclin analogue,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?36/53/37716?source=see_link\">",
"     iloprost",
"    </a>",
"    has been shown to significantly decrease pulmonary artery pressure and pulmonary vascular resistance, as well as increase cardiac index [",
"    <a class=\"abstract\" href=\"UTD.htm?24/40/25226/abstract/107\">",
"     107",
"    </a>",
"    ]. In a series of 20 NYHA Class III-IV patients with HIV-related pulmonary hypertension treated with continuous",
"    <a class=\"drug drug_general\" href=\"UTD.htm?0/22/359?source=see_link\">",
"     epoprostenol",
"    </a>",
"    infusion, the results at three months follow-up was an increase in the six minute walk test of 183 m from baseline and an improvement in the NYHA Class in 19 of 20 patients [",
"    <a class=\"abstract\" href=\"UTD.htm?24/40/25226/abstract/108\">",
"     108",
"    </a>",
"    ]. There are a few small studies that show benefit from epoprostenol and the endothelin-1 antagonist,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?39/16/40200?source=see_link\">",
"     bosentan",
"    </a>",
"    &nbsp;[",
"    <a class=\"abstract\" href=\"UTD.htm?24/40/25226/abstract/105\">",
"     105",
"    </a>",
"    ]. At present, the treatment of pulmonary hypertension in patients with AIDS is similar to that of patients with idiopathic pulmonary arterial hypertension.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h1\">",
"     CARDIAC TUMORS",
"    </span>",
"    &nbsp;&mdash;&nbsp;One of the findings suggesting that HIV infection was a new, unusual disease was the appearance of Kaposi's sarcoma in young men, a disease seen previously almost exclusively in old men. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?11/52/12103?source=see_link\">",
"     \"AIDS-related Kaposi sarcoma: Clinical manifestations and diagnosis\"",
"    </a>",
"    .) Among patients with AIDS, Kaposi's sarcoma can involve the myocardium or the pericardium, and can cause pericardial effusion and, in some cases, tamponade [",
"    <a class=\"abstract\" href=\"UTD.htm?24/40/25226/abstract/18,109,110\">",
"     18,109,110",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Non-Hodgkin lymphoma is a malignancy often seen in the patient with AIDS. The tumor is usually widespread, but can present as a primary cardiac lymphoma [",
"    <a class=\"abstract\" href=\"UTD.htm?24/40/25226/abstract/111\">",
"     111",
"    </a>",
"    ]. When lymphoma involves the heart, it is usually diffusely infiltrative, but can form nodules and even intracavitary masses [",
"    <a class=\"abstract\" href=\"UTD.htm?24/40/25226/abstract/20,112-115\">",
"     20,112-115",
"    </a>",
"    ]. Cardiac lymphoma can cause heart failure, superior vena caval syndrome, atrial and ventricular arrhythmias, and heart block. With intracavitary growth, the masses cause mechanical obstruction to the blood flow across the valves. In such cases, surgical resection is indicated. Chemotherapy and radiation therapy have produced variable results [",
"    <a class=\"abstract\" href=\"UTD.htm?24/40/25226/abstract/112,116,117\">",
"     112,116,117",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h1\">",
"     VALVULAR DISEASE",
"    </span>",
"    &nbsp;&mdash;&nbsp;Three main types of valvular disease have been associated with HIV infection:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Nonbacterial thrombotic endocarditis",
"     </li>",
"     <li>",
"      Infective endocarditis",
"     </li>",
"     <li>",
"      Mitral valve prolapse",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h2\">",
"     Nonbacterial thrombotic endocarditis (NBTE)",
"    </span>",
"    &nbsp;&mdash;&nbsp;Nonbacterial thrombotic (marantic) endocarditis consists of sterile vegetations, which can occur on any of the valves. This was a common finding at autopsy, especially in patients with wasting diseases. It may present as systemic embolization, but is otherwise clinically silent; no valvular disturbance occurs. Before 1989, NBET was found in 10 percent of autopsies in the United States in AIDS patients. The incidence has markedly decreased since then, possibly due to the virtual disappearance of cachexia in these patients. There have been no cases reported in AIDS patients since 1989 [",
"    <a class=\"abstract\" href=\"UTD.htm?24/40/25226/abstract/8\">",
"     8",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16\">",
"    <span class=\"h2\">",
"     Infective endocarditis",
"    </span>",
"    &nbsp;&mdash;&nbsp;Infective endocarditis in HIV-infected patients occurs almost exclusively in IDUs [",
"    <a class=\"abstract\" href=\"UTD.htm?24/40/25226/abstract/12,118-120\">",
"     12,118-120",
"    </a>",
"    ]. In 105 HIV-infected patients with IE, the mean age of the patients was 30.1 years, and the predisposing condition for HIV infection was IDU in 94.3 percent [",
"    <a class=\"abstract\" href=\"UTD.htm?24/40/25226/abstract/119\">",
"     119",
"    </a>",
"    ]. As in IE in IDU who are not HIV-infected, the most common valve involved is the tricuspid valve and the most common organism Staphylococcus aureus [",
"    <a class=\"abstract\" href=\"UTD.htm?24/40/25226/abstract/119,120\">",
"     119,120",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    One retrospective study demonstrated that the incidence of IE in HIV-infected patients has declined with the introduction of HAART [",
"    <a class=\"abstract\" href=\"UTD.htm?24/40/25226/abstract/120\">",
"     120",
"    </a>",
"    ]. Presenting symptoms were similar to those seen in HIV-uninfected patients and included fever, chills, and shortness of breath. In a multivariate analysis, an increased risk of IE was associated with a low CD4 count (&lt;50",
"    <span class=\"nowrap\">",
"     cells/microL),",
"    </span>",
"    high HIV RNA levels (&gt;100,000",
"    <span class=\"nowrap\">",
"     copies/mL)",
"    </span>",
"    and a history of IDU.",
"   </p>",
"   <p>",
"    The treatment approach to IE in HIV-infected patients is similar to the approach to those who are HIV-seronegative; clinicians must consider the possibility of methicillin resistant S. aureus endocarditis [",
"    <a class=\"abstract\" href=\"UTD.htm?24/40/25226/abstract/120\">",
"     120",
"    </a>",
"    ]. Response to antibiotic therapy is similar in IVDUs whether or not they are HIV-infected [",
"    <a class=\"abstract\" href=\"UTD.htm?24/40/25226/abstract/121\">",
"     121",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?39/17/40215?source=see_link\">",
"     \"Infective endocarditis in injection drug users\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?40/24/41352?source=see_link\">",
"     \"Diagnostic approach to infective endocarditis\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?19/37/20058?source=see_link\">",
"     \"Antimicrobial therapy of native valve endocarditis\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17\">",
"    <span class=\"h1\">",
"     LONG QT SYNDROME",
"    </span>",
"    &nbsp;&mdash;&nbsp;QT prolongation and TdP have been described in patients with HIV infection, even in the absence of drug therapy. In one study, 29 percent of hospitalized patients with HIV infection had QT prolongation [",
"    <a class=\"abstract\" href=\"UTD.htm?24/40/25226/abstract/122\">",
"     122",
"    </a>",
"    ]. Postulated mechanisms include myocarditis, a subclinical cardiomyopathy, and autonomic neuropathy [",
"    <a class=\"abstract\" href=\"UTD.htm?24/40/25226/abstract/123\">",
"     123",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    In addition,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?21/43/22199?source=see_link\">",
"     pentamidine",
"    </a>",
"    may promote TdP both directly and by causing hypomagnesemia [",
"    <a class=\"abstract\" href=\"UTD.htm?24/40/25226/abstract/124\">",
"     124",
"    </a>",
"    ] and HIV protease inhibitors (eg,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?3/25/3482?source=see_link\">",
"     saquinavir",
"    </a>",
"    ) can directly cause the long QT syndrome by blocking the HERG channel [",
"    <a class=\"abstract\" href=\"UTD.htm?24/40/25226/abstract/125,126\">",
"     125,126",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?22/55/23418?source=see_link\">",
"     \"Acquired long QT syndrome\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?39/32/40458?source=see_link\">",
"     \"HIV protease inhibitors\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H18\">",
"    <span class=\"h1\">",
"     AUTONOMIC DYSFUNCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;In the pre-HAART era, studies demonstrated autonomic nervous system (ANS) involvement affecting both parasympathetic and sympathetic divisions in a significant proportio of patients [",
"    <a class=\"abstract\" href=\"UTD.htm?24/40/25226/abstract/127,128\">",
"     127,128",
"    </a>",
"    ]. One study found that compared to controls, HIV-infected patients taking potent ART regimens for at least three years had an increased resting heart rate and decreased short-term heart rate variability indicating parasympathetic dysfunction [",
"    <a class=\"abstract\" href=\"UTD.htm?24/40/25226/abstract/129\">",
"     129",
"    </a>",
"    ]. Autonomic dysfunction can lead to QTc prolongation and malignant ventricular arrhythmias.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H19\">",
"    <span class=\"h1\">",
"     METABOLIC ABNORMALITIES ASSOCIATED WITH ANTIRETROVIRAL THERAPY",
"    </span>",
"    &nbsp;&mdash;&nbsp;There are many studies suggesting that chronic HIV therapy is associated with the development of several metabolic disturbances, which may have a negative effect on cardiovascular risk. Whether HIV infection itself is a risk factor for cardiovascular disease is unclear.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H20\">",
"    <span class=\"h2\">",
"     Lipid abnormalities",
"    </span>",
"    &nbsp;&mdash;&nbsp;Alterations in serum lipid values have been reported in HIV-infected patients. This topic is discussed in detail elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?26/1/26650?source=see_link\">",
"     \"Epidemiology of cardiovascular disease and risk factors in HIV-infected patients\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?0/3/49?source=see_link\">",
"     \"Management of dyslipidemia and cardiovascular risk in the HIV-infected patient\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H21\">",
"    <span class=\"h2\">",
"     Lipodystrophy",
"    </span>",
"    &nbsp;&mdash;&nbsp;HIV-infected patients may have evidence of the lipodystrophy syndrome, which includes peripheral fat wasting",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    fat deposition in combination with insulin resistance and hyperlipidemia. This topic is discussed elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?25/43/26298?source=see_link\">",
"     \"Epidemiology, clinical manifestations, and diagnosis of HIV-associated lipodystrophy\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?43/36/44617?source=see_link\">",
"     \"Treatment of HIV-associated lipodystrophy\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H22\">",
"    <span class=\"h1\">",
"     PERIPHERAL ARTERY DISEASE",
"    </span>",
"    &nbsp;&mdash;&nbsp;In the general population, peripheral artery disease (PAD) is associated with traditional cardiovascular risk factors, such as smoking, diabetes, hypertension, and hypercholesterolemia. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?29/31/30201?source=see_link\">",
"     \"Clinical features, diagnosis, and natural history of lower extremity peripheral artery disease\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Little is known about PAD in HIV-infected patients. The prevalence of this disorder was investigated in 92 consecutively enrolled HIV-infected adults (mean age 50 years) by using a claudication questionnaire and by measuring the systolic ankle-brachial blood pressure index (ABI) at rest and after exercise [",
"    <a class=\"abstract\" href=\"UTD.htm?24/40/25226/abstract/130\">",
"     130",
"    </a>",
"    ]. Patients with PAD by ABI were further evaluated with duplex scanning of the lower limb arteries. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?10/16/10506?source=see_link&amp;anchor=H58544655#H58544655\">",
"     \"Noninvasive diagnosis of arterial disease\", section on 'Ankle-brachial index'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The following findings were noted:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Claudication was reported by 15 percent of patients through the questionnaire.",
"     </li>",
"     <li>",
"      Among the 16 patients who had an abnormal ABI, all had evidence of atherosclerotic",
"      <span class=\"nowrap\">",
"       occlusions/stenoses",
"      </span>",
"      of the iliac or femoral arteries on duplex scanning. Age, diabetes, smoking, and low CD4+ T lymphocyte counts were identified as independent predictors. Twenty-one percent of HIV-infected patients had peripheral vascular disease compared to the expected prevalence in the general population of 3 percent at age 60.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    However, another study of 91 patients with two or more cardiovascular risk factors found a low prevalence of peripheral artery disease using similar instruments [",
"    <a class=\"abstract\" href=\"UTD.htm?24/40/25226/abstract/131\">",
"     131",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Potential mechanisms of PAD in HIV-infected patients include lifestyle risk factors (eg, smoking), the negative impact of certain antiretroviral medications on serum lipids, and direct viral injury to the arterial wall.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H23\">",
"    <span class=\"h1\">",
"     VENOUS THROMBOSIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;There have been increasing reports of deep venous thrombosis in patients with HIV infection [",
"    <a class=\"abstract\" href=\"UTD.htm?24/40/25226/abstract/132-134\">",
"     132-134",
"    </a>",
"    ]. There is evidence that some HIV-infected patients have coagulation abnormalities, which can result in a prothrombotic state. Although most of the changes described are cytopenias (anemia, neutropenia, and thrombocytopenia), an increase in protein S,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?39/34/40489?source=see_link\">",
"     heparin",
"    </a>",
"    cofactor II deficiency, and type 1 plasminogen activator inhibitor have been demonstrated in HIV-infected patients. Moreover, D-dimer levels have been found to increase, suggesting that HIV infection might be associated with a prethrombotic state [",
"    <a class=\"abstract\" href=\"UTD.htm?24/40/25226/abstract/135\">",
"     135",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The following studies are illustrative of the range of results:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      In a review of 42,935 individuals ages 13 years and older with HIV infection observed for 2.4 years, the incidence of thrombosis was 2.6 per 1000 person-years. Factors significantly associated with thrombosis were opportunistic illness, megestrolacetate, hospitalization, and increasing age [",
"      <a class=\"abstract\" href=\"UTD.htm?24/40/25226/abstract/136\">",
"       136",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      In a review of 4752",
"      <span class=\"nowrap\">",
"       HIV/AIDS",
"      </span>",
"      patients, 45 (0.95 percent) were found to have deep vein thrombosis. Three patients developed a pulmonary embolism. Statistically, deep venous thrombosis in AIDS patients was approximately 10 times greater than in the general population [",
"      <a class=\"abstract\" href=\"UTD.htm?24/40/25226/abstract/137\">",
"       137",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      In a retrospective review of 131 HIV-infected patients seen over a five-year period, there were 10 instances of deep vein thrombosis, mostly involving the lower extremities. Nine of the patients with venous thrombosis had a CD4 count &lt;200",
"      <span class=\"nowrap\">",
"       cells/microL",
"      </span>",
"      and one had a CD4 count of &gt;200",
"      <span class=\"nowrap\">",
"       cells/microL",
"      </span>",
"      (p = 0.00004) [",
"      <a class=\"abstract\" href=\"UTD.htm?24/40/25226/abstract/138\">",
"       138",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      In a study of 109 HIV-infected patients with advanced disease, 10 percent developed venous thrombosis and 6 percent arterial thrombosis [",
"      <a class=\"abstract\" href=\"UTD.htm?24/40/25226/abstract/139\">",
"       139",
"      </a>",
"      ]. A variety of laboratory abnormalities were documented, including protein C deficiency (9 percent), increased factor VIII concentrations (41 percent), high fibrinogen concentrations (22 percent), and free protein S deficiency (60 percent).",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H24\">",
"    <span class=\"h1\">",
"     CLINICAL APPROACH",
"    </span>",
"    &nbsp;&mdash;&nbsp;The history and physical examination are the best screens for cardiovascular involvement in HIV-infected patients, looking for signs and symptoms of possible cardiovascular illness. There appears to be no advantage in finding subclinical disease; thus, routine echocardiography is not indicated.",
"   </p>",
"   <p>",
"    The clinical presentation of cardiomyopathy is similar in HIV-infected patients as in those who are not infected. The initial symptoms are nonspecific: as an example, dyspnea may be due to pulmonary involvement or cardiac disease. Echocardiography can help differentiate between these possibilities.",
"   </p>",
"   <p>",
"    More specific signs of cardiac involvement are an S3 gallop, a pericardial friction rub, pulmonary edema or a pathologic murmur. Right-sided heart failure can be due to idiopathic pulmonary arterial hypertension. When these findings are present, transthoracic echocardiogram can demonstrate pericardial effusion, valvular insufficiency, and regional hypokinesis affecting the left ventricle. Invasive catheterization is not necessary, unless coronary artery disease has to be excluded.",
"   </p>",
"   <p>",
"    Myocardial biopsy is recommended by some physicians, but its utility is controversial. The finding of a treatable etiology of myocarditis is rare. At present, there is no definite evidence that steroids or immunosuppressive agents are more effective than conventional management in patients with myocarditis. The potential benefit of immunosuppressive agents for this indication in HIV-seronegative patients is discussed elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?10/39/10874?source=see_link\">",
"     \"Natural history and therapy of myocarditis in adults\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The treatment of the AIDS patient with heart failure is similar to that of other patients, consisting of angiotensin converting enzyme inhibitors, beta-blockers,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?28/27/29113?source=see_link\">",
"     digoxin",
"    </a>",
"    , and diuretics for fluid control. In addition, drugs that have been implicated in cardiomyopathy should be discontinued and a possibly causal infection (such as toxoplasmosis) should be treated if present.",
"   </p>",
"   <p>",
"    With increasing evidence that HIV-infected patients, especially those on ART regimens, have an increased risk of atherosclerotic disease, including coronary artery disease, special attention to eliminating conventional cardiovascular risk factors such as smoking, controlling hypertension and diabetes, lowering LDL and triglycerides and raising HDL, and reducing weight in overweight patients is important. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?26/1/26650?source=see_link\">",
"     \"Epidemiology of cardiovascular disease and risk factors in HIV-infected patients\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    In light of the overall improved prognosis with the advent of potent antiretroviral therapy, procedures such as coronary bypass or valve replacement should be done for the same indications as in uninfected subjects, unless the patient has advanced immunosuppression and high risk of mortality from AIDS-related complications [",
"    <a class=\"abstract\" href=\"UTD.htm?24/40/25226/abstract/140\">",
"     140",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"PATIENT_INFORMATION\">",
"    <span class=\"h1\">",
"     INFORMATION FOR PATIENTS",
"    </span>",
"    &nbsp;&mdash;&nbsp;UpToDate offers two types of patient education materials, &ldquo;The Basics&rdquo; and &ldquo;Beyond the Basics.&rdquo; The Basics patient education pieces are written in plain language, at the 5",
"    <sup>",
"     th",
"    </sup>",
"    to 6",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10",
"    <sup>",
"     th",
"    </sup>",
"    to 12",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.",
"   </p>",
"   <p>",
"    Here is the patient education article that is relevant to this topic. We encourage you to print or e-mail this topic to your patients. (You can also locate patient education articles on a variety of subjects by searching on &ldquo;patient info&rdquo; and the keyword(s) of interest.)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Beyond the Basics topic (See",
"      <a class=\"medical medical_patient\" href=\"UTD.htm?11/53/12115?source=see_link\">",
"       \"Patient information: Pericarditis (Beyond the Basics)\"",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H25350235\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The most frequent clinical manifestation of cardiovascular disease in patients with AIDS is pericardial disease. The majority of pleural effusions among symptomatic patients are due to infection or malignancy. (See",
"      <a class=\"local\" href=\"#H4\">",
"       'Pericarditis'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The three major forms of myocardial disease in patients with AIDS include symptomatic cardiomyopathy, decreased left ventricular function, as demonstrated on echocardiography, and focal myocarditis, which is usually seen incidentally found at autopsy. (See",
"      <a class=\"local\" href=\"#H7\">",
"       'Myocardial disease'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Infective endocarditis in HIV-infected patients occurs almost exclusively among injection drug users. The clinical presentation and approach to treatment are similar to patients without HIV infection. (See",
"      <a class=\"local\" href=\"#H14\">",
"       'Valvular disease'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Prolongation of the QT interval can be related to particular medications, such as",
"      <a class=\"drug drug_general\" href=\"UTD.htm?21/43/22199?source=see_link\">",
"       pentamidine",
"      </a>",
"      or",
"      <a class=\"drug drug_general\" href=\"UTD.htm?3/25/3482?source=see_link\">",
"       saquinavir",
"      </a>",
"      . Saquinavir is no longer considered a first line agent for the treatment of HIV infection. (See",
"      <a class=\"local\" href=\"#H17\">",
"       'Long QT syndrome'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      There are many studies suggesting that chronic HIV therapy is associated with the development of several metabolic disturbances, which may have a negative effect on cardiovascular risk. Whether HIV infection itself is a risk factor for cardiovascular disease is unclear. (See",
"      <a class=\"local\" href=\"#H19\">",
"       'Metabolic abnormalities associated with antiretroviral therapy'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/40/25226/abstract/1\">",
"      Lewis W. Cardiomyopathy in AIDS: a pathophysiological perspective. Prog Cardiovasc Dis 2000; 43:151.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/40/25226/abstract/2\">",
"      Sani MU. Myocardial disease in human immunodeficiency virus (HIV) infection: a review. Wien Klin Wochenschr 2008; 120:77.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/40/25226/abstract/3\">",
"      Lipshultz SE, Chanock S, Sanders SP, et al. Cardiovascular manifestations of human immunodeficiency virus infection in infants and children. Am J Cardiol 1989; 63:1489.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/40/25226/abstract/4\">",
"      Luginbuhl LM, Orav EJ, McIntosh K, Lipshultz SE. Cardiac morbidity and related mortality in children with HIV infection. JAMA 1993; 269:2869.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/40/25226/abstract/5\">",
"      Cammarosano C, Lewis W. Cardiac lesions in acquired immune deficiency syndrome (AIDS). J Am Coll Cardiol 1985; 5:703.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/40/25226/abstract/6\">",
"      Tershakovec AM, Frank I, Rader D. HIV-related lipodystrophy and related factors. Atherosclerosis 2004; 174:1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/40/25226/abstract/7\">",
"      DAD Study Group, Friis-M&oslash;ller N, Reiss P, et al. Class of antiretroviral drugs and the risk of myocardial infarction. N Engl J Med 2007; 356:1723.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/40/25226/abstract/8\">",
"      Fisher SD, Lipshultz SE. Epidemiology of cardiovascular involvement in HIV disease and AIDS. Ann N Y Acad Sci 2001; 946:13.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/40/25226/abstract/9\">",
"      Pugliese A, Gennero L, Vidotto V, et al. A review of cardiovascular complications accompanying AIDS. Cell Biochem Funct 2004; 22:137.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/40/25226/abstract/10\">",
"      Corallo S, Mutinelli MR, Moroni M, et al. Echocardiography detects myocardial damage in AIDS: prospective study in 102 patients. Eur Heart J 1988; 9:887.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/40/25226/abstract/11\">",
"      Himelman RB, Chung WS, Chernoff DN, et al. Cardiac manifestations of human immunodeficiency virus infection: a two-dimensional echocardiographic study. J Am Coll Cardiol 1989; 13:1030.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/40/25226/abstract/12\">",
"      De Castro S, Migliau G, Silvestri A, et al. Heart involvement in AIDS: a prospective study during various stages of the disease. Eur Heart J 1992; 13:1452.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/40/25226/abstract/13\">",
"      Hsia J, Ross AM. Pericardial effusion and pericardiocentesis in human immunodeficiency virus infection. Am J Cardiol 1994; 74:94.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/40/25226/abstract/14\">",
"      Heidenreich PA, Eisenberg MJ, Kee LL, et al. Pericardial effusion in AIDS. Incidence and survival. Circulation 1995; 92:3229.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/40/25226/abstract/15\">",
"      Estok L, Wallach F. Cardiac tamponade in a patient with AIDS: a review of pericardial disease in patients with HIV infection. Mt Sinai J Med 1998; 65:33.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/40/25226/abstract/16\">",
"      Eisenberg MJ, Gordon AS, Schiller NB. HIV-associated pericardial effusions. Chest 1992; 102:956.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/40/25226/abstract/17\">",
"      Reynolds MM, Hecht SR, Berger M, et al. Large pericardial effusions in the acquired immunodeficiency syndrome. Chest 1992; 102:1746.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/40/25226/abstract/18\">",
"      Chen Y, Brennessel D, Walters J, et al. Human immunodeficiency virus-associated pericardial effusion: report of 40 cases and review of the literature. Am Heart J 1999; 137:516.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/40/25226/abstract/19\">",
"      Flum DR, McGinn JT Jr, Tyras DH. The role of the 'pericardial window' in AIDS. Chest 1995; 107:1522.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/40/25226/abstract/20\">",
"      Lewis W. AIDS: cardiac findings from 115 autopsies. Prog Cardiovasc Dis 1989; 32:207.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/40/25226/abstract/21\">",
"      Gouny P, Lancelin C, Girard PM, et al. Pericardial effusion and AIDS: benefits of surgical drainage. Eur J Cardiothorac Surg 1998; 13:165.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/40/25226/abstract/22\">",
"      Maher D, Harries AD. Tuberculous pericardial effusion: a prospective clinical study in a low-resource setting--Blantyre, Malawi. Int J Tuberc Lung Dis 1997; 1:358.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/40/25226/abstract/23\">",
"      Dronda F, Suzacq C. [Pericardial tuberculosis complicated with heart tamponade as presentation form of acquired immunodeficiency syndrome]. Rev Clin Esp 1997; 197:502.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/40/25226/abstract/24\">",
"      Nogueira G, Macedo AJ, Paix&atilde;o A, et al. [Cardiovascular morbidity in children with human immunodeficiency virus infection]. Acta Med Port 1998; 11:1051.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/40/25226/abstract/25\">",
"      S&aacute; I, M&ocirc;&ccedil;o R, Cabral S, et al. Constrictive pericarditis of tuberculous etiology in the HIV-positive patient: case report and review of the literature. Rev Port Cardiol 2006; 25:1029.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/40/25226/abstract/26\">",
"      Sudano I, Spieker LE, Noll G, et al. Cardiovascular disease in HIV infection. Am Heart J 2006; 151:1147.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/40/25226/abstract/27\">",
"      Ntsekhe M, Mayosi BM. Cardiac manifestations of HIV infection: an African perspective. Nat Clin Pract Cardiovasc Med 2009; 6:120.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/40/25226/abstract/28\">",
"      Gowda RM, Khan IA, Mehta NJ, et al. Cardiac tamponade in patients with human immunodeficiency virus disease. Angiology 2003; 54:469.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/40/25226/abstract/29\">",
"      Cegielski JP, Lwakatare J, Dukes CS, et al. Tuberculous pericarditis in Tanzanian patients with and without HIV infection. Tuber Lung Dis 1994; 75:429.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/40/25226/abstract/30\">",
"      Blanchard DG, Hagenhoff C, Chow LC, et al. Reversibility of cardiac abnormalities in human immunodeficiency virus (HIV)-infected individuals: a serial echocardiographic study. J Am Coll Cardiol 1991; 17:1270.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/40/25226/abstract/31\">",
"      Ziskind AA, Pearce AC, Lemmon CC, et al. Percutaneous balloon pericardiotomy for the treatment of cardiac tamponade and large pericardial effusions: description of technique and report of the first 50 cases. J Am Coll Cardiol 1993; 21:1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/40/25226/abstract/32\">",
"      Marcy PY, Bondiau PY, Brunner P. Percutaneous treatment in patients presenting with malignant cardiac tamponade. Eur Radiol 2005; 15:2000.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/40/25226/abstract/33\">",
"      Small PM, Schecter GF, Goodman PC, et al. Treatment of tuberculosis in patients with advanced human immunodeficiency virus infection. N Engl J Med 1991; 324:289.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/40/25226/abstract/34\">",
"      Sunderam G, McDonald RJ, Maniatis T, et al. Tuberculosis as a manifestation of the acquired immunodeficiency syndrome (AIDS). JAMA 1986; 256:362.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/40/25226/abstract/35\">",
"      Syed FF, Mayosi BM. A modern approach to tuberculous pericarditis. Prog Cardiovasc Dis 2007; 50:218.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/40/25226/abstract/36\">",
"      Maisch B, Seferovi�� PM, Risti�� AD, et al. Guidelines on the diagnosis and management of pericardial diseases executive summary; The Task force on the diagnosis and management of pericardial diseases of the European society of cardiology. Eur Heart J 2004; 25:587.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/40/25226/abstract/37\">",
"      Boulanger E, G&eacute;rard L, Gabarre J, et al. Prognostic factors and outcome of human herpesvirus 8-associated primary effusion lymphoma in patients with AIDS. J Clin Oncol 2005; 23:4372.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/40/25226/abstract/38\">",
"      Levine AM. AIDS-associated malignant lymphoma. Med Clin North Am 1992; 76:253.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/40/25226/abstract/39\">",
"      Licci S, Narciso P, Morelli L, et al. Primary effusion lymphoma in pleural and pericardial cavities with multiple solid nodal and extra-nodal involvement in a human immunodeficiency virus-positive patient. Leuk Lymphoma 2007; 48:209.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/40/25226/abstract/40\">",
"      Sanna P, Bertoni F, Zucca E, et al. Cardiac involvement in HIV-related non-Hodgkin's lymphoma: a case report and short review of the literature. Ann Hematol 1998; 77:75.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/40/25226/abstract/41\">",
"      Longo-Mbenza B, Seghers KV, Phuati M, et al. Heart involvement and HIV infection in African patients: determinants of survival. Int J Cardiol 1998; 64:63.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/40/25226/abstract/42\">",
"      Anderson DW, Virmani R, Reilly JM, et al. Prevalent myocarditis at necropsy in the acquired immunodeficiency syndrome. J Am Coll Cardiol 1988; 11:792.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/40/25226/abstract/43\">",
"      Barbaro G, Di Lorenzo G, Grisorio B, Barbarini G. Cardiac involvement in the acquired immunodeficiency syndrome: a multicenter clinical-pathological study. Gruppo Italiano per lo Studio Cardiologico dei pazienti affetti da AIDS Investigators. AIDS Res Hum Retroviruses 1998; 14:1071.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/40/25226/abstract/44\">",
"      Lanjewar DN, Katdare GA, Jain PP, Hira SK. Pathology of the heart in acquired immunodeficiency syndrome. Indian Heart J 1998; 50:321.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/40/25226/abstract/45\">",
"      Twagirumukiza M, Nkeramihigo E, Seminega B, et al. Prevalence of dilated cardiomyopathy in HIV-infected African patients not receiving HAART: a multicenter, observational, prospective, cohort study in Rwanda. Curr HIV Res 2007; 5:129.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/40/25226/abstract/46\">",
"      Hofman P, Drici MD, Gibelin P, et al. Prevalence of toxoplasma myocarditis in patients with the acquired immunodeficiency syndrome. Br Heart J 1993; 70:376.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/40/25226/abstract/47\">",
"      Rabaud C, May T, Amiel C, et al. Extracerebral toxoplasmosis in patients infected with HIV. A French National Survey. Medicine (Baltimore) 1994; 73:306.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/40/25226/abstract/48\">",
"      Niedt GW, Schinella RA. Acquired immunodeficiency syndrome. Clinicopathologic study of 56 autopsies. Arch Pathol Lab Med 1985; 109:727.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/40/25226/abstract/49\">",
"      Dittrich H, Chow L, Denaro F, Spector S. Human immunodeficiency virus, coxsackievirus, and cardiomyopathy. Ann Intern Med 1988; 108:308.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/40/25226/abstract/50\">",
"      Barbaro G. Reviewing the cardiovascular complications of HIV infection after the introduction of highly active antiretroviral therapy. Curr Drug Targets Cardiovasc Haematol Disord 2005; 5:337.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/40/25226/abstract/51\">",
"      Goldblum N, Daefler S, Llana T, et al. Susceptibility to HIV-1 infection of a human B-lymphoblastoid cell line, DG75, transfected with subgenomic DNA fragments of Epstein-Barr virus. Dev Biol Stand 1990; 72:309.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/40/25226/abstract/52\">",
"      Cenacchi G, Re MC, Furlini G, et al. Human immunodeficiency virus type 1 antigen detection in endomyocardial biopsy: an immunomorphological study. Microbiologica 1990; 13:145.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/40/25226/abstract/53\">",
"      Wu AY, Forouhar F, Cartun RW, et al. Identification of human immunodeficiency virus in the heart of a patient with acquired immunodeficiency syndrome. Mod Pathol 1990; 3:625.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/40/25226/abstract/54\">",
"      Grody WW, Cheng L, Lewis W. Infection of the heart by the human immunodeficiency virus. Am J Cardiol 1990; 66:203.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/40/25226/abstract/55\">",
"      Rodriguez ER, Nasim S, Hsia J, et al. Cardiac myocytes and dendritic cells harbor human immunodeficiency virus in infected patients with and without cardiac dysfunction: detection by multiplex, nested, polymerase chain reaction in individually microdissected cells from right ventricular endomyocardial biopsy tissue. Am J Cardiol 1991; 68:1511.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/40/25226/abstract/56\">",
"      Shannon, RP, Mathier, MA, Manleod, S, et al. Macrophages not cardiomyocytes are the reservoir for lentivirus in SIV cardiomyopathy. Circulation 1999; 100:1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/40/25226/abstract/57\">",
"      Currie PF, Jacob AJ, Foreman AR, et al. Heart muscle disease related to HIV infection: prognostic implications. BMJ 1994; 309:1605.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/40/25226/abstract/58\">",
"      Roy VP, Prabhakar S, Pulvirenti J, Mathew J. Frequency and factors associated with cardiomyopathy in patients with human immunodeficiency virus infection in an inner-city hospital. J Natl Med Assoc 1999; 91:502.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/40/25226/abstract/59\">",
"      Cardoso JS, Moura B, Martins L, et al. Left ventricular dysfunction in human immunodeficiency virus (HIV)-infected patients. Int J Cardiol 1998; 63:37.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/40/25226/abstract/60\">",
"      Schuster I, Th&ouml;ni GJ, Ed&eacute;rhy S, et al. Subclinical cardiac abnormalities in human immunodeficiency virus-infected men receiving antiretroviral therapy. Am J Cardiol 2008; 101:1213.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/40/25226/abstract/61\">",
"      Herskowitz A, Wu TC, Willoughby SB, et al. Myocarditis and cardiotropic viral infection associated with severe left ventricular dysfunction in late-stage infection with human immunodeficiency virus. J Am Coll Cardiol 1994; 24:1025.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/40/25226/abstract/62\">",
"      De Castro S, d'Amati G, Gallo P, et al. Frequency of development of acute global left ventricular dysfunction in human immunodeficiency virus infection. J Am Coll Cardiol 1994; 24:1018.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/40/25226/abstract/63\">",
"      Fink L, Reichek N, Sutton MG. Cardiac abnormalities in acquired immune deficiency syndrome. Am J Cardiol 1984; 54:1161.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/40/25226/abstract/64\">",
"      Levy WS, Simon GL, Rios JC, Ross AM. Prevalence of cardiac abnormalities in human immunodeficiency virus infection. Am J Cardiol 1989; 63:86.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/40/25226/abstract/65\">",
"      Herskowitz A, Vlahov D, Willoughby S, et al. Prevalence and incidence of left ventricular dysfunction in patients with human immunodeficiency virus infection. Am J Cardiol 1993; 71:955.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/40/25226/abstract/66\">",
"      Hakas JF Jr, Generalovich T. Spontaneous regression of cardiomyopathy in a patient with the acquired immunodeficiency syndrome. Chest 1991; 99:770.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/40/25226/abstract/67\">",
"      Maserati R, Parisi A, Pan A, Lanzarini L. Rapidly reversible cardiomyopathy in an AIDS patient. AIDS 1991; 5:1145.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/40/25226/abstract/68\">",
"      Leidig GA Jr. Clinical, echocardiographic, and electrocardiographic resolution of HIV-related cardiomyopathy. Mil Med 1991; 156:260.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/40/25226/abstract/69\">",
"      Barbaro G, Di Lorenzo G, Grisorio B, Barbarini G. Incidence of dilated cardiomyopathy and detection of HIV in myocardial cells of HIV-positive patients. Gruppo Italiano per lo Studio Cardiologico dei Pazienti Affetti da AIDS. N Engl J Med 1998; 339:1093.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/40/25226/abstract/70\">",
"      Sep&uacute;lveda RT, Jiang S, Beischel J, et al. Cocaine injection and coxsackievirus B3 infection increase heart disease during murine AIDS. J Acquir Immune Defic Syndr 2000; 25 Suppl 1:S19.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/40/25226/abstract/71\">",
"      Yu Q, Larson DF, Watson RR. Heart disease, methamphetamine and AIDS. Life Sci 2003; 73:129.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/40/25226/abstract/72\">",
"      Liang H, Wang X, Chen H, et al. Methamphetamine enhances HIV infection of macrophages. Am J Pathol 2008; 172:1617.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/40/25226/abstract/73\">",
"      Herskowitz A, Willoughby S, Wu TC, et al. Immunopathogenesis of HIV-1-associated cardiomyopathy. Clin Immunol Immunopathol 1993; 68:234.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/40/25226/abstract/74\">",
"      Zandman-Goddard G, Shoenfeld Y. HIV and autoimmunity. Autoimmun Rev 2002; 1:329.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/40/25226/abstract/75\">",
"      Schocken DD, Holloway JD, Powers PS. Weight loss and the heart. Effects of anorexia nervosa and starvation. Arch Intern Med 1989; 149:877.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/40/25226/abstract/76\">",
"      de Simone G, Scalfi L, Galderisi M, et al. Cardiac abnormalities in young women with anorexia nervosa. Br Heart J 1994; 71:287.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/40/25226/abstract/77\">",
"      Kavanaugh-McHugh AL, Ruff A, Perlman E, et al. Selenium deficiency and cardiomyopathy in acquired immunodeficiency syndrome. JPEN J Parenter Enteral Nutr 1991; 15:347.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/40/25226/abstract/78\">",
"      Hurwitz BE, Klaus JR, Llabre MM, et al. Suppression of human immunodeficiency virus type 1 viral load with selenium supplementation: a randomized controlled trial. Arch Intern Med 2007; 167:148.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/40/25226/abstract/79\">",
"      Wharton JM, Demopulos PA, Goldschlager N. Torsade de pointes during administration of pentamidine isethionate. Am J Med 1987; 83:571.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/40/25226/abstract/80\">",
"      Herskowitz A, Willoughby SB, Baughman KL, et al. Cardiomyopathy associated with antiretroviral therapy in patients with HIV infection: a report of six cases. Ann Intern Med 1992; 116:311.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/40/25226/abstract/81\">",
"      Lewis W, Grupp IL, Grupp G, et al. Cardiac dysfunction occurs in the HIV-1 transgenic mouse treated with zidovudine. Lab Invest 2000; 80:187.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/40/25226/abstract/82\">",
"      Domanski MJ, Sloas MM, Follmann DA, et al. Effect of zidovudine and didanosine treatment on heart function in children infected with human immunodeficiency virus. J Pediatr 1995; 127:137.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/40/25226/abstract/83\">",
"      Lewis W. Mitochondrial DNA replication, nucleoside reverse-transcriptase inhibitors, and AIDS cardiomyopathy. Prog Cardiovasc Dis 2003; 45:305.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/40/25226/abstract/84\">",
"      Koehler A, Lewis W. Mitochondrial cardiomyopathy in HIV-1 patients treated with zidovudine. Lab Invest 1995; 72:33A.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/40/25226/abstract/85\">",
"      L&auml;hdevirta J, Maury CP, Teppo AM, Repo H. Elevated levels of circulating cachectin/tumor necrosis factor in patients with acquired immunodeficiency syndrome. Am J Med 1988; 85:289.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/40/25226/abstract/86\">",
"      Cohen MC, Huberman MS, Nesto RW. Recombinant alpha 2 interferon-related cardiomyopathy. Am J Med 1988; 85:549.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/40/25226/abstract/87\">",
"      Monsuez JJ, Escaut L, Teicher E, et al. Cytokines in HIV-associated cardiomyopathy. Int J Cardiol 2007; 120:150.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/40/25226/abstract/88\">",
"      Barbaro G, Di Lorenzo G, Soldini M, et al. Intensity of myocardial expression of inducible nitric oxide synthase influences the clinical course of human immunodeficiency virus-associated cardiomyopathy. Gruppo Italiano per lo Studio Cardiologico dei pazienti affetti da AIDS (GISCA). Circulation 1999; 100:933.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/40/25226/abstract/89\">",
"      Twu C, Liu NQ, Popik W, et al. Cardiomyocytes undergo apoptosis in human immunodeficiency virus cardiomyopathy through mitochondrion- and death receptor-controlled pathways. Proc Natl Acad Sci U S A 2002; 99:14386.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/40/25226/abstract/90\">",
"      Fiala M, Popik W, Qiao JH, et al. HIV-1 induces cardiomyopathyby cardiomyocyte invasion and gp120, Tat, and cytokine apoptotic signaling. Cardiovasc Toxicol 2004; 4:97.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/40/25226/abstract/91\">",
"      Olinski R, Gackowski D, Foksinski M, et al. Oxidative DNA damage: assessment of the role in carcinogenesis, atherosclerosis, and acquired immunodeficiency syndrome. Free Radic Biol Med 2002; 33:192.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/40/25226/abstract/92\">",
"      Pozzan G, Pagliari C, Tuon FF, et al. Diffuse-regressive alterations and apoptosis of myocytes: possible causes of myocardial dysfunction in HIV-related cardiomyopathy. Int J Cardiol 2009; 132:90.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/40/25226/abstract/93\">",
"      Himelman RB, Dohrmann M, Goodman P, et al. Severe pulmonary hypertension and cor pulmonale in the acquired immunodeficiency syndrome. Am J Cardiol 1989; 64:1396.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/40/25226/abstract/94\">",
"      Mesa RA, Edell ES, Dunn WF, Edwards WD. Human immunodeficiency virus infection and pulmonary hypertension: two new cases and a review of 86 reported cases. Mayo Clin Proc 1998; 73:37.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/40/25226/abstract/95\">",
"      Speich R, Jenni R, Opravil M, et al. Primary pulmonary hypertension in HIV infection. Chest 1991; 100:1268.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/40/25226/abstract/96\">",
"      Pellicelli AM, Barbaro G, Palmieri F, et al. Primary pulmonary hypertension in HIV patients: a systematic review. Angiology 2001; 52:31.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/40/25226/abstract/97\">",
"      Petitpretz P, Brenot F, Azarian R, et al. Pulmonary hypertension in patients with human immunodeficiency virus infection. Comparison with primary pulmonary hypertension. Circulation 1994; 89:2722.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/40/25226/abstract/98\">",
"      Silva-Cardoso J, Moura B, Ferreira A, et al. Predictors of myocardial dysfunction in human immunodeficiency virus-infected patients. J Card Fail 1998; 4:19.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/40/25226/abstract/99\">",
"      Opravil M, Pech&egrave;re M, Speich R, et al. HIV-associated primary pulmonary hypertension. A case control study. Swiss HIV Cohort Study. Am J Respir Crit Care Med 1997; 155:990.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/40/25226/abstract/100\">",
"      Sitbon O, Lascoux-Combe C, Delfraissy JF, et al. Prevalence of HIV-related pulmonary arterial hypertension in the current antiretroviral therapy era. Am J Respir Crit Care Med 2008; 177:108.",
"     </a>",
"    </li>",
"    <li>",
"     Reinsch, N, Buhr, C, Krings, P, et al. Effect of gender and highly active antiretroviral therapy on HIV-related pulmonary arterial hypertension: results of the HIV-HEART Study. HIV Med 2008 Jn 16 [Epub ahead of print].",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/40/25226/abstract/102\">",
"      Kim J, Ruff M, Karwatowska-Prokopczuk E, et al. HIV envelope protein gp120 induces neuropeptide Y receptor-mediated proliferation of vascular smooth muscle cells: relevance to AIDS cardiovascular pathogenesis. Regul Pept 1998; 75-76:201.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/40/25226/abstract/103\">",
"      Kanmogne GD, Primeaux C, Grammas P. Induction of apoptosis and endothelin-1 secretion in primary human lung endothelial cells by HIV-1 gp120 proteins. Biochem Biophys Res Commun 2005; 333:1107.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/40/25226/abstract/104\">",
"      Pellicelli AM, Palmieri F, Cicalini S, Petrosillo N. Pathogenesis of HIV-related pulmonary hypertension. Ann N Y Acad Sci 2001; 946:82.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/40/25226/abstract/105\">",
"      Limsukon A, Saeed AI, Ramasamy V, et al. HIV-related pulmonary hypertension. Mt Sinai J Med 2006; 73:1037.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/40/25226/abstract/106\">",
"      Zuber JP, Calmy A, Evison JM, et al. Pulmonary arterial hypertension related to HIV infection: improved hemodynamics and survival associated with antiretroviral therapy. Clin Infect Dis 2004; 38:1178.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/40/25226/abstract/107\">",
"      Ghofrani HA, Friese G, Discher T, et al. Inhaled iloprost is a potent acute pulmonary vasodilator in HIV-related severe pulmonary hypertension. Eur Respir J 2004; 23:321.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/40/25226/abstract/108\">",
"      Nunes H, Humbert M, Sitbon O, et al. Prognostic factors for survival in human immunodeficiency virus-associated pulmonary arterial hypertension. Am J Respir Crit Care Med 2003; 167:1433.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/40/25226/abstract/109\">",
"      Stotka JL, Good CB, Downer WR, Kapoor WN. Pericardial effusion and tamponade due to Kaposi's sarcoma in acquired immunodeficiency syndrome. Chest 1989; 95:1359.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/40/25226/abstract/110\">",
"      Chyu KY, Birnbaum Y, Naqvi T, et al. Echocardiographic detection of Kaposi's sarcoma causing cardiac tamponade in a patient with acquired immunodeficiency syndrome. Clin Cardiol 1998; 21:131.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/40/25226/abstract/111\">",
"      Constantino A, West TE, Gupta M, Loghmanee F. Primary cardiac lymphoma in a patient with acquired immune deficiency syndrome. Cancer 1987; 60:2801.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/40/25226/abstract/112\">",
"      Little RF, Gutierrez M, Jaffe ES, et al. HIV-associated non-Hodgkin lymphoma: incidence, presentation, and prognosis. JAMA 2001; 285:1880.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/40/25226/abstract/113\">",
"      Roldan EO, Moskowitz L, Hensley GT. Pathology of the heart in acquired immunodeficiency syndrome. Arch Pathol Lab Med 1987; 111:943.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/40/25226/abstract/114\">",
"      Goldfarb A, King CL, Rosenzweig BP, et al. Cardiac lymphoma in the acquired immunodeficiency syndrome. Am Heart J 1989; 118:1340.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/40/25226/abstract/115\">",
"      Kelsey RC, Saker A, Morgan M. Cardiac lymphoma in a patient with AIDS. Ann Intern Med 1991; 115:370.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/40/25226/abstract/116\">",
"      Montalbetti L, Della Volpe A, Airaghi ML, et al. Primary cardiac lymphoma. A case report and review. Minerva Cardioangiol 1999; 47:175.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/40/25226/abstract/117\">",
"      Sturm A, Noppeney R, Reimer J, et al. [AIDS and non-Hodgkin's lymphoma: initial cardiac manifestations of highly malignant B-cell lymphoma 18 years after HIV infection]. Dtsch Med Wochenschr 2001; 126:364.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/40/25226/abstract/118\">",
"      Currie PF, Sutherland GR, Jacob AJ, et al. A review of endocarditis in acquired immunodeficiency syndrome and human immunodeficiency virus infection. Eur Heart J 1995; 16 Suppl B:15.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/40/25226/abstract/119\">",
"      Cicalini S, Forcina G, De Rosa FG. Infective endocarditis in patients with human immunodeficiency virus infection. J Infect 2001; 42:267.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/40/25226/abstract/120\">",
"      Gebo KA, Burkey MD, Lucas GM, et al. Incidence of, risk factors for, clinical presentation, and 1-year outcomes of infective endocarditis in an urban HIV cohort. J Acquir Immune Defic Syndr 2006; 43:426.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/40/25226/abstract/121\">",
"      Mir&oacute; JM, del R&iacute;o A, Mestres CA. Infective endocarditis in intravenous drug abusers and HIV-1 infected patients. Infect Dis Clin North Am 2002; 16:273.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/40/25226/abstract/122\">",
"      Kocheril AG, Bokhari SA, Batsford WP, Sinusas AJ. Long QTc and torsades de pointes in human immunodeficiency virus disease. Pacing Clin Electrophysiol 1997; 20:2810.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/40/25226/abstract/123\">",
"      Villa A, Foresti V, Confalonieri F. Autonomic neuropathy and prolongation of QT interval in human immunodeficiency virus infection. Clin Auton Res 1995; 5:48.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/40/25226/abstract/124\">",
"      Eisenhauer MD, Eliasson AH, Taylor AJ, et al. Incidence of cardiac arrhythmias during intravenous pentamidine therapy in HIV-infected patients. Chest 1994; 105:389.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/40/25226/abstract/125\">",
"      Anson BD, Weaver JG, Ackerman MJ, et al. Blockade of HERG channels by HIV protease inhibitors. Lancet 2005; 365:682.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/40/25226/abstract/126\">",
"      Justo D. Methadone-induced long QT syndrome vs methadone-induced torsades de pointes. Arch Intern Med 2006; 166:2288; author reply 2289.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/40/25226/abstract/127\">",
"      Cohen JA, Laudenslager M. Autonomic nervous system involvement in patients with human immunodeficiency virus infection. Neurology 1989; 39:1111.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/40/25226/abstract/128\">",
"      Freeman R, Roberts MS, Friedman LS, Broadbridge C. Autonomic function and human immunodeficiency virus infection. Neurology 1990; 40:575.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/40/25226/abstract/129\">",
"      Lebech AM, Kristoffersen US, Mehlsen J, et al. Autonomic dysfunction in HIV patients on antiretroviral therapy: studies of heart rate variability. Clin Physiol Funct Imaging 2007; 27:363.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/40/25226/abstract/130\">",
"      Periard D, Cavassini M, Taff&eacute; P, et al. High prevalence of peripheral arterial disease in HIV-infected persons. Clin Infect Dis 2008; 46:761.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/40/25226/abstract/131\">",
"      Bernal E, Masi&aacute; M, Padilla S, et al. Low prevalence of peripheral arterial disease in HIV-infected patients with multiple cardiovascular risk factors. J Acquir Immune Defic Syndr 2008; 47:126.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/40/25226/abstract/132\">",
"      Dillmon MS, Saag MS, Hamza SH, et al. Unusual thromboses associated with protein S deficiency in patients with acquired immunodeficiency syndrome: case reports and review of the literature. AIDS Res Hum Retroviruses 2005; 21:753.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/40/25226/abstract/133\">",
"      Majluf-Cruz A, Silva-Estrada M, S&aacute;nchez-Barboza R, et al. Venous thrombosis among patients with AIDS. Clin Appl Thromb Hemost 2004; 10:19.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/40/25226/abstract/134\">",
"      Micieli E, Dentali F, Giola M, et al. Venous and arterial thrombosis in patients with HIV infection. Blood Coagul Fibrinolysis 2007; 18:259.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/40/25226/abstract/135\">",
"      Toulon P. [Hemostasis and human immunodeficiency virus (HIV) infection]. Ann Biol Clin (Paris) 1998; 56:153.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/40/25226/abstract/136\">",
"      Sullivan PS, Dworkin MS, Jones JL, Hooper WC. Epidemiology of thrombosis in HIV-infected individuals. The Adult/Adolescent Spectrum of HIV Disease Project. AIDS 2000; 14:321.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/40/25226/abstract/137\">",
"      Saber AA, Aboolian A, LaRaja RD, et al. HIV/AIDS and the risk of deep vein thrombosis: a study of 45 patients with lower extremity involvement. Am Surg 2001; 67:645.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/40/25226/abstract/138\">",
"      Saif MW, Bona R, Greenberg B. AIDS and thrombosis: retrospective study of 131 HIV-infected patients. AIDS Patient Care STDS 2001; 15:311.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/40/25226/abstract/139\">",
"      Lijfering WM, Sprenger HG, Georg RR, et al. Relationship between progression to AIDS and thrombophilic abnormalities in HIV infection. Clin Chem 2008; 54:1226.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/40/25226/abstract/140\">",
"      Filsoufi F, Salzberg SP, Harbou KT, et al. Excellent outcomes of cardiac surgery in patients infected with HIV in the current era. Clin Infect Dis 2006; 43:532.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 3699 Version 6.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1103-201.65.114.212-C0B5FDA9AB-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f24_40_25226=[""].join("\n");
var outline_f24_40_25226=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H25350235\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      TYPES OF CARDIAC DISEASE",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      EPIDEMIOLOGY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      PERICARDITIS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      Treatment",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      Prognosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      MYOCARDIAL DISEASE",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      Focal myocarditis",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      - Role of direct HIV infection",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      Subclinical and clinical dilated cardiomyopathy",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      - Possible etiology",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      PULMONARY HYPERTENSION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      CARDIAC TUMORS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      VALVULAR DISEASE",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      Nonbacterial thrombotic endocarditis (NBTE)",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H16\">",
"      Infective endocarditis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H17\">",
"      LONG QT SYNDROME",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H18\">",
"      AUTONOMIC DYSFUNCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H19\">",
"      METABOLIC ABNORMALITIES ASSOCIATED WITH ANTIRETROVIRAL THERAPY",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H20\">",
"      Lipid abnormalities",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H21\">",
"      Lipodystrophy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H22\">",
"      PERIPHERAL ARTERY DISEASE",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H23\">",
"      VENOUS THROMBOSIS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H24\">",
"      CLINICAL APPROACH",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#PATIENT_INFORMATION\">",
"      INFORMATION FOR PATIENTS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H25350235\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?11/52/12103?source=related_link\">",
"      AIDS-related Kaposi sarcoma: Clinical manifestations and diagnosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?22/55/23418?source=related_link\">",
"      Acquired long QT syndrome",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?19/37/20058?source=related_link\">",
"      Antimicrobial therapy of native valve endocarditis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?18/52/19273?source=related_link\">",
"      Cardiac tamponade",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?29/31/30201?source=related_link\">",
"      Clinical features, diagnosis, and natural history of lower extremity peripheral artery disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?36/47/37625?source=related_link\">",
"      Clinical presentation and diagnostic evaluation of acute pericarditis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?40/24/41352?source=related_link\">",
"      Diagnostic approach to infective endocarditis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?26/1/26650?source=related_link\">",
"      Epidemiology of cardiovascular disease and risk factors in HIV-infected patients",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?25/43/26298?source=related_link\">",
"      Epidemiology, clinical manifestations, and diagnosis of HIV-associated lipodystrophy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?22/28/22986?source=related_link\">",
"      Etiology and pathogenesis of myocarditis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?39/32/40458?source=related_link\">",
"      HIV protease inhibitors",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?39/17/40215?source=related_link\">",
"      Infective endocarditis in injection drug users",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?0/3/49?source=related_link\">",
"      Management of dyslipidemia and cardiovascular risk in the HIV-infected patient",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?29/40/30345?source=related_link\">",
"      Mitochondrial toxicity of HIV nucleoside reverse transcriptase inhibitors",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?10/39/10874?source=related_link\">",
"      Natural history and therapy of myocarditis in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?12/36/12872?source=related_link\">",
"      Nitric oxide, other hormones, cytokines, and chemokines in heart failure",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?10/16/10506?source=related_link\">",
"      Noninvasive diagnosis of arterial disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?18/47/19193?source=related_link\">",
"      Overview of pulmonary hypertension in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?11/53/12115?source=related_link\">",
"      Patient information: Pericarditis (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?43/36/44617?source=related_link\">",
"      Treatment of HIV-associated lipodystrophy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?2/36/2633?source=related_link\">",
"      Tuberculous pericarditis",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f24_40_25227="Detection methods for abnormal hemoglobins";
var content_f24_40_25227=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=HEME%2F57389&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=7\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=HEME%2F57389&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=7\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Testing protocol for detection of hemoglobinopathies",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td>",
"        Clinical evaluation (anemia, polycythemia, cyanosis)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        CBC, reticulocyte count, peripheral smear, Heinz body prep",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Electrophoresis on cellulose acetate &plusmn; electropheresis on citrate agar,",
"        <strong>",
"         or",
"        </strong>",
"        isoelectric focusing on agarose",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1_start\">",
"        HPLC methods to separate and identify mutant Hb",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        &bull; Cation exchange HPLC (Hb quantitation)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        &bull; Reversed phase HPLC (globin chain separation)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1_start\">",
"        Special tests",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        &bull; Isopropanol, heat stability (unstable Hbs)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        &bull; Oxygen affinity (p50)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1_start\">",
"        DNA-based methods",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        &bull; PCR amplification and sequencing of globin genes",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        &bull; PCR detection of deletions",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f24_40_25227=[""].join("\n");
var outline_f24_40_25227=null;
var title_f24_40_25228="Pediatric intubation equipment";
var content_f24_40_25228=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=EM%2F73906&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=EM%2F73906&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Equipment sizing",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tr>",
"      <td class=\"subtitle1\">",
"       Age",
"      </td>",
"      <td class=\"subtitle1\">",
"       Blade size and type",
"      </td>",
"      <td class=\"subtitle1\">",
"       Uncuffed tube size (mm ID)",
"      </td>",
"      <td class=\"subtitle1\">",
"       Cuffed tube size (mm ID)",
"      </td>",
"      <td class=\"subtitle1\">",
"       Stylet size",
"      </td>",
"      <td class=\"subtitle1\">",
"       Insertion depth (cm)",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Newborn",
"      </td>",
"      <td>",
"       1 straight",
"      </td>",
"      <td>",
"       3-3.5",
"      </td>",
"      <td>",
"       N/A",
"      </td>",
"      <td>",
"       Pediatric",
"      </td>",
"      <td>",
"       9-10",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       6 months",
"      </td>",
"      <td>",
"       1 straight",
"      </td>",
"      <td>",
"       3.5-4.0",
"      </td>",
"      <td>",
"       3.0-3.5",
"      </td>",
"      <td>",
"       Pediatric",
"      </td>",
"      <td>",
"       11-12",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       1 years",
"      </td>",
"      <td>",
"       1-1.5 straight",
"      </td>",
"      <td>",
"       4.0",
"      </td>",
"      <td>",
"       3.5",
"      </td>",
"      <td>",
"       Pediatric",
"      </td>",
"      <td>",
"       12",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       2 years",
"      </td>",
"      <td>",
"       1.5-2 straight",
"      </td>",
"      <td>",
"       4.5",
"      </td>",
"      <td>",
"       4.0",
"      </td>",
"      <td>",
"       Pediatric",
"      </td>",
"      <td>",
"       13-14",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       5 years",
"      </td>",
"      <td>",
"       2 straight or curved",
"      </td>",
"      <td>",
"       5.0",
"      </td>",
"      <td>",
"       4.5",
"      </td>",
"      <td>",
"       Pediatric x 2*",
"      </td>",
"      <td>",
"       14-15",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       8 years",
"      </td>",
"      <td>",
"       2 straight or curved",
"      </td>",
"      <td>",
"       6.0",
"      </td>",
"      <td>",
"       5.5",
"      </td>",
"      <td>",
"       Adult",
"      </td>",
"      <td>",
"       16-18",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       10 years",
"      </td>",
"      <td>",
"       2-3 straight or curved",
"      </td>",
"      <td>",
"       6.5",
"      </td>",
"      <td>",
"       6.0",
"      </td>",
"      <td>",
"       Adult",
"      </td>",
"      <td>",
"       18-20",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       12 years",
"      </td>",
"      <td>",
"       2-3 straight or curved",
"      </td>",
"      <td>",
"       7.0",
"      </td>",
"      <td>",
"       6.5",
"      </td>",
"      <td>",
"       Adult",
"      </td>",
"      <td>",
"       20-21",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       15 years",
"      </td>",
"      <td>",
"       3 straight or curved",
"      </td>",
"      <td>",
"       7.0",
"      </td>",
"      <td>",
"       6.5",
"      </td>",
"      <td>",
"       Adult",
"      </td>",
"      <td>",
"       20-21",
"      </td>",
"     </tr>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"     mm ID: internal diameter in mm.",
"     <br>",
"      * Use two pediatric stylets in children of this size to ensure adequate endotracheal tube stiffness.",
"     </br>",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f24_40_25228=[""].join("\n");
var outline_f24_40_25228=null;
var title_f24_40_25229="HT and cognitive function";
var content_f24_40_25229=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=OBGYN%2F71955&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=OBGYN%2F71955&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    HT does not affect cognitive function",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 382px; height: 265px; background-image: url(data:image/gif;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Data from the Nurses' Health Study shows a lack of relationship between use of hormone replacement therapy in nondemented older women and cognitive function as determined by the telephone version of the Mini-Mental State Examination (MMSE).",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Data from: Grodstein F, Chen J, Pollen DA, et al. Postmenopausal hormone therapy and cognitive function in healthy older women.&nbsp;J Am Geriatr Soc 2000; 48:746.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f24_40_25229=[""].join("\n");
var outline_f24_40_25229=null;
var title_f24_40_25230="Management of hemodynamically unstable pelvic fracture";
var content_f24_40_25230=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=SURG%2F74206&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=SURG%2F74206&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 567px\">",
"   <div class=\"ttl\">",
"    Management of hemodynamically unstable pelvic fracture",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 547px; height: 444px; background-image: url(data:image/gif;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"     SICU: surgical intensive care unit; CT: computed tomography.",
"     <br>",
"      * If not already in place.",
"      <br>",
"       <font class=\"bullet\">",
"        &bull;",
"       </font>",
"       Exploratory laparotcomy or thoracotomy may be performed first if injuries in the chest or abdomen are the more likely the source of the patient's hemodynamic instability.",
"       <br>",
"        &Delta; CT of the abdomen and pelvis performed as soon as feasible after operation, although the patient may require other treatment in the SICU first.",
"       </br>",
"      </br>",
"     </br>",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f24_40_25230=[""].join("\n");
var outline_f24_40_25230=null;
var title_f24_40_25231="TEE IAS";
var content_f24_40_25231=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic2\" style=\"width: 1040px;\">",
"  <div class=\"videoplayer\" h264=\"./images/CARD/50099/intsepan_conv.mp4?title=TEE+IAS\" style=\"width:320px;height:256px\">",
"  </div>",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Interatrial septal aneurysm",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 237px; height: 189px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    The transesophageal echocardiogram shows a large aneurysm of the interatrial septum.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Thomas Binder, MD. University of Vienna.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f24_40_25231=[""].join("\n");
var outline_f24_40_25231=null;
